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Abstract 
Maternal infection during pregnancy increases the risk of several neuropsychiatric 
disorders later in life, many of which have a component of dopaminergic (DA) 
dysfunction, including schizophrenia, autism spectrum disorders (ASD), and 
attention deficit hyperactivity disorder (ADHD).  The majority of DA neurons are 
found in the adult midbrain; as such the midbrain is a key region of interest 
regarding these disorders.  The literature is conflicting regarding the behavioral 
alterations following maternal immune activation (MIA) exposure, and the cellular 
and molecular consequences of MIA on the developing midbrain remain to be fully 
elucidated.  Thus, this thesis aimed to establish the consequences of acute and mild 
MIA on offspring dopamine-related behaviors, as well as the associated cellular and 
molecular disturbances of MIA on offspring midbrains.   
We utilized a rat model of MIA using low dose (50μg/kg, I.P.) of LPS 
administered at different gestational ages.  Our first study indicated that MIA at later 
gestational ages significantly increased pro-inflammatory IL-1β expression, and 
reduced HSD11B2 expression in the placenta, which is an important regulator of 
fetal development.  In utero LPS exposure at later gestational ages also impaired the 
growth of neurons from affected offspring.  This study identified key gestational 
stages during which MIA resulted in differential effects.  We utilized these time 
points in subsequent studies, the next of which investigated neurobehavioral 
outcomes following MIA.  Our results from that study showed that motor differences 
occurred in juvenile offspring following MIA at E16 only, and these differences 
were compensated for in adolescence.  Then, there was a decline in motor behavior 
capabilities in adulthood, again only for animals exposed to MIA on E16 (and not 
E12).  Furthermore, our results also demonstrated adolescent and adult offspring that 
were exposed to MIA at E12 had diminished responses to amphetamine in reward 
seeking behaviors.  In our final study, we aimed to investigate the molecular and 
cellular changes following MIA which might explain these behavioral alterations.  
This final study showed a differential inflammatory response in fetal midbrains 
depending on gestational age of exposure as well as differential developmental 
alterations.  For example, LPS exposure at E16 resulted in decreased VM 
neurosphere size after 7DIV and this was associated with an increased susceptibility 
to neurotoxic effects of pro-inflammatory cytokines for VM neurospheres and VM 
DA neurons treated in culture.  In utero LPS exposure at E16 also reduced DA 
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neuron count of fetal VM, measured by TH staining.  However, there were no 
differences in DA neuron number in juvenile, adolescent, or adult offspring.  
Similarly, LPS exposure did not alter cell number or morphology of glial cells in the 
midbrains of affected offspring. 
In conclusion, this thesis indicated later rat pregnancy (E16) as vulnerable 
time for MIA to affect the development of the nigrostriatal pathway and subsequent 
behavioral outcomes, possibly implicating a role for MIA in increased risk for 
disorders associated with motor behavior, like PD.  These effects may be mediated 
through alterations in the placenta and altered inflammatory mediators in the 
offspring brain.  This thesis has also shown that MIA in earlier rat pregnancy (E12) 
results in altered mesocorticolimbic function, and in particular MIA on E12 resulted 
in a differential response to amphetamine in affected offspring, which may implicate 
a role for MIA in increasing the risk for disorders associated with this pathway, 
including drug tolerance and addiction.   
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Chapter 1: 
 
General Introduction 
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1.0 Introduction 
During development the nervous system is assembled and sculpted by an 
orchestrated series of neurodevelopmental events that ultimately generate and refine 
the neural circuitry that govern all facets of human behavior.  Fetal programming 
describes how alterations in the fetal environment during specific periods of 
vulnerability during pregnancy may cause perturbations in this normal 
developmental program, thereby altering the structure and function of organs 
including the nervous system (Schlotz & Phillips, 2009).  This phenomenon has the 
potential for physiological changes, leading to susceptibility for disease later in life 
(known as the Barker Hypothesis) (Bateson et al., 2004; de Boo & Harding, 2006; 
Schlotz & Phillips, 2009).  Indeed, much evidence suggests that perinatal factors, 
including nutrition deficiency, maternal exposure to drugs or toxins, maternal stress, 
fetal hypoxia, low birth weight, and prenatal maternal infection have been implicated 
in adverse outcomes, most notably adult disease (Del Giudice, 2012; Faa et al., 
2014; Seremak-Mrozikiewicz et al., 2014).   
Many clinical and epidemiological studies have now shown that prenatal 
maternal infection and subsequent maternal immune activation (MIA) can increase 
the risk in affected offspring for a number of neurodevelopmental and 
neuropsychiatric disorders later in life, including schizophrenia (Brown et al., 2004a; 
Brown et al., 2005; Brown & Derkits, 2010), autism spectrum disorders (ASD) 
(Zerbo et al., 2013a; Zerbo et al., 2013b) and cerebral palsy (CP) (Pakula et al., 
2009; Shatrov et al., 2010).  Many of the epidemiological findings have been 
corroborated using pre-clinical models of MIA, including administration of 
lipopolysaccharide (LPS) to pregnant rats which has been shown to result in 
cognitive impairments, brain lesions, behavioral abnormalities, and neurological 
disease (Bell & Hallenbeck, 2002; Golan et al., 2005; Bilbo & Schwarz, 2009; 
Boksa, 2010; Patterson, 2011b).  Furthermore, research from animal models, which 
is supported by epidemiological evidence (Brown et al., 2000b; Atladóttir et al., 
2010), has suggested that timing and nature of immunogen exposure, combined with 
environmental factors and genetic predisposition, are critical determinants of 
offspring outcome (Meyer et al., 2007; Boksa, 2010).  While MIA is indeed likely to 
affect many brain regions, these findings have significant implications for the 
development of the midbrain and the associated dopaminergic neurons therein, 
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which have been the focus of intensive investigation given their degeneration in 
Parkinson’s disease (PD) (Toulouse & Sullivan, 2008; Lees et al., 2009).  Indeed, the 
increase risk in many of the neuro-related diseases post MIA are dependent on 
dopaminergic neurons and/or proper functioning of the dopaminergic system, 
including schizophrenia (Brown, 2006; Brown & Derkits, 2010; Anderson & Maes, 
2012; Seeman, 2013).  Thus, it is imperative to fully elucidate the consequences and 
the mechanisms of how MIA influences the midbrain and dopaminergic systems in 
order to better understand the etiology and progression of many of these diseases and 
disorders.   
The aim of this review chapter is to provide a detailed account of the 
literature: I begin by reviewing the epidemiological and clinical evidence linking 
MIA and with adverse neuro-related outcomes, and then describe the relationship of 
neurodevelopmental processes to timing of infection.  Next, I detail the animal 
models used to investigate these associations further and review the data showing the 
developmental and behavioral abnormalities in affected offspring as a result of MIA.  
I conclude with an overview of midbrain development and the implications of MIA 
for midbrain development and subsequent dopaminergic function in affected 
offspring.  Finally, I describe the aims of this PhD thesis.      
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1.1 Epidemiological and Clinical Evidence 
Epidemiological evidence has shown that MIA leads to increased risk of 
neurodevelopmental and neuropsychiatric disorders including CP, ASD, ADHD, and 
schizophrenia in affected offspring.  While the comprehensive etiologies of these 
disorders are not yet fully elucidated, prenatal MIA has been implicated as a risk 
factor in epidemiological and clinical studies, the findings from which are reviewed 
below. 
 
1.1.1 Cerebral Palsy 
“Cerebral palsy” is an umbrella term used to describe a group of syndromes with 
varying levels of severity affecting gross motor function and posture, which arise 
following lesions or developmental abnormalities in the immature/developing fetal 
or infant brain (Mutch et al., 1992; Rosenbaum et al., 2002; Sankar & Mundkur, 
2005; Rosenbaum et al., 2007).  The brain lesion/abnormalities associated with CP 
are not progressive, and motor impairments are permanent (Mutch et al., 1992; Cans, 
2000; Smithers-Sheedy et al., 2014).  Epidemiological evidence including 
retrospective studies, population based studies, as well as meta-analyses have 
provided evidence for a link between prenatal or intrauterine infection and brain 
lesions or CP (Himmelmann et al., 2011; McIntyre et al., 2013).  In fact, Odding et 
al. reports that intrauterine infections are one of “the most important risk factors for 
CP”, amongst low birth weight and multiple gestation (i.e. twin or triplet 
pregnancies) (Odding et al., 2006).  Indeed, one or more indicators of intrauterine 
maternal infection, including maternal fever exceeding 38°C or chorioamnionitis 
(infection of the fetal amnion and chorion membranes), were present in only 2.9% of 
control children, versus 22% of children with CP in a population-based case-control 
study (Grether & Nelson, 1997). 
Prenatal infection, including urinary tract infection, clinical sepsis, and 
chorioamnionitis, which is possibly the most comprehensively researched form of 
MIA in terms of CP, have been associated with increased risk of CP development 
and white matter damage in affected offspring (Dammann & Leviton, 1998; 
Himmelmann et al., 2011; McIntyre et al., 2013; Bangash et al., 2014).  
Periventricular leukomalacia (PVL) is a form of white matter brain injury, consisting 
of brain lesions near the lateral ventricles which are the most important identifiable 
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risk factors for developing CP (Yoon et al., 2003).  The lesions have been reported in 
7-26% of low birth weight babies (under 1500g), and 62-80% of these children 
developed CP (Yoon et al., 1997).  Maternal diagnosis of chorioamnionitis 
significantly increased the risk for PVL in low birth weight infants (500-1700g) 
(Verma et al., 1997).  Similarly, the risk of CP increased from 12 to 39 per 1000 
births in low birthweight babies from mothers diagnosed with chorioamnionitis 
(Nelson & Ellenberg, 1978). Furthermore, chorioamnionitis significantly increased 
the risk for PVL in preterm infants (Perlman et al., 1996; Shevell et al., 2013), and 
approximately 28% of instances of CP in preterm infants is attributable to this 
infection as well (Nelson & Willoughby, 2000). Indeed, chorioamnionitis increases 
the risk of CP from 3 to 17% (Murphy et al., 1995).  Population based studies as 
well as meta-analysis reviews have also found significant relationships between 
chorioamnionitis and increased risk of CP in normal weight and full term babies 
(O'Shea et al., 1998; Wu et al., 2000; Wu et al., 2003).  Indeed, infection-related 
factors including bacterial growth in urine during pregnancy, any infection during 
pregnancy, severe infection during pregnancy, and antibiotic therapy during 
pregnancy constituted strong independent risk factors for spastic hemiplegia 
subgroup of CP in a case-controlled, population-based study of full term children 
with CP (Ahlin et al., 2013).  However another recent study showed no association 
between antibiotic use during pregnancy and risk of CP (Meeraus et al., 2015).  
Indeed, self-reported vaginal infections which received no antibiotic treatment were 
associated with an increased risk of spastic CP, more particularly than antibiotic 
treated vaginal infections (Streja et al., 2013).  These data suggest that adverse 
effects of MIA in relation to increase CP risk are not associated with the treatment of 
maternal infection but perhaps the illness itself and/or related processes. 
An important question is whether the timing of infection is significant with 
relation to increased risk of offspring CP development, as MIA at different stages of 
pregnancy is likely to impact on the neurodevelopmental events occurring at that 
time.  Interestingly, chorioamnionitis and maternal genitourinary infections that 
occur in the first two trimesters have been associated with increased risk of CP in 
preterm or low birthweight infants (Mann et al., 2009).  In agreement with this, 
another study found that maternal lower urinary tract infections treated with 
antibacterial prescriptions in the first trimester were associated with increased risk of 
CP in all births, however they also showed that genito-urinary tract infections in the 
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third trimester were associated with CP as well (Miller et al., 2013).  Finally, a 
population based control study demonstrated an increased risk of CP in both preterm 
and full term infants of mothers who had any infection during their hospitalization 
for delivery, however this study neglected to examine maternal infection during any 
other stage of pregnancy so it is not known if there was another infection earlier 
acting as a confounding factor (Neufeld et al., 2005).  These data seem to suggest 
that infection at any point during pregnancy is a risk factor of CP, but as the studies 
were not well controlled for this, more precise investigations must be conducted to 
validate a critical window or the lack thereof. 
Results from clinical studies have also supported the epidemiological data.  
For example histological examination of the placenta post maternal infection, 
including chorioamnionitis, has confirmed infection-induced alterations in placental 
structure as a risk factor for CP (Grether & Nelson, 1997; Shevell et al., 2013).  
Examination of tissue for levels of cytokines has also proved valuable as umbilical 
cord plasma concentration of interleukin (IL)-6 was significantly higher with the co-
occurrence of PVL (Yoon et al., 1996), and Martinez et al. showed higher median 
amniotic fluid levels of IL-6 as well as more positive amniotic fluid cultures (for 
aerobic and anaerobic bacteria) in cases where the child developed PVL and 
intraventricular hemorrhage (Martinez et al., 1998).  Thus, concentrations of IL-6 
and IL-1β in the amniotic fluid have been shown to identify infants who are at risk 
for developing white matter lesions (Yoon et al., 1997).  This suggests a potential 
role for cytokine levels to be used as potential predictors of CP risk in future.   
 
1.1.2 Autism Spectrum Disorders 
Autism spectrum disorders (ASDs) are developmental disorders characterized by 
communication and social interaction deficits, repetitive behaviors, and restricted 
interests which present in early childhood and limit/impair everyday functioning for 
affected people throughout life (Nightingale, 2012; Lauritsen, 2013).  Individuals 
with copy number variants as well as a history of maternal infection during 
pregnancy were associated with increased occurrence of the social communicative 
impairments and repetitive/restrictive behavioral symptoms of ASD (Mazina et al., 
2015), thus prenatal or early life infection is widely hypothesized as a possible step 
in the etiology for ASD along with genetic contributions (Libbey et al., 2005; 
Brown, 2012; Samsam et al., 2014).  Indeed, viral infection has been referred to as 
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the “principal non-genetic cause of autism” (Ciaranello & Ciaranello, 1995) and 
inpatient diagnosis of infection during pregnancy has been attributed to a 30% 
increased risk in ASD, according to a study using the Swedish nationwide register 
based birth cohort encompassing 2,371,403 people of which 24,414 have ASD (Lee 
et al., 2015).  
Women with infections (namely bacterial) diagnosed during an admission to 
the hospital had increased risk of delivering an infant with ASD (Zerbo et al., 
2013b), and multiple infections during pregnancy was a further risk factor (Zerbo et 
al., 2013b).  Specifically, numerous case studies are available detailing an 
association of cytomegalovirus (CMV) infection and the development of ASD in 
affected offspring (Stubbs, 1978; Markowitz, 1983; Ivarsson et al., 1990; Yamashita 
et al., 2003; Sweeten et al., 2004).  Furthermore, one early study looked at 243 
children exposed to maternal congenital rubella and 7% had autism in preschool 
(Chess et al., 1978), demonstrating an increased risk of ASD following maternal 
rubella during pregnancy; more recent work is in agreement with these findings 
(Landrigan, 2010).  Also, a study looking at 143 children diagnosed with ASD and 
200 control children demonstrated that maternal respiratory infection/asthma as well 
as maternal vaginal infection are possible risk factors for ASD (George et al., 2014).  
Finally, placental abnormalities have also been implicated in ASD as Anderson 
found a significantly greater occurrence of trophoblast inclusions in placenta from 
mothers of children with ASD (Anderson et al., 2007). 
As developmental processes during different stages of pregnancy might be 
differentially affected by maternal infection, a number of studies have also examined 
whether the timing of infection affected the increased risk of ASD.  The study based 
on the Swedish nationwide register showed that timing of infection did not influence 
risk, and an elevated risk was associated with MIA in all trimesters (Lee et al., 
2015), however they did not distinguish between types of infection.  Maternal rubella 
in early pregnancy is associated with increased risk of ASD (Landrigan, 2010).  In a 
population study of Denmark, looking at children born between 1980 and 2005, 
maternal viral infection in the first trimester or bacterial infection in the second 
trimester were shown to be associated with a diagnosis of ASD in the offspring 
(Atladóttir et al., 2010).  The findings of case studies suggest that timing of CMV in 
the third trimester increases risk for offspring to develop ASD (Yamashita et al., 
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2003).  These data may suggest that the timing and type of infection have differential 
associations to the risk of ASD in affected offspring. 
Clinical findings have demonstrated immune dysregulation and/or 
inflammation in some people with ASD, including changes in cytokine profiles 
(Gupta et al., 2010; Gesundheit et al., 2013; Goines & Ashwood, 2013; Rossignol & 
Frye, 2014).  Indeed, a number of studies have investigated cytokine and chemokine 
levels, including tumor necrosis factor (TNF), interferon (IFN)-γ, IL-6, IL-8, and C-
C motif chemokine 2 (MCP-1), and have demonstrated increased levels of these 
immunological biomarkers in the cerebrospinal fluid (CSF) of people with ASD 
(Pardo et al., 2005; Vargas et al., 2005; Chez et al., 2007).  Autoimmune markers 
have even been implicated in disease severity as positive associations with ASD 
severity level have been shown from serum levels of anti-nuclear antibodies 
(Mostafa & Kitchener, 2009), anti-ganglioside MI antibodies (Mostafa & Al-Ayadhi, 
2011), and antineuronal antibodies (Mostafa & Al-Ayadhi, 2012) in children with 
ASD.  Furthermore, using a high-sensitivity c-reactive protein (hs-CRP) test to 
evaluate the inflammatory response in individuals with different ASD severity 
diagnosis demonstrated a significantly higher hs-CRP level in severe ASD compared 
to the mild-to-moderate group (Khakzad et al., 2012).  The altered immune profile 
associated with ASD may be related to an initial insult of MIA, as mid-gestational 
maternal serum levels of IFN-γ, IL-4, and IL-5 were significantly associated with a 
50% increased risk of ASD (Goines et al., 2011), and furthermore amniotic fluid 
with increased TNF-α and TNF-β levels (Abdallah et al., 2013) as well as altered 
pathology of the placenta, including trophoblast inclusions (Anderson et al., 2007), 
are associated with increased risk of ASD.  Indeed, preclinical research has shown 
that the placenta provides the fetus with hematopoietic stem cells (Gekas et al., 
2005), allowing for the possibility that maternal infection could permanently alter the 
peripheral immune system of the offspring (Patterson, 2009), later resulting in the 
immune profiles observed in these clinical studies.   
 
1.1.3 Attention Deficit Hyperactivity Disorder 
Attention-Deficit Hyperactivity Disorder (ADHD) is a disorder associated with 
significant problems in attention, increased impulsiveness, and excessive activity 
symptoms which impact daily social and occupational activities (American 
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Psychiatric Association [APA], 2013; Barkley, 2014).  ADHD is commonly referred 
to as a ‘childhood disorder’ as the age of onset is in early childhood, most symptoms 
usually presenting by age 12 (Willcutt et al., 2012; APA, 2013), however though 
symptoms decline with age, it is generally accepted as a life-long disorder 
(McGough & Barkley, 2004; Faraone et al., 2006; Willcutt et al., 2012; Barkley, 
2014).  For ADHD comparatively less is known about the impact of maternal 
infection as a risk factor for its development.  However, perinatal exposure to 
infection has been shown to alter the behavior in offspring, including increasing 
hyperactivity (Hornig et al., 1999; Silva et al., 2014).  In a cohort study of children 
with ADHD, children with undifferentiated attention –deficit disorder (UADD), and 
a control group, researchers found that the greater number of medical conditions 
prior or during their first pregnancy increased the risk of delivering a child with an 
ADHD (McIntosh et al., 1995).  Furthermore, maternal illness/infection has been 
associated with ADHD and impaired cognitive functioning in progeny (Milberger et 
al., 1997).  In a retrospective study, using data from 84,721 children who were born 
from 1996 to 2002, showed that there is an increased risk of developing ADHD 
following maternal genitourinary infection (GU) (Mann & McDermott, 2011).  
Interestingly specific diagnosis mattered as chlamydia, trichomoniasis, urinary tract 
infection (UTI), and candidiasis have been associated with the increased risk of 
ADHD, while gonorrhea was not (Mann & McDermott, 2011).  In agreement with 
this, another study correlated maternal UTI with increased risk of offspring ADHD 
diagnosis (Silva et al., 2014). Finally, mothers who had both a GU infection as well 
as pre-eclampsia (a disorder of the placenta which leads to systemic inflammation) 
were 53% more likely to have a child with ADHD (Mann & McDermott, 2011).   
 
1.1.4 Schizophrenia 
Schizophrenia is a psychiatric disorder characterized positive symptoms, including 
hallucinations and/or delusions; negative symptoms, including flat affect and 
inability to experience pleasure; and cognitive symptoms, including impaired 
attention and memory (APA, 2013).  Dopamine plays a key role in the 
pathophysiology this disorder (Lau et al., 2013), evidence which stems from the 
‘dopamine hypothesis’ which proposes that the positive symptoms of schizophrenia 
are due to hyperactive mesolimbic dopamine projections and subsequent 
hyperstimulation of striatal D2 receptors and the negative symptoms and cognitive 
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impairments result from reduced mesocortical dopamine projections and associated 
hypostimulation of prefrontal cortex D1 receptors (Davis et al., 1991; Howes & 
Kapur, 2009).   
It has been proposed that if infections could be prevented during pregnancy, 
more than 30% of schizophrenia cases could be eliminated (Brown & Derkits, 2010).  
Indeed, the Danish national register allowed for a population based study in which 
they investigated the risk of schizophrenia associated with numerous obstetric 
events, and found a modest association between maternal infection and the risk of 
offspring developing schizophrenia (Byrne et al., 2007).  Furthermore, evidence has 
shown increased risk of schizophrenia in individuals that were exposed to the 
influenza virus during pregnancy (Mednick et al., 1988; Mednick et al., 1994), 
rubella (Patterson, 2009), measles (Brown & Patterson, 2011), mumps (O'Callaghan 
et al., 1994), varicella zoster (O'Callaghan et al., 1994), diphtheria (Watson et al., 
1984), toxoplasmosis (Patterson, 2009), and genital or reproductive infections, 
including herpes simplex virus type 2 (HSV-2) (Buka et al., 2008; Patterson, 2009).  
There is increasing evidence showing heightened risk of offspring developing 
schizophrenia from mothers who contracted infections during pregnancy, and a few 
reviews have been published on this topic (Brown & Derkits, 2010; Brown & 
Patterson, 2011).  While this body of evidence is enormous, this next section 
attempts to succinctly review the most important literature on this topic. 
At first, epidemiological studies used ecologic designs, whereby data used at 
a population level compared to epidemics were used to look at disease exposure. 
Mendick pioneered investigations associating influenza epidemics to neurological 
adversity in affected offspring, importantly showing an association between second 
trimester influenza exposure with an increase in schizophrenia incidence in offspring 
(Mednick et al., 1988; Mednick et al., 1994).  Following Mendick’s work, over 26 
other studies have looked at the incidence of schizophrenia following flu epidemics.  
These include studies from a Denmark cohort with cases from 1911 to 1950 (Barr et 
al., 1990), a UK cohort and any effect of the 1957 A2 influenza epidemic 
(O'Callaghan et al., 1991; Cooper, 1992; Fahy et al., 1992; Sham et al., 1992), and a 
Japanese cohort examining the 1957 influenza epidemic (Kunugi et al., 1992; 
Izumoto et al., 1999), among numerous others, including (Wright et al., 1995), 
which have found significant increases in schizophrenia risk among offspring 
exposed to maternal influenza in the second trimester.  However, studies with similar 
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design, including one with a much larger case sample from the US, have reported no 
correlation between second trimester maternal flu and schizophrenia (Torrey et al., 
1991; Selten & Slaets, 1994; Susser et al., 1994; Westergaard et al., 1999; Sørensen 
et al., 2009).  While important as the initial reports in this field, these studies had key 
mechanistic faults, including the fact that cases of schizophrenia were not directly 
related to a maternal diagnosis of infection, but instead only correlated to 
pregnancies occurring at the same time as a flu epidemic, which could lead to 
overestimations and misclassification of offspring exposure to maternal flu. 
As the previous studies use ecologic study designs, resulting in inconsistent 
and nonspecific data, there was a motivation for further research to utilize well 
characterized birth cohorts, which provide many mechanistic improvements 
compared to the ecologic design including the use of clinical diagnosis of infection 
and longitudinal assessment of offspring.  Two major studies using only documented 
perinatal infections, found no correlation with influenza and schizophrenia within a 
small sample size (Crow et al., 1991; Cannon et al., 1996).  When a larger sample 
size was used, medical records of over 12,000 pregnant women showed a clear 
association between maternal respiratory infection and 2-fold increased risk of 
offspring developing schizophrenia (Penner & Brown, 2007).  Similarly, specific 
diagnostic criteria as well as maternal interviews regarding maternal respiratory 
infection during the second trimester were used along with follow up of offspring 
status to find an increased risk of schizophrenia and schizophrenia spectrum 
disorders (SSD) in offspring adulthood (Brown et al., 2000b).  Influenza was not the 
only illness investigated in this way.  Indeed, a Copenhagen Perinatal Cohort, which 
was made up of 9,125 offspring delivered by 8,949 women from 1959 to 1961, was 
used to find an increased risk of schizophrenia correlated to bacterial infection in the 
first trimester (Sørensen et al., 2009).  Furthermore, maternal genital/reproductive 
infections within the first few weeks of pregnancy is associated with a significantly 
increased risk of offspring developing schizophrenia (Babulas et al., 2006). 
Studies further improved as the use of biomarker measurement during 
individual pregnancy and subsequent follow up of offspring became common 
practice.  One study used influenza antibody levels from the mother at different time 
points during gestation in order to directly associate maternal flu with incidence of 
schizophrenia, and demonstrated that the risk of developing schizophrenia increased 
by a factor of 7 after flu exposure in the first trimester, as well as a 3-fold increased 
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risk associated with early-mid gestation influenza exposure (Brown et al., 2004a).  
Serological confirmation has also been used to establish a correlation between 
mothers with clinical rubella in early pregnancy with a 5 fold increased risk of non-
affective psychosis in young adulthood (Brown et al., 2000a), as well as a 20%  
increased risk for schizophrenia or SSD in middle-aged adults (Brown et al., 2001).  
Furthermore, maternal serum from birth cohort studies from the US and Denmark 
has shown that increased levels of maternal IgG antibody to HSV-2 is a risk factor 
for schizophrenia in offspring (Buka et al., 2001a; Buka et al., 2008; Mortensen et 
al., 2010).   These maternal HSV-2 findings were not replicated in a smaller cohort 
(Brown et al., 2006), though it has been suggested that the null result is due to lack 
of power and small sample size and other mechanistic differences (60 schizophrenia 
cases) (Brown & Derkits, 2010).  Elevated levels of maternal IgG antibodies to 
Toxoplasma gondii, a parasite which causes toxoplasmosis, were also associated 
with increased risk of schizophrenia in the US Prenatal Determinants of 
Schizophrenia (PDS) cohort (Brown et al., 2005) as well as the Danish birth cohort 
(Mortensen et al., 2007).  Immune biomarkers including TNF-α, (Buka et al., 
2001b), IL-8 (Brown et al., 2004b), IL-5 and IL-6 (Abdallah et al., 2013), and C-
reactive protein levels (Canetta et al., 2014) are associated with increased risk of 
psychosis and/or schizophrenia  in offspring.  Some believe that the relationship of 
maternal infection and schizophrenia initiates continued altered immune functioning 
in affected offspring because medication naïve patients with schizophrenia have 
demonstrated elevated blood levels of IL-1β, IL-6, TNF, and IL-2 (Upthegrove et al., 
2014) and, following prenatal vaginal infection, a susceptibility to illness in infancy 
was associated with increased risk of later psychotic experience (Betts et al., 2014).   
As has been touched on above, many studies have tried to assess specific 
infection type as well as relationship to timing of infection and the relationship to 
schizophrenia risk.  To briefly summarize, peri-conceptual genital/reproductive 
infection (Babulas et al., 2006), influenza in the first or second trimester (Brown et 
al., 2004a), bacterial infection in the first trimester (Sørensen et al., 2009), 
respiratory infection in the second trimester (Brown et al., 2000b), and HSV-2 in the 
third trimester/at delivery (Buka et al., 2001a; Buka et al., 2008) are associated with 
increased risk of schizophrenia in affected offspring. While most studies seem to 
lack the power to make firm statistical conclusions, according to the systematic 
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review by Khandaker et al, it seems that there is a trend for increased risk of 
schizophrenia following exposure to maternal infection in earlier stages of pregnancy 
(Khandaker et al., 2013), and as such this should certainly be investigated and 
validated further.   
 
1.1.5 Parkinson’s Disease 
A final disease of note is Parkinson’s disease (PD), which is a degenerative disorder 
most notably affecting the motor system.  The hallmark clinical symptoms associated 
with PD include resting tremor, bradykinesia (slow movement, often associated with 
impaired ability to adjust body position), rigidity, or postural imbalance (Litvan et 
al., 2003).  These motor symptoms arise from a slow and progressive degeneration 
of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) (Gibb & 
Lees, 1991; Damier et al., 1999; Toulouse & Sullivan, 2008).  Epidemiological 
databases are not yet old enough to examine the association of maternal infection 
and later risk of PD in affected offspring and as such, a clear association (or the lack 
there of) between MIA and PD remains to be determined.  However, initial 
investigations took place in the 80s using influenza epidemic data and a cohort of 
people with PD.  The initial study identified an increased risk of developing PD if an 
individual was born in specific years which were close to influenza pandemics of 
1890-1930 (Mattock et al., 1988).  Hence, they evaluated if the risk of developing 
PD was associated with the influenza mortality rate for the year of the individual’s 
birth (ranging from 1900-1930), and the investigations resulted in a significant 
correlation between influenza mortality rates and the year of birth of people who 
later developed PD by some (Mattock et al., 1988), but were not replicated by others 
(Ebmeier et al., 1989).  As mentioned previously, this type of study has numerous 
mechanistic concerns and that may account for the discrepancy in results as well as 
the reason that no further crude epidemiological investigations were subsequently 
conducted regarding the relationship of MIA to PD.  Regardless of the lack of 
epidemiological evidence, the idea that MIA might have a role in PD etiology 
remains an intriguing focus of on-going research.  A common postmortem finding in 
the SN of Parkinson’s patients is increased microglial activation and cytokine levels: 
TNF-α, IL-1ß, IL-6, IL-8, IL-10 and IL-12, implicating immune/ inflammatory 
involvement the pathology of PD (McGeer et al., 1988; Banati et al., 1998; Imamura 
et al., 2003; Koziorowski et al., 2012; Perry, 2012).  Also, many of the genes posing 
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genetic risk factor to PD, including LRRK2 (Wallings et al., 2015), NR4A2 (Han & 
Cao, 2012), and PARK7 (Waak et al., 2009; Voros et al., 2013), have immune-
related functions.  Furthermore, a hypothesis has emerged that MIA may prime 
microglia to maintain inflammatory processes throughout the lifespan, leading to 
altered responses to neuronal death and protein aggregation, which in turn results in 
subsequent progression of the α-synuclein aggregates into Lewy bodies that are the 
pathological hallmark of PD (reviewed in Glass et al., 2010; Tomé et al., 2013; 
Knuesel et al., 2014).  Thus, there seems to be a relationship between immune 
mechanisms and PD pathology which must be investigated further to be fully 
understood, and equally it will be imperative to determine if an association exists 
between MIA and PD once the epidemiological data becomes available. 
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1.2 Critical Windows 
The development of the human brain is a highly complex and dynamic sequence of 
overlapping events.  These events are highly orchestrated and controlled through 
genetic direction, epigenetic regulation, and environmental influence (Tau & 
Peterson, 2010).  For these reasons, elucidating how disruptions in this 
neurodevelopmental program may lead to neurodevelopmental and neuropsychiatric 
diseases and disorders remains a challenge for neuroscientists,  particularly as many 
of the most prevalent disorders are thought to originate following combined 
alterations in genes and environment (Fishbein, 2000; Tsuang, 2000; Warner & 
Schapira, 2003; Le et al., 2008; Berardi et al., 2015).  For example, there is a genetic 
component in schizophrenia, as the heritability index for schizophrenia is 75% 
(Andersen, 2003), but twin studies have demonstrated that concordance is never 
100% for monozygotic (identical) twins, suggesting that environmental factors have 
an important impact in disease development (Tsuang, 2000).  Similar evidence has 
also been reported for PD, which has numerous genetic risk factors but they only 
account for about 30% of the familial and 3-5% of the sporadic cases (Houlden & 
Singleton, 2012; Klein & Westenberger, 2012).  This is because environmental 
factors are able to mediate and modulate gene functions which are subsequently 
expressed in the final phenotype (Fishbein, 2000).  Thus, the importance of 
environmental factors on the final outcome and disease progression is obvious.  
Pregnancy is the first instance that developing brains are exposed to different 
environments, and we know from an insurmountable body of evidence that what 
happens during pregnancy has lifelong impact on the developing embryo (Barker, 
2002; de Boo & Harding, 2006; Schlotz & Phillips, 2009; Faa et al., 2014; Seremak-
Mrozikiewicz et al., 2014) because disruptions in developmental processes can lead 
to profound structural and functional alterations in brain development (Thompson et 
al., 2009a; Ben-Ari, 2013).  MIA is one such disruption, and it may be the initiating 
insult which alters the developmental trajectory toward increased vulnerability to 
later insults and subsequent development of future disease (Schlotz & Phillips, 2009; 
Faa et al., 2014; Knuesel et al., 2014).  Importantly, insults such as MIA may have a 
greater effect on neural development if the event occurs during certain 
developmental windows more than others, giving rise to critical windows for 
sensitivity (Andersen, 2003).  Therefore, it is important to investigate the timing of 
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neurodevelopmental processes in order to understand the potential consequences of 
infection at different developmental stages.   
 
1.2.1 Neurogenesis 
Beginning around the 5
th
 gestational (GA) week, neuronal progenitor cells (NPCs) 
are born and by about GA week 8 they differentiate into neuronal cell types or glia 
(Tau & Peterson, 2010).  Then cells are subsequently laid down in an evolutionarily 
conserved manner, establishing older regions first (Jacobson & Rao, 1991; 
Andersen, 2003).  Hence, different brain regions have specific developmental 
schedules.  For example, hippocampal neurogenesis peaks around GA week 9 (Rakic 
& Nowakowski, 1981) but may continue into the postnatal period (Borre et al., 
2014), and cortical neurogenesis began around the same time, but continued up to 
2.5 years of age (Workman et al., 2013).  This suggests that a disruption may alter 
process of neurogenesis more in one brain region than the other, depending on the 
timing the insult occurred. 
In order for the developmental program to progress correctly, gene 
expression is tightly controlled. Epigenetic mechanisms play a large role in this 
control, and in fact regulate neurogenesis (Shen et al., 2005).  These mechanisms, 
including DNA methylation and histone modification, are processes that result in 
functional changes to the genome, without altering the DNA sequence itself (Bird, 
2007).  Importantly, these changes can be maintained through cell divisions for the 
duration of the existence of the cell and into future cell generations, and as such are 
essential for development (Jaenisch & Bird, 2003; Bird, 2007; Saitou et al., 2012), 
but also have the potential for negative consequences, including cancer (Muñoz et 
al., 2012).  Hence, non-genetic factors have the power to alter how genes are 
expressed, and disruptions in this process have cascading effects.  For example, 
DNA methylation that occurs during the differentiation of germ cells has the 
potential to alter the function of all cells stemming from the affected progenitors 
(Reik et al., 2001; Saitou et al., 2012), which may have implications for neuronal 
function later in development.  Importantly, it has been proposed that increased 
cytokine production, such as that which occurs during MIA, may alter the epigenetic 
regulation of genes (Jasoni et al., 2014).  Furthermore, evidence has supported the 
association of copy number variants (CNVs; variations in the number of copies of 
one or more sections of DNA in a cell) and maternal infection during pregnancy in 
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increased severity of ASD symptomology (Mazina et al., 2015), providing a link 
between epigenetics, MIA, and more severe ASD symptoms.  Thus, MIA during the 
period of neurogenesis has potential to lead to adverse consequences, possibly 
stemming from epigenetic modifications.  
 
1.2.2 Neuronal Migration 
Immature neurons must migrate from the germinal zones within which they are 
generated to their final place of residence (Sidman & Rakic, 1973).  Migration peaks 
at GA weeks 12-20 and the process is largely completed by GA weeks 26-29 (de 
Graaf-Peters & Hadders-Algra, 2006).  The migrating neurons require the guidance 
of glial fibers along which the neurons move (Hatten, 2002; Chao et al., 2009), and 
neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF) 
(Pahnke et al., 2004), to accomplish this.   
Errors in neuronal migration following genetic mutations can lead to 
improper gyri and culi patterning, resulting in the smooth brain disorder called 
lissencephaly, which is associated with significant developmental delays as well as 
decreased life expectancy (Olson & Walsh, 2002).  Epidemiological evidence from 
patients with neuronal migration disorders has suggested a role for prenatal events 
including infections in the pathogenesis of these disorders (Palmini et al., 1994).  
Furthermore, schizophrenia, which has increased risk following MIA (Patterson, 
2007; 2009; Brown & Patterson, 2011), has been proposed to be linked to 
disturbance in neuronal migration by some (Weinberger, 1999), but this was not seen 
by others (Heinsen et al., 1996).  In schizophrenia postmortem studies, however, 
abnormal expression of reelin (a gene involved in neuronal migration) has been 
observed (Fatemi et al., 2000b) and subsequently others have indicated the need for 
further research to substantially identify the role of cell migration in schizophrenia 
pathology (Lewis & Levitt, 2002).  Poor neuronal migration can also cause ectopic 
cortical tissue in white matter which may lead to seizure disorders (Tau & Peterson, 
2010).  White matter injury is a hallmark of CP (Yoon et al., 1997; Dammann & 
Leviton, 1998), the increased risk of which is also associated with MIA (Ahlin et al., 
2013; Miller et al., 2013).  Thus, there is cause for further investigation into the 
possible effects of MIA on neuronal migration. 
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1.2.3 Axonal and Dendritic Growth 
By about the 16
th
 week of gestation, neurons that have completed migration begin to 
branch outward, extending axons and arborizing dendrites (Jacobson & Rao, 1991).  
Both of these actions are promoted by neurotrophins and growth factors, including 
nerve growth factor (NGF), basic fibroblast growth factor (FGFb), brain derived 
neurotrophic factor (BDNF), and neurotrophin (NT)-3 (Cohen-Cory & Fraser, 1995; 
McAllister, 2000; Pérez-Domper et al., 2013).  As axons extend they begin to form 
connections, and these connections along with growth factors BDNF, NGF, GDNF, 
as well as neuronal and glial cross talk (Lemke, 2001) assist in the final placement of 
neurons (Jacobson & Rao, 1991; Andersen, 2003).   
 Loss of dendrites and spines has been implicated in schizophrenia (Glantz & 
Lewis, 2000; Broadbelt et al., 2002).  Furthermore, cytokines are able to cross the 
placenta following MIA (Zaretsky et al., 2004), and cytokines have been shown to 
inhibit dendritic growth and complexity of cortical neurons (Gilmore et al., 2004), 
suggesting possible implications for MIA in this developmental window as well.  
Indeed, this is in complete agreement with research from our lab group which 
showed that this developmental window (late gestation in the rat) is sensitive to the 
effects of MIA as we found increased IL-1β levels in the placenta as well as altered 
neurite length in superior cervical ganglion (SCG) neurons cultured from offspring 
that had been exposed to LPS on E18 (Straley et al., 2014). 
 
1.2.4 Programmed Cell Death 
The developmental program initially produces more cells than are actually needed 
(Yamaguchi & Miura, 2015), and so it must eliminate the excess.  Programmed cell 
death (PCD) is initiated in the second trimester, peaking in GA weeks 19-23 to get 
rid of post-mitotic cells (Tau & Peterson, 2010).  Approximately 50% of neurons are 
destroyed during this phase in which PCD is the default mechanism and only those 
neurons which are able to access enough growth factors can avoid apoptosis (Pérez-
Domper et al., 2013).  This neuronal refinement results in morphological 
rearrangement as the system strives to match the numbers of neurons to the 
requirements of the target field they innervate (Andersen, 2003).   
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 PCD is highly conserved evolutionarily, suggesting critical importance in 
developmental processes (Yamaguchi & Miura, 2015), and there is a general absence 
of PCD in the adult brain as there is no need for a global decline in neuronal 
numbers (Tower, 2014).  Yet, aberrant PCD in adulthood is associated with 
progressive degenerative diseases such as PD (Vila & Przedborski, 2003; Perier et 
al., 2012; Franco-Iborra et al., 2015) and Alzheimer’s disease (AD) (Glass et al., 
2010; Tower, 2014).  Some have suggested that immune mediators, including TNF-α 
and IL-1β, might directly initiate neuronal apoptosis in degenerative diseases 
because the neuropathology is associated with neuroinflammation (increased 
astrogliosis and microgliosis) (Glass et al., 2010), but also apoptosis can result from 
deficits in its own regulation (Vaux, 1993).  As such, it is possible that disturbances 
during the development phase might prime this process to remain unusually active 
throughout life, possibly driven by increased inflammatory mediators, resulting in 
increased cell death and associated neurological disease. 
 
1.2.5 Synaptogenesis 
While PCD is occurring, during the second trimester, neurons that do not become 
fated for apoptosis continue migrating toward their targets, and subsequently 
dendritic branching and axon extension increase with the assistance of growth 
factors (Pérez-Domper et al., 2013) and glial cells signaling (Haydon, 2001; Eroglu 
& Barres, 2010).  These processes, along with the help of scaffolding cells (Lopez-
Bendito et al., 2006) help orchestrate synaptogenesis.  Synaptogenesis is the process 
of forming functional synapses between neurons, and it involves precisely aligning a 
neurotransmitter release site in the presynaptic neuron’s axon terminal with receptors 
on the dendrite of the postsynaptic target neuron (Jacobson & Rao, 1991).  Synaptic 
density continues to increase in a near logarithmic and region dependent manner 
from the late second trimester, following birth and throughout infancy, resulting in 
overproduction of synapses and receptors in early youth (Andersen, 2003; Levitt, 
2003; Tau & Peterson, 2010).  For example, the timing of synaptogenesis differs 
across specific cortical layers, beginning during the second trimester in the deeper 
layers first (Huttenlocher, 1990; Huttenlocher & Dabholkar, 1997; Zecevic, 1998), 
and synaptic density peaks at around 6 months of age in the primary visual cortex 
(Huttenlocher & De Courten, 1986) after which levels begin to decline, and the 
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prefrontal cortex reaches maximum levels around 8 months, at about 50% higher 
than adult levels, continuing through 2-4 years of age (Huttenlocher, 1979; Kostović 
et al., 1995; Huttenlocher & Dabholkar, 1997; Lenroot & Giedd, 2006).  The 
regionally dependent timeline for cortex development was further validated by a 
subsequent longitudinal MRI study that showed the primary visual cortex and 
somatic sensory cortex reach peak thickness first, followed by higher order areas like 
the prefrontal cortex (Shaw et al., 2008) 
The axonal glycoprotein neural cell adhesion molecule L1 (mediator of 
cytoskeleton and extracellular matrix interaction) is impaired by fetal alcohol 
exposure (Ramanathan et al., 1996).  Thus, it has been suggested that the occurrence 
of fetal alcohol exposure during the cell migration/synaptogenesis phase of 
development, contributes to characteristics of fetal alcohol syndrome (Tau & 
Peterson, 2010).  Indeed, events that occur during this developmental stage, such as 
maternal separation or neglect, are implicated in adverse outcomes for the affected 
infant brain, including decreased synaptogenesis (Perry, 2002).  This has been 
confirmed in animal studies which showed improved hippocampal synaptogenesis, 
and associated increases in N-methyl-D-aspartate (NMDA) receptor subunit, (which 
is important in synaptic plasticity and memory function (Li & Tsien, 2009)) and 
BDNF following improved maternal care in rats (Liu et al., 2000).   
 
1.2.6 Myelination 
Myelination begins in the last trimester, but the vast majority occurs after birth 
(Ulfig et al., 1998; Back et al., 2001; Jakovcevski et al., 2007), following maturation 
of oligodendrocytes, the myelin forming glial cells (Lappe-Siefke et al., 2003; 
Funfschilling et al., 2012). This process of encasing myelin around neuron axons is 
essential for normal brain function as it allows for rapid and efficient nervous system 
communication (Deoni et al., 2011).  Myelination is a feature of the dramatic brain 
growth seen in newborns and toddlers (Dekaban, 1978; Tau & Peterson, 2010).  
Following this most productive phase in infancy, myelination begins to slow after 
about 1 year of life, though it continues steadily afterward into adulthood (Barnea-
Goraly et al., 2005; Gao et al., 2009).   
Disturbance of myelination is hallmark characteristic of PVL (Iida et al., 
1995) and as such is associated with CP, which has increased risk following a 
number of prenatal events including maternal infection (Wu et al., 2000; Sankar & 
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Mundkur, 2005; Pakula et al., 2009; Ahlin et al., 2013).  Importantly, it may be the 
pre-myelinating oligodendrocytes which are sensitive to environmental insults as a 
study examining myelin production and oligodendrocyte progression demonstrated 
that the vulnerable window for PVL occurs during late oligodendrocyte progenitor 
phase at 23-32 gestational weeks, before the process of myelination is highly active 
(Back et al., 2001).  This indicates that while a certain developmental process may 
be altered in disease pathology, the important critical window could actually be a 
preceding phase.   For example, if MIA occurs during GA week 23 and alters 
oligodendrocyte maturation, this could lead to poor myelination and later 
development of PVL and/or CP.  
 
1.2.7 Synaptic Pruning/ Brain Re-wiring 
Concurrently with myelination, during infancy, synaptic density reaches peak levels 
and subsequently the brain undergoes a competitive elimination of synapses, 
allowing for correction of superfluous cells and synapses (Cowan et al., 1984).  
Indeed, it has been proposed that pruning of synapses occurs in order to work toward 
the desired synaptic density for the brain regions to have the best synaptic 
transmission efficiency (Andersen, 2003; Eroglu & Barres, 2010), as synaptic 
pruning helps with the ‘rewiring’ of the brain toward more adult-typical, more 
energy efficient connections (Spear, 2013).  The time course for this developmental 
phase depends on brain region: sensory and motor regions begin after birth, 
association cortices and corpus callosum comes next, finally followed by regions 
which support higher cognitive functions (Levitt, 2003).  The brain does not finish 
pruning synapses until much later, reaching average adult levels by adolescence 
(Huttenlocher, 1979; Glantz et al., 2007) or young adulthood (Petanjek et al., 2011).  
Neurochemical and molecular modifications also occur during adolescence, along 
with the notable structural changes associated with the synaptic pruning and 
subsequent neuronal rewiring of the adolescent brain (Paus et al., 2008).  All of these 
changes occur in response to genetic cues as well as environmental stimuli, and are 
extremely important in determining the final appearance of the mature brain (Paus et 
al., 2008; Berardi et al., 2015).  Indeed, environmental information from before and 
during adolescence influences the structural and functional alterations (Berardi et al., 
2015), and in fact the information is incorporated permanently into the mature brain 
(Andersen, 2003).  This suggests that the rearrangements that occur in the adolescent 
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developmental phase set the final stage for how the brain functions from that point 
forward. 
Abnormalities in synaptic pruning and plasticity processes have been 
associated with ASD (Onore et al., 2012) because of the increased size in infant 
ASD brains observed with MRI (Dager et al., 2008).  Though there are other 
possible explanations for the enlarged brain size, including reduced apoptosis or 
abnormal brain patterning (Belmonte et al., 2004; Tau & Peterson, 2010), 
implicating other developmental phases in ASD as well.  During adolescence, the 
remarkable developmental changes observed coincide with altered pharmacological 
sensitivity, with reports of enhanced sensitivity to the positive pleasure rewards 
initiated by drugs and decreased sensitivity to the negative aspects of a stimuli 
(Doremus-Fitzwater et al., 2010), as well as dramatic changes in the hypothalamic-
pituitary-adrenal (HPA) axis in response to stress (Eiland & Romeo, 2013).  
Developmental changes are especially responsive to this altered pharmacological 
sensitivity and stress response changes (Andersen, 2003), and as such the highly 
plastic adolescent brain is exceptionally vulnerable to pathological insult during this 
time.  Therefore, if a predisposition due to genetic risk and in utero adversity like 
MIA previously occurred, and the adolescent rewiring would incorporate this 
information, another insult during adolescence has the potential to continue the brain 
down a developmental trajectory toward neurodevelopmental and 
neuropsychological disorders, such as schizophrenia and mood disorders which 
happen to have a peak age of onset in adolescence (Paus et al., 2008; Berardi et al., 
2015).   
 
1.2.8 Conclusion 
Brain development is a highly orchestrated temporally specific, and yet dynamic 
process, involving genetic input as well as adaptation to environmental factors 
(Berardi et al., 2015).   MIA is one type of prenatal insult which has the ability to 
affect different aspects of fetal brain development depending on the time during 
pregnancy in which the infection occurs (Andersen, 2003; Knuesel et al., 2014), and 
therein lies a potential for certain developmental periods to be more vulnerable to 
MIA and result in subsequent alterations in developmental trajectory.  This suggests 
that the key to understanding disease development is dependent on our 
understanding of the long lasting effects of initial insults like MIA as the first step in 
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a potential for disease development.  Therefore, having insight into critical windows 
of vulnerability is imperative with regards to disease prevention. There is abundant 
evidence suggesting potential vulnerable windows for MIA to increase the risk of 
disease (see first section “Epidemiological and Clinical Evidence”); however it will 
be important for future research to establish links in causality, and which critical 
windows and developmental processes are associated with which specific diseases.  
And of extreme importance, we need to identify the initial vulnerable period within 
which altered environment might instigate adverse developmental outcomes.  For 
example, dendrite loss is a characteristic of schizophrenia (Glantz & Lewis, 2000; 
Broadbelt et al., 2002) but it may not be the dendrite growth developmental phase 
which is most vulnerable, but instead a previous developmental window, which 
when altered then leads to poor dendrite growth downstream.  Only within that 
framework of knowledge, can we identify where MIA is most detrimental in terms of 
fetal outcome, and attempt to identify appropriate preventions.  Therefore, continued 
study of  normal neurodevelopmental processes, as well as identifying the systems 
which are most vulnerable to deviations in their developmental trajectory will help 
us to identify where prevention needs to occur to protect from MIA and its adverse 
effects on neurodevelopmental outcomes in affected offspring. 
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Figure 1: Hypothesized sequence of events contextualized within the temporal 
profile of neurodevelopment and neuropsychological disorder onset. 
Neurodevelopmental phases are temporally organized and tightly regulated, 
providing the possibility for specific critical windows of vulnerability in which there 
is an increased risk of aversive outcomes following an insult such as MIA.  If MIA 
occurs during a critical window, it may alter the developmental program in such a 
way as to leave the offspring more susceptible to further insults over time and to 
different neuropsychological disorders throughout life.  Numerous diseases, with 
unique etiologic and pathologic characteristics, are associated with MIA, although 
the exact mechanistic role(s) of MIA in disease progression is still part of ongoing 
investigations.  In order to fully elucidate the effects of MIA, and subsequently 
discern how and when to prevent negative outcomes, continued investigations into 
the critical windows of vulnerability is crucial.   
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1.3 Animal Models 
While correlations between maternal infection and increased risk of developing 
numerous diseases later in life has been shown (see section “Epidemiological and 
Clinical Evidence”), causation has yet to be fully elucidated.  To this end, animal 
models are widely used, most commonly with murines.  Animal models allow 
researchers to ask specific questions within the wide area of MIA, especially in 
relation to timing of infection (both gestational time point and duration of infection) 
and dose (i.e. modeling mild or severe infections).  The main animal models used are 
described in detail below, and then the effects of these models on offspring will be 
discussed in subsequent sections. 
 
1.3.1 Influenza 
The first animal models in MIA utilized infecting pregnant rodents with an intranasal 
(IN) droplet inoculation of human influenza (Fatemi et al., 1999; Fatemi et al., 
2002a; Fatemi et al., 2002b).  Influenza is a virus, consisting of an increasing 
number of subtypes, which commonly induces antiviral as well as proinflammatory 
innate immune responses (Wu et al., 2011).  Pattern-recognition receptors (PRRs) 
recognize viral RNA and hence are necessary for detecting influenza infection within 
the cell.  PRRs consist of TLR-7, retinoic acid inducible gene-I (RIG-1), and 
nucleotide binding oligomerization domain (NOD)-like receptors (NLRs) (Pang & 
Iwasaki, 2011).  Single stranded viral RNA binds to TLR7 and double-stranded viral 
RNA binds to TLR3 and RIG-1 which causes a signal cascade leading to increased 
production of proinflammatory cytokines and type 1 interferons (Alexopoulou et al., 
2001; Heil et al., 2004).  Interferons such as IFN-α and IFN-β inhibit protein 
synthesis and thus limit the ability of the virus to replicate (Kreijtz et al., 2011).  
Type 1 interferons also stimulate dendritic cells, which help to initiate innate 
immune response (Banchereau & Steinman, 1998; Steinman, 1998).  As many rodent 
models of influenza resulted in death from the infection (Van Reeth, 2000), studies 
now generally uses a lower dose than estimated human disease viral load, such as 
10−4.5 of 6.5 log 10 (CCID50), which induces a moderate but non-lethal viral 
infection (Fatemi et al., 2008). Experimental influenza is usually administered 
intranasally. 
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The time course for this infection is pretty well known for humans and 
rodents.  In humans, nasal lavage fluid IL-6 and IFN-α levels and IL-6 plasma levels 
peak at day 2 along with the most significant symptoms, including temperature and 
mucus production (Hayden et al., 1998).  TNF-α peaks after 3 days in plasma and 4 
days in nasal fluid, concurrent with viral shedding.  IL-8 peaks at 4-6 days, which is 
the same time most symptoms in the lower respiratory tract are observed.  
Importantly, similar results have been reported from patients with naturally 
occurring acute influenza (Kaiser et al., 2001), suggesting that the viral time course 
is consistent irrespective of how it was caught.  In order to translate rodent influenza 
studies to human, the time course was determined using a normal rodent, i.e. animals 
that were not pregnant.  These studies provided numerous reports of early or 
immediate rises in numerous cytokine levels, including IFN-𝛼, TNF-α, IL-1 α, IL-1β 
and IL-6, in bronchoalveolar lavage (BAL) fluids along with the normal rodent 
clinical symptoms which includes anorexia, lethargy, and decreased body 
temperature (Vacheron et al., 1990; Hennet et al., 1992; Peper & Van Campen, 
1995; Kurokawa et al., 1996).  Specifically, increases in BAL IL-6 is observed first 
within 1 day of infection, and with a slight decrease remains significantly above 
basal levels until day 6 which is when the virus is fatal for most mice strains (Hennet 
et al., 1992).  TNF-α BAL levels increase significantly the first day, peak by 36h and 
then decrease while IFN-γ BAL levels are first detected at 36h, peak at 2 days and 
decline until death (Hennet et al., 1992).  Rats show a similar time course in that 
when administered influenza, IL-1α, IFN-α, IL-6, TNF-α, GRO-α, and MIP1β are 
reported at increased levels in lung tissue shortly following inoculation, and IFN-γ, 
IL4, IL10 and IL12-p40 are seen at increased levels slightly later, during viral 
replication (3 d), and then again during pulmonary inflammation (up to 3 weeks) 
(Ottolini et al., 2005).  This model has decreased in popularity over the past decade, 
largely due to the long time course and the development of more controllable 
models.  Indeed, influenza has a very different time course to its subsequent models 
(described below) in that the immune responses to influenza takes a day or two to 
appear and certain symptoms take weeks to resolve, whereas the other models are 
much more acute making them easier to monitor and control.   
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1.3.2 LPS 
LPS is a large molecule that constitutes a major component of the cell wall in Gram 
negative bacteria (Raetz & Dowhan, 1990).  LPS consists of three main constituents: 
a lipid domain, a core oligosaccharide, and a polysaccharide (Raetz & Whitfield, 
2002).  The hydrophobic area of the molecule (Lipid A) is an endotoxin and induces 
a strong immune response in animals, and as such is a well-characterized model for 
bacterial infection (Galanos et al., 1985; Raetz & Whitfield, 2002).  The immunogen 
binds to toll like receptor (TLR)-4, which activates an immune response (Faure et 
al., 2000; Lin et al., 2000).  TLR-4 recruits numerous proteins, resulting in the 
activation of mitogen-activated protein kinases (MAPKs) as well as nuclear 
translocation of nuclear Factor-kappaβ (NF-kβ) and the activation for transcription 
factors, which initiate expression of pro-inflammatory cytokines such as IL-1β, 
TNF-α, and IL-6 (Wang et al., 2006; Girard et al., 2010).   
LPS has been injected intraperitoneally (I.P.), intravenously (I.V.), 
intranigrally (I.N.), or subcutaneously (S.C.) in doses ranging from 50μg/kg up to 
700μg/kg [for comprehensive review (Boksa, 2010)].  Following administration, 
LPS has shown to increase blood levels of IL-1β, IL-6, and TNF-α, as well as 
produce fever in rodents (Gayle et al., 2004; Ashdown et al., 2006).  Furthermore, an 
increase in pro-inflammatory cytokines IL-1β, IL-6, and TNF-α has been observed in 
the placenta and increased TNF-α levels have been demonstrated in amniotic fluid 
following maternal exposure to LPS (200μg/kg (Girard et al., 2010); 500μg/kg or 
2.5mg/kg (Urakubo et al., 2001)).  In particular, IL-1β significantly increases 
following maternal LPS exposure, with levels 20-fold higher than IL-6 and 50-fold 
higher than TNF-α in the placenta (Girard et al., 2010) suggesting that IL-1β may 
play a greater role in fetal programming compared to the other cytokines.  In fact, 
when LPS is co-administered with IL-1Ra, LPS induced cytokine expression in the 
placenta was reduced (Girard et al., 2010), implicating a potential preventative 
therapy in protecting against MIA and its adverse outcomes.   
The time course for this endotoxin is pretty well understood.  In humans, LPS 
injection induces an early increase of pro inflammatory cytokines TNF-α and IFN-γ, 
quickly followed by a dramatic increase in IL-6, which has been shown to reach 
peak levels 3-4 hours post injection (Kemna et al., 2005). Anti-inflammatory 
cytokine IL-10 peaks 2-3 hours post injection, and at 4 hours there was no change in 
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IL-1β in humans (Kemna et al., 2005).  In pigs, TNF-α is increased 10 fold 2 h post 
I.P. injection and is still elevated at 4 h, but is returned to normal by 8 h; IL-6 is 
increased at 2 h and peaks at 4 h with levels 200 fold greater than baseline and has 
returned to control levels by 12 h (Webel et al., 1997).  In the rat, plasma cytokine 
levels have also been analyzed following I.V. and I.P injections: IL-1β increases 
shortly following LPS, peaking at 1.5 h (6.5 fold from basal level) and returns to 
basal levels by 3.5 h post; IL-6 begins to increase 1 h after LPS and peaks at 1.5 h 
(15.1 fold increase) and returns to basal levels after 5 h; TNF-α increases as early as 
30 min post LPS and peaks at 1 h post injection (11.6 fold increase) and returns to 
normal at 3.5 h post injection (Kakizaki et al., 1999).  In another study, radiolabeled 
LPS was present in maternal organs and amniotic sac 1h after injection and in the 
placenta 2-8h post injection, and importantly this study demonstrated that LPS does 
not cross the placental barrier as no radiolabeled LPS was observed in the fetus 
(Ashdown et al., 2006).  
It has been known for some time that there is a wide variability in the 
endotoxin, as it is produced from bacteria.  Indeed, different batches or lots result in 
different pyrogenic and cytokinogenic activity (Ray et al., 1991).  For example, as 
Boksa first reported, there are numerous factors that have been shown to alter the 
effect of LPS on animal temperature: higher room temperature, I.V. administration, 
and higher doses of LPS all increase the likelihood of the animal being hypothermic 
rather than hyperthermic (Derijk et al., 1994; Fofie & Fewell, 2003; Boksa, 2010).  
Because of this information, researchers using LPS must be aware of the different 
results possible, and in order to compare studies in the literature effectively the 
specifics of the batch/lot and other experimental factors need to be explicit.    
 
1.3.3 Poly I:C  
Polyinosinic:polycytidylic acid (Poly(I:C)) is a synthetic double-stranded RNA (ds-
RNA) analog which mimics a viral infection (Field et al., 1967; Fortier et al., 2004).  
It consists of a pair of strands of polyinsoinic and polyctidylic acids.  Poly(I:C) 
works through TLR-3, which is expressed in the endosomal compartment where it 
recognizes microbial nucleic acids like dsRNA (Alexopoulou et al., 2001; Savva & 
Roger, 2013).  After Poly(I:C) binds to TLR3, signals are sent via Toll-IL-1 (TIR) 
domain-containing adaptor molecule-1 (TICAM-1) to activate the transcription 
factors interferon regulatory factor 3 (IRF-3), NF-kB, and AP-1, leading to the 
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induction of type I IFN, cytokine/chemokine production and dendritic cell (DC) 
maturation (Alexopoulou et al., 2001; Oshiumi et al., 2003; Yamamoto et al., 2003).  
Initiation of the immune response depends heavily on DCs as they stimulate B and T 
lymphocytes (Banchereau & Steinman, 1998; Steinman, 1998).  Poly I:C has been 
shown to induce pro-inflammatory cytokine production from dendritic cells (Cella et 
al., 1999; Verdijk et al., 1999) while decreasing anti-inflammatory cytokine IL-10 
(Gilmore et al., 2005; Meyer et al., 2006b).  In addition, Poly(I:C) also induces type 
1 interferons IFN-α and IFN-β (Alexopoulou et al., 2001). 
Poly(I:C), like LPS, is injected intraperitoneally, intravenously or 
subcutaneously.  In rodents, Poly(I:C) has been shown to increase sickness behaviors 
as early as 30min post treatment, including anhedonia, lethargy, hunched posture, 
hind limb stiffness, decrease locomotion, decrease body weight up to 6 h 
(Cunningham et al., 2007; Gandhi et al., 2007; Smith et al., 2007).  There is also an 
observed bi-phasic temperature response whereby hyperthermia occurs from 4-8h 
post treatment and hypothermia is observed 12-24 h post treatment (Smith et al., 
2007).  Poly I:C (750μg/kg) has been shown to increase rat plasma levels of IL-1β, 
IL-6, and TNF-α (Fortier et al., 2004).  Furthermore, maternal administration of 
Poly(I:C) (10 or 20 mg/kg) resulted in increased TNF-α levels, and decreased BDNF 
and NGF levels in the rat placenta (Gilmore et al., 2005).   
The time course of cytokine induction following Poly(I:C) has been 
investigated in rodents.  Firstly, in mice, systemic Poly(I:C) induced IFN-β 
beginning 1 h and peaking to 5000-fold increase on control levels at 3 h with a 
decrease toward control levels after 24h; systemic Poly(I:C) also increases levels of 
IL-6 which peaks at 3 h with 10,000-fold over control levels and continues to be 
elevated even at 24 h; IL-1β induction increases 100-fold at 3 h and subsequently 
decreases rapidly back to basal levels; finally, TNF-α is clearly induced by 1 h, 
peaks at 1000-fold above control level at 3 h, and persists through 12 h (Cunningham 
et al., 2007).  Following maternal administration of Poly(I:C) (4.5mg/kg on E16.5) 
in the mouse, there were two waves of cytokine expression in placenta, one at 2h 
post injection characterized by increased IL-6 and another at 4h demonstrating 
increased levels of IL-1β, TNF-α, and IFN-γ (Koga et al., 2009).  In rats, peripheral 
Poly(I:C) increased plasma IL-6 concentration 5-fold 2 h post injection and this 
returned to baseline by 4 h; plasma TNF-α increased 4-fold at 2 h; plasma 
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concentration of IL-1β was unaffected by Poly(I:C) but was only measured up to 8 h 
(Fortier et al., 2004).   
 
1.3.4 Cytokine Administration 
The final, and least common, animal model is direct administration of cytokines 
themselves.  IL-6 and IL-1β are most commonly used (Samuelsson et al., 2006; 
Smith et al., 2007; Meyer et al., 2008d).  At pathophysiological concentrations, IL-
1β (0.5, 1.0, 2.0 and 8.0 ng/24 h), and less effectively TNF-α (20, 100, or 300 ng/24 
h), IL-6 (100 ng/24 h), and IL-8 (20 ng/24 h), induced dose dependent anorexia in 
rats (Plata-Salamán et al., 1996). Furthermore, an increase in cortisol (CORT) and 
adrenocorticotropic hormone (ACTH) levels 4 h post IL-6 injection (9 μg/kg) has 
also been observed (Samuelsson et al., 2004).  However, IL-6 (9 μg/kg) has also 
been reported to not produce any obvious sickness behavioral as measured by food 
intake, weight change, body temperature, or maternal care (Samuelsson et al., 2006).   
Some studies investigating the mechanisms behind MIA use direct cytokine 
administration alongside one of the aforementioned models.  They have found that 
the addition of IL-6 increases the severity of sickness in the animals.  For example, 
when IL-6 was administered alongside influenza, animals were more severely ill and 
either died or suffered miscarriage, compared to when they were subjected to 
influenza alone (Smith et al., 2007).   
 
1.3.5 Importance of Immunogen, Dosage, and Timing 
While all of these animal models have expanded knowledge of numerous diseases, 
they are not without caveats.  Firstly, different diseases are associated with increased 
risk following different types of maternal infections (see section “Epidemiological 
Evidence”).  Animal models are in agreement with this, showing different, though 
sometimes overlapping, immune responses following administration of different 
immunogens (Meyer et al., 2007; Meyer et al., 2009; Boksa, 2010; Harvey & Boksa, 
2012).  Each immunogen affects the immune response differently, and are not 
directly comparable to the live infection which they model. For example, LPS 
administration does not have the exact same physiological response as sepsis, and 
Poly(I:C) has a very different time course to influenza virus (Meyer et al., 2009).  
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However, they do initiate the immune response with the key feature being the 
cytokine induction mechanisms of innate immunity (Meyer et al., 2009).   
Secondly, the dosage of the immunogen used in animal models also has a 
range of effects.  For example, a particularly high dose can lead to fetal mortality and 
small litter sizes (Entrican, 2002; French et al., 2013).  Furthermore, immunogen 
dose can also play a role in the cytokine response.  As cytokines are thought to 
contribute to the MIA effects on fetal brain development (Smith et al., 2007), it is 
important to understand how different dosages of immunogen alter cytokine profiles 
of the mother and fetus.  For example, injections with different doses of Poly(I:C) 
resulted in dose dependent IL-10 expression in mouse serum at 1h and 6h post 
injection (Meyer et al., 2005).  Furthermore, in studies that utilize a ‘chronic 
infection’ model in which the animal receives multiple injections throughout 
pregnancy, the additional stress the dam experiences due to the injections may 
confound results (Meyer et al., 2009). This is because maternal stress itself has been 
shown to lead to epigenetic programming and adverse behavioral outcomes in 
offspring (Talge et al., 2007; Zucchi et al., 2013), so it would be challenging to 
discern if any adverse effects were due to the MIA or the stress caused by multiple 
injections.   
Finally, the timing during pregnancy which an infection occurs is an intrinsic 
variable to fetal developmental outcome (see section “Critical Windows”).  Indeed, 
many preclinical studies have observed different developmental and behavioral 
consequences from MIA depending on gestational time points (reviewed in Meyer et 
al., 2007; Boksa, 2010), and these effects will be described in detail in the next 
section.  Phenotypical differences that result depending on timing of MIA may help 
researchers to distinguish disease pathologies.  For instance, most MIA studies 
administer the immunogen in mid to late gestational period of the rat, roughly 
correlating to the central nervous system (CNS) development occurring in the second 
trimester in the human (Clancy et al., 2007), which is also the time point most 
associated with infection leading to increased risk of schizophrenia and ASD (see 
“epidemiological and clinical evidence” section).  Alternatively, in CP models, MIA 
has been administered during the developmental window associated with 
myelination (approx. E18-P9 in the rat) (Burd et al., 2012).  Hence, the fact remains 
that the gestational time point must be included as a controlled variable in MIA 
animal models. 
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1.3.6 Translational Validity 
Developmental progression, in terms of major events and general temporal 
arrangement, seems to be widely evolutionarily conserved (Finlay & Darlington, 
1995; Andersen, 2003; Katz, 2007) and as such, preclinical research helps to 
hypothesize theories and validate knowledge for human situations.  The most 
common preclinical models are from rodents, and the rat model in particular has 
been validated as a good model for most human developmental processes (Watson et 
al., 2006).  In fact, the location of regulatory genes required for much of 
development has been conserved for both the human and rat (Akashi, 2001).  
Furthermore, both humans and rats are altricial species (they are relatively immobile 
and require mother for nourishment after birth), so they have relatively low CNS 
development at birth and this similarity allows the rat to be a well suited model for 
human CNS development particularly in the postnatal developmental period (Watson 
et al., 2006).  The rat undergoes key developmental stages on average 2 days later 
than the mouse, and therefore results in difference of rodent gestation length (about 
22 days for rat and 19 for mouse) (Mason, 1993; Clancy et al., 2007).  It is usually 
accepted that the gestational period of rats and mice roughly correlates to the 
developmental biology of the first and second trimester of human pregnancy, and the 
first week after birth in rodents would correspond to the final trimester of human 
pregnancy (Clancy et al., 2007) (see Figure 2).  This ‘rule of thumb’ is presumed to 
stem from comparative neuroanatomy studies which demonstrated that neural tube 
formation occurs during weeks 3-4 in human gestation and on E10.5-11 in the rat 
(Semple et al., 2013), and that the brain growth spurt that occurs around birth in 
humans, peaks at P7 in the rat (Dobbing & Sands, 1979; Semple et al., 2013).  
Furthermore, the weight of the cortex plateaus at around 2-3 years of age in the 
human, and the corresponding age in the rat is about P20 (Dobbing & Sands, 1979; 
Semple et al., 2013).   
While the rodent models are common, they are far from perfect.  
Comparisons cannot be made in a direct linear manner between any mammals 
because developmental processes progress at different rates depending on brain 
region, and the temporal profile of these differs between species (Jakovcevski et al., 
2009).  For example, studies of human brain development show that neocortical 
neurogenesis begins at the same relative time as mouse (GA week 5/E10), but new 
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neurons are still being born in the human brains long after they have relatively 
ceased in the mouse (Mo et al., 2007; Mo & Zecevic, 2008), and similar findings of 
differential temporal length with regards to oligodendrogenesis between humans and 
mice has also been shown (Jakovcevski et al., 2009).  Furthermore, changes in grey 
matter take much longer in the human compared to the rat, for example, human 
frontal lobe grey matter reaches peak volume at around puberty (11-12 years) 
(Bansal et al., 2008) and the temporal lobe grey matter is maxed in adolescence (16-
17 years) (Semple et al., 2013) but these volumetric plateaus are observed in most 
brain structures at P20 in the mouse (Chuang et al., 2011).  Another concern in 
species translation is that of precocial (more mobile and independent infants) and 
altricial differences, as precocial offspring like guinea pigs have relatively more 
developed CNS at birth compared to altricial animals like humans (Watson et al., 
2006).  It is difficult to translate developmental information across species if one 
species undergoes more extensive development postnatally and is therefore affected 
by a greater range of environmental factors, versus a species which has a more 
developed brain at birth.  However, even animals with the same developmental 
pattern show differences.  For example, human dentate gyrus neurogenesis is only 
about 80% complete in the human at birth, whereas only about 20% in the rat, even 
though both animals are considered altricial (Watson et al., 2006). In fact, the peak 
of this hippocampal neurogenesis in the human occurs in the first trimester (Clancy 
et al., 2007), but from E14-E17 in the rat (Rice & Barone Jr, 2000), which does not 
fit into the normal translational timeframe used by many preclinical models.  Along 
similar lines, behavioral developmental outcomes are extremely difficult to parallel 
across animal models, as different species have evolved with different behavioral 
needs and responses due to circumstantial adaptive pressures (Watson et al., 2006).    
While important to discuss, these differences may be of minimal 
consequence as researchers have demonstrated that developmental event order is 
highly evolutionarily conserved, and even developmental programs which could be 
separated throughout the course of evolution are so well preserved as to be easily 
predicted with one model for all neurodevelopmental events in all species (Workman 
et al., 2013).  Also, researchers have identified many of the evolutionary and 
developmental differences which may influence the translational validity, thus 
making it more legitimate to make claims in instances that appear consistent (Watson 
et al., 2006; Katz, 2007).  For example, though the time scales differ, the process that 
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humans and rodents follow for cell proliferation are almost parallel (Bayer et al., 
1993).  Furthermore, the primary interneurons of the cerebral cortex arise in slightly 
different ways, with the human neurons originating from two different locations 
(dorsal forebrain or ventral forebrain) (Letinic et al., 2002), and the rodent 
interneurons arising mainly from the ventral region (Powell et al., 2001); even 
though the development procedures involve slightly different process, the necessity 
and mechanism for interneurons to migrate long distances to reach the correct area of 
the cortex appears to be conserved in both species (Levitt, 2003).  Furthermore, 
cerebral cortex development in the human begins at about E56 and lasts through 
P400, whereas in the rat the same developmental processes goes from E12-P16, so 
even though the development processes take different lengths of time, the 
mechanisms and key stages are conserved enough that they are easily compared 
(Levitt, 2003; Semple et al., 2013).  Importantly, the major developmental phases 
seem to line up with major developmental stages as is evident from synaptic pruning 
and remodeling, processes that are most prolific during adolescence in both species 
(Semple et al., 2013).  Following on from those observations, researchers have used 
neuroscience, evolutionary science, and statistic modeling to establish models that 
extrapolate timing of brain development from animal to human, and these are 
improving all the time (Clancy et al., 2001; Clancy et al., 2007; Workman et al., 
2013).  These models are based on a comprehensive sampling of developmental 
literature, as well as allometric growth, which is the idea that increases in size of 
different organs occurs at different rates, and that is used because a correlation was 
shown between developmental duration and adult brain volume across mammals 
(Passingham, 1985; Workman et al., 2013).  While these methods are relatively 
dependable, we must strive for continued improvement in translation strategies as 
well as verification of the same.  To help with this, work with nonhuman primate 
studies (Liu et al., 2008), and human imaging studies, such as ultrafast MRI which 
allow for capture and quantification of brain images of progeny during pregnancy 
(Clouchoux & Limperopoulos, 2012) and after birth (Gousias et al., 2013) are 
becoming more popular. 
In summary, animal models provide insight into MIA events and are valuable 
for neuroscience research, and most neural events fall into a predictable pattern 
allowing for generalized theoretical translation of preclinical studies.  However, it is 
an oversimplification to directly extrapolate from animal models to human 
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pathologies, and depending on the developmental process and brain region a 
translation may not fit into our generalized “rule of thumb” timeline comparison.  
Thus, when researchers describe temporal features of developmental processes, it is 
imperative to remember that the developmental timeline must be in the context of the 
specific animal tested and the brain maturation processes of that species.  To then 
draw conclusions or extrapolate about other species, namely human, researchers 
should properly address the inexact nature of translating and make relative 
comparisons as opposed to exact connections while we continue to increase validity 
in translational modeling.   
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Figure 2: Temporal relativity of rat and human neuron development 
This timeline depicts neuronal development within generalized temporal profiles and 
key developmental milestones illustrated for rats relative to humans.  These species 
have structured developmental patterns which are mostly evolutionarily conserved, 
and the developmental timelines are somewhat understood for each.  Thus, 
researchers utilize the rat as a good translational model for many, but not all, human 
neuronal processes.  
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1.4 Effects of MIA on Offspring Behavior 
One of the most common ways animal models are used to understand the effects of 
MIA is through behavior studies.  These models of MIA have shown that exposure 
to LPS, Poly(I:C), and influenza result in behavioral outcomes consistent with 
symptoms of neuropsychiatric disorders such as schizophrenia and ASD, including 
deficits in attention, memory, social behavior, and pre-pulse inhibition (Patterson, 
2011a; Harvey & Boksa, 2012; Meyer, 2013).  These and other behavioral 
characteristics that arise in animals following MIA are reviewed. 
 
1.4.1 Pre-pulse Inhibition 
Pre-pulse inhibition (PPI) is a neurological phenomenon present across species in 
which a weaker stimulus presented before a stronger stimulus reduces the amplitude 
of the final response elicited by the stronger stimulus (Braff et al., 2001).  PPI is a 
measure of sensorimotor gaiting, as such deficits in PPI are associated with an 
inability to filter out extraneous environmental stimuli, which leads to sensory 
overload and cognitive fragmentation (Braff & Geyer, 1990; Swerdlow et al., 1994).  
People with schizophrenia and ASD exhibit sensorimotor gating deficits (including 
PPI) with characteristic inability to regulate sensory, motor, and/or attentional 
processes (Braff et al., 2001; Wynn et al., 2005; Perry et al., 2007; Braff et al., 
2014), thus PPI is widely studied in animal models of neurological disease (Geyer et 
al., 2001; Nestler & Hyman, 2010; Powell et al., 2012; Young et al., 2014) and is 
one of the most prolific behavioral assays used in MIA models (Meyer et al., 2007; 
Boksa, 2010).   
Deficits in PPI have been observed in adult rat offspring following chronic 
exposure to LPS (1mg/kg, every other day of gestation (Borrell et al., 2002); 
2mg/kg, every day (Romero et al., 2010)) or more acute LPS exposure (50 or 100 
μg/kg, E15 and E16 or E18 and E19) (Fortier et al., 2007)).  In agreement with this, 
acute Poly(I:C) (4mg/kg on E15) exposure resulted in PPI impairments in juvenile 
(P34-35) and adult (P56-57 (Wolff & Bilkey, 2008; Howland et al., 2012) or >P90 
(Dickerson et al., 2010; Mattei et al., 2014)) rat offspring.  Interestingly, Wolff and 
Bilkey demonstrated that adverse behavioral effects following MIA were not due to 
maternal weight loss (Wolff & Bilkey, 2010) which is a common symptom of illness 
in rodents (Sim et al., 2009; Hill et al., 2015).  However, others did not replicate this 
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finding, and in fact demonstrated that offspring who were exposed to Poly(I:C) 
(4mg/kg on E15) and whose mothers lost weight in response to the immunogen had 
more behavioral deficits than the offspring exposed to Poly(I:C) whose mothers 
gained weight following the injection (Missault et al., 2014), suggesting that 
maternal response to infection is a factor in fetal outcome.  Another group 
demonstrated that the duration of MIA may contribute to the difference in effects as 
a one-time administration of Poly(I:C) (8mg/kg) on E14 had no association to 
maternal weight change and PPI of offspring, but after chronic administration (E14-
E18) offspring from mothers who lost weight after the Poly(I:C) exposure 
demonstrated significantly altered PPI (Vorhees et al., 2012; 2015).   
Deficits in PPI following MIA have also been shown in mice.  For example, 
one of the earliest studies investigating how MIA affects this behavior, by Shi, 
Fatemi and others, showed a deficit in PPI in the acoustic startle response of 
offspring exposed to influenza virus on E9.5 (Shi et al., 2003).  Consistently, chronic 
Poly(I:C) (5mg/kg) exposure from E12-E17 (Ozawa et al., 2006) or on E10.5, 12.5 
and 14.5 (Malkova et al., 2014) resulted in inhibited PPI.  Interestingly, others have 
demonstrated a greater effect when MIA occurs earlier in mouse pregnancy 
compared to later.  Indeed, Poly(I:C) (5 mg/kg) on E9, but not on E17, resulted in 
inhibited PPI in adult offspring (Meyer et al., 2008b; 2008c; 2008d; Vuillermot et 
al., 2010; 2011; 2012).  This was confirmed by others who found PPI deficits in 
adolescent and young adult offspring (P28-56; P63) following prenatal exposure to 
Poly(I:C) on E9.5 (20mg/kg (Shi et al., 2003); 60mg/kg (Makinodan et al., 2008)).  
Importantly, lower doses of Poly(I:C) did not lead to deficits in PPI: a 2.5mg/kg dose 
administered to pregnant mice on E9 resulted in no differences in PPI of adult 
progeny, however the 5mg/kg dose did result in deficits (Lipina et al., 2013).  Taken 
together, these suggest that PPI deficits are age and dose dependent, and specifically 
that the middle of gestation in the mouse is a particularly vulnerable time for higher 
doses of Poly(I:C) to affect PPI of affected offspring later in life.   
Interestingly, the mouse Poly(I:C) model has demonstrated that the adverse 
behavioral outcomes resulting from MIA are mediated, at least in part, by IL-6 
(Smith et al., 2007; Lipina et al., 2013).  Indeed, maternal injection of IL-6 on its 
own, administered on E12.5, resulted in PPI and other behavioral deficits in adult 
offspring, while MIA (PolyI:C, 20mg/kg) in IL-6 knockout mice did not result in 
behavioral changes (Smith et al., 2007). Furthermore, co-administration of anti-IL-6 
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antibody with Poly(I:C) (20mg/kg) prevented the behavioral deficits caused by 
Poly(I:C) MIA (Smith et al., 2007).  This is consistent with a subsequent study 
utilizing a mutant mouse model combined with MIA: Disrupted-In-Schizophrenia-1 
(Disc1)-L100P
+/-
 mice were administered Poly(I:C) (5mg/kg) on E9 and the 
offspring demonstrated more profound behavioral deficits with the combination of 
genetic and environmental factors, compared to just the mutation alone, and co-
administration of anti-IL-6 antibody and Poly(I:C) prevented the schizophrenic 
behaviors in the offspring (Lipina et al., 2013).   
 
1.4.2 Latent Inhibition 
Latent inhibition (LI) is another attentional phenomenon found across species in 
which acquisition of a conditioned response is slower after pre-exposure to the 
conditioned stimulus.  Hence, LI demonstrates an organism’s ability to ignore 
irrelevant stimuli, and as such is a good measure of attentional processes or 
disruption of the same, and organisms with impaired attentional shifting express the 
LI effect in conditions where control animals do not (Weiner, 2003).  Attentional 
processes, including LI deficits are symptomatic in schizophrenia (Braff, 1993; 
Braunstein-Bercovitz et al., 2002).  Therefore, LI protocols are used in many rodent 
models of schizophrenia (Weiner & Arad, 2009), even though the translational 
validity has been scrutinized recently (Schmidt-Hansen & Le Pelley, 2012).  In MIA 
studies, a few different paradigms have been used to examine LI, including a 
drinking suppression after tone-shock pairing (Zuckerman et al., 2003; Zuckerman & 
Weiner, 2005; Piontkewitz et al., 2011a; Piontkewitz et al., 2011b) or else initiating 
a freezing conditioned response after tone-shock pairing (Meyer et al., 2006a; Meyer 
et al., 2006c).  MIA has resulted in adult LI deficits following in utero Poly(I:C) 
exposure in the rat (4mg/kg) on E15 or E17 (Zuckerman & Weiner, 2005).  This has 
also been demonstrated in the mouse, with LI deficits resulting from Poly(I:C) 
exposure on E9 (5 mg/kg) (Meyer et al., 2006c; 2008d; Lipina et al., 2010; 2011; 
2012), E12.5 (20mg/kg) (Smith et al., 2007), or E15 (4mg/kg) (Piontkewitz et al., 
2011a; 2011b).  Interestingly, LI deficits were not found in adolescent or young adult 
rats (P35, P45, P56), but they were seen at later ages in males (at P70 and P90) and 
females (at P90) following Poly(I:C) (4mg/kg) on E15, suggesting that effects of 
MIA on LI are sex and age dependent (Piontkewitz et al., 2011a).   
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1.4.3 Maze Testing 
The Morris water maze (MWM) is another of the more common behavioral assays in 
MIA studies.  It is a navigation task in which the animal is placed in a pool and must 
locate a platform, thus this behavioral assay provides a robust readout of spatial 
learning and memory (Mulder & Pritchett, 2003).  This test has been used to 
demonstrate a spatial learning deficit in adolescent rats (P28) that had been exposed 
to LPS (500 μg/kg) on E19 (Lanté et al., 2008).  This is in agreement with another 
study that found rat offspring had diminished platform acquisition in MWM 
following Poly(I:C) (8mg/kg) on E14-E18 (Vorhees et al., 2015).  Similarly, 
multiple exposure to prenatal cytokines (IL-6, 9 μg/kg) in middle (E8, 10 and 12) or 
late (E16, 18 and 20) pregnancy also decreased adult offspring (P140) spatial 
learning in MWM (Samuelsson et al., 2004; Samuelsson et al., 2006). Interestingly, 
the spatial learning differences commonly found in the MWM are exacerbated by 
age, as one study looked at young adult (3 month), adult (10 month) and aged (20 
month-old) rats after they had been exposed to prenatal LPS (0.79mg/kg) on E8, 10, 
and 12; the spatial learning and memory deficits observed in MIA offspring were 
more significant with age, implicating MIA in increased risk of memory 
deterioration in older age (Hao et al., 2010).  The MWM is also used to assess 
reversal learning by using a paradigm where the animal learns an initial 
discrimination task, and then they must learn to reverse this choice.  MIA has 
resulted in conflicting effects on reversal learning in rodents because maternal 
exposure to Poly(I:C) (4mg/kg) on E15 or E17 resulted in enhanced reversal learning 
in two different MWM tasks for rats (Zuckerman & Weiner, 2005).  However, others 
showed impaired reversal learning in the MWM following Poly(I:C) in mice 
(5mg/kg, on E17 (Meyer et al., 2006b) and in rats (8mg/kg, E14-E18 (Vorhees et al., 
2015)). As the timing of MIA was similar for all of these studies, one possible 
explanation for the differences is the dose of Poly(I:C) used and taken together these 
data might suggest that lower dose of Poly(I:C) leads to reversal learning benefits 
while a higher dose leads to detrimental effects.  Another use of the MWM can be to 
assess associative learning whereby a cue, such as a platform with a ball or flag 
mounted above the water, is used to help the animal find the platform.  In this 
scenario, researchers found no difference in cued learning for rats exposed to in 
utero Poly(I:C) (8mg/kg) from E14-E18 (Vorhees et al., 2015).  Certain cells of the 
entorhinal cortex and hippocampus, which work to map space outside of the 
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organism, increase in firing when rats approach a hidden platform MWM trials but 
not a cued platform (Vorhees & Williams, 2014), and perhaps this difference 
explains why rats exposed to MIA suffer in the hidden platform MWM task, but not 
in the cued protocol.  However, another group did find a decrease in associative 
learning in the cued water maze for adult mice that were exposed to LPS in utero 
(120 μg/kg) on E17 (Golan et al., 2005).  Rats and mice have demonstrated different 
abilities in water mazes previously (Whishaw & Tomie, 1996), with mice showing 
an inferior performance compared to rats as well as displaying off task behaviors that 
rats do not (Vorhees & Williams, 2014), and perhaps this predisposition to 
substandard performance in the behavioral assay is exacerbated by MIA in the 
mouse, accounting for the difference in results.    
 Dry mazes are also often used to assess memory of MIA offspring.  One such 
example, that is often used to assess spatial recognition memory, is the elevated y-
maze.  It is based on the principle that animals would rather explore a novel arm of 
the maze versus revisiting one they had previously encountered (Conrad et al., 
2003).  Mice exposed to Poly(I:C) (5mg/kg) in late gestation (E17) developed severe 
spatial learning and memory deficits as demonstrated by increased time exploring 
the familiar arm versus the novel one and compared to control animal times; these 
memory deficits are similar to those associated with Alzheimer’s disease (Krstic et 
al., 2012).  This is in agreement with others who have demonstrated decreased 
spatial and working memory performance in adult mice following exposure to 
Poly(I:C) (5 mg/kg) on E17 (Meyer et al., 2008d) and chronic LPS (8μg/kg) 
exposure from E8-E15 in the radial arm maze (Wang et al., 2010), which is similar 
to the y-maze except for having more arms to utilize in experimental design.  Finally, 
the elevated plus maze is a different test which provides key insight into the anxiety 
and/or depression levels of an animal.  It is based on the rodent characteristic 
aversion to open spaces, and animals with increased anxiety will avoid the open arms 
(Hogg, 1996; Costa et al., 2014).  MIA increased this anxiety behavior as MIA 
offspring that were expose to LPS (25μg/kg) on E9 had reduced time spent in the 
open arms of the elevated plus maze compared to control offspring (Depino, 2015).   
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1.4.4 Novel Object Recognition 
The novel object (NO) task is another memory assay in which the animal is 
presented with a familiar object and a novel one.  Control animals generally 
remember the familiar object and therefore spend more time investigating the new 
object, thus an animal that spends similar amounts of time with the two objects, or 
more time with the familiar object, is considered to have alterations memory 
function (Antunes & Biala, 2012).  MIA seems to affect this process in rats as those 
exposed to gestational LPS (0.5mg/kg, administered every other day E14-E20) 
demonstrated impaired NO recognition (Graciarena et al., 2010).  In agreement with 
this, rats exposed to Poly(I:C) (4mg/kg) on E15 had reduced NO preference 
compared to control animals (Wolff et al., 2011).  Importantly, this group 
demonstrated that the behavioral decline was not due to decreased preference for 
novelty, providing evidence that it is strictly a memory impairment (Wolff et al., 
2011).  Research with mice is in complete agreement with these findings, as 
decreased NO recognition has been demonstrated following in utero exposure to 
Poly(I:C) (5mg/kg) from E12-E17 in the affected adult mouse offspring (Ozawa et 
al., 2006).  Interestingly, LPS exposure in mice at E9 (300 μg/kg) resulted in 
increased exploration of the familiar object (Coyle et al., 2009), indicative of a 
memory deficit, while LPS administered at E17 (120 μg/kg) showed increased novel 
object recognition (Golan et al., 2005), suggesting that LPS exposure in middle 
pregnancy of mice leads to more detrimental memory outcomes in offspring 
compared to a later exposure.  
 
1.4.5 Social Interaction/ Communication 
Because social behavior deficits are common in ASD and schizophrenia, a social 
interaction test is commonly used in animal models of these disorders (Tordjman et 
al., 2007; Harvey & Boksa, 2012).  Many researchers have reported deficiencies in 
social interaction behaviors of offspring that were exposed to MIA in mid-
pregnancy.  For example, when two novel mice from the same experiment group 
were placed together for social interaction, mice born to mothers infected with 
influenza on E9.5 engaged in social interaction 2.7-fold less frequently than mice 
born to saline injected mothers (Shi et al., 2003).  Aside from this basic experimental 
paradigm, most other social interaction assessments utilize the three chamber 
apparatus to compare the time a rodent spends investigating each area, and these 
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compartments will hold a similar or novel animal, a novel object, or else remain 
empty (Silverman et al., 2010).  These different experimental paradigms provide 
evidence for different aspects of social behavior.  For example, preference for a 
novel or familiar mouse assesses social memory and ability for the animal to 
discriminate familiar or novel social stimuli (O’Tuathaigh et al., 2007).  
Interestingly, this paradigm showed no differences between mice exposed to MIA 
(Poly(I:C), 5mg/kg) or saline on E9 (Lipina et al., 2013), suggesting that MIA does 
not affect social memory.  In another paradigm, preference for another animal over 
an empty chamber indicates social motivation (Brodkin et al., 2004). Utilizing this 
protocol, mice exposed to Poly(I:C) on E9 (5mg/kg)(Lipina et al., 2013), on E9.5 
(20mg/kg) (Soumiya et al., 2011a), or on E12.5 (Smith et al., 2007) showed a 
decline in motivation for social interaction as they opted to spend more time in a 
chamber with only an empty cylinder rather than a interacting with a novel same-sex 
mouse.  The final experimental paradigm, which compares the time a rodent spends 
with a novel object versus an unfamiliar animal, is one of the most common 
experimental procedures because this paradigm does not require memory functioning 
(Malkova et al., 2012) and because it is thought to mirror human ASD symptoms in 
that a socially impaired animal will spend more time investigating the novel object 
compared to the other animal (Silverman et al., 2010).  Indeed, one group saw this 
social interaction deficit in adult MIA offspring that had been exposed to Poly(I:C) 
(5mg/kg) on E10.5, 12.5, and 14.5 (Malkova et al., 2012).   
This group went a step further by investigating communication behaviors, 
including acoustic and chemical signals, as these communication techniques are 
important to rodent social behavior (Malkova et al., 2012) and deficits in 
communication are also characteristic of ASD (APA 2013).  In this study, MIA male 
and female pups born to mothers who were administered Poly(I:C) (5mg/kg, on 
E10.5, 12.5, and 14.5) demonstrated deficits in the total number and syllable 
repertoire of ultrasonic vocalization (USV)s, and adult males had reduced USV 
response to social stimuli (Malkova et al., 2012).  This is entirely consistent with 
another group that has found communication deficits in male rat pups and social 
interaction impairments in adult offspring following in utero LPS exposure 
(100μg/kg) on E9.5 (Kirsten et al., 2010b; Kirsten et al., 2012; Kirsten et al., 2015).  
Furthermore, as scent marks (urinary traces) are used to identify mice, mark 
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territory, and attract mates, olfactory communication is also important for mice 
(Hurst, 2009).  MIA males showed diminished olfactory communication as they 
deposited half scent marks compared to controls when stimulated with female urine 
(Malkova et al., 2012).  Taken together, these impairments in social interactions and 
associated communication behaviors may be indicative of numerous symptoms 
observed in people with ASD, further validating these preclinical models for 
disorders associated with MIA.  
 
1.4.6 Open Field and Pharmaceutical Treatments 
Locomotion and exploratory behaviors have also been assessed following MIA 
because these behaviors can provide information on motor functioning and anxiety 
in test subjects (Eilam, 2003; Prut & Belzung, 2003).  Locomotor activity in an 
arena, termed the “open field” (OF) test, was increased at 3 months, but decreased at 
17 months in adult rats following prenatal exposure to LPS (1mg/kg) on E10.5, 
indicating a greater age-related decline in motor functioning in animals exposed to 
LPS in utero compared to control animals (Ling et al., 2009).  Furthermore, 
influenza exposure on E9.5 (Shi et al., 2003; Moreno et al., 2011) and Poly(I:C) 
exposure on E12.5 (20mg/kg) (Smith et al., 2007) resulted in decreased OF 
exploration in adult mice.  Depending on the measurement, decrease exploration can 
also be indicative of anxiety-like behavior as a more anxious animal will tend to 
avoid the center of the arena (Prut & Belzung, 2003).  Hence, some researchers have 
reported increased anxiety in offspring exposed to MIA in mid pregnancy using the 
OF test, including mice exposed to LPS (25μg/kg on E9) (Depino, 2015) or 
Poly(I:C) (20mg/kg on E9.5) (Soumiya et al., 2011a).  Inconsistent findings are 
prevalent with the OF test, however, as another group reported increased locomotor 
activity in adult mice following Poly(I:C) on E17 (2mg/kg) (Vuillermot et al., 2012).   
OF testing is not always a simple case of placing an animal in an arena, and 
indeed pharmaceuticals are often used in OF behavior assessments as they can 
exacerbate subtle differences in motor functioning (Bernardi et al., 1986; Jackson et 
al., 1994; Rodríguez et al., 2013) and because excessively increased amphetamine 
(AMPH)-induced activity is considered to mimic the exacerbation of psychotic 
symptoms following AMPH exposure in people with schizophrenia (Laruelle et al., 
1996).  One group showed an increase in adult rat AMPH-induced locomotion 
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following an LPS model of MIA (50 or 100 μg/kg) on E18 and E19 (Fortier et al., 
2007).  This was confirmed by multiple groups using Poly(I:C) MIA models which 
demonstrated increased AMPH, methamphetamine (MAP) and/or MK-801 (N-
methyl-D-aspartate (NMDA) agonist) induced locomotion following in utero MIA 
exposure in rats (4 mg/kg, on E15 or E17) (Zuckerman et al., 2003; Zuckerman & 
Weiner, 2005; Piontkewitz et al., 2011a; Piontkewitz et al., 2011b) and mice (2 or 5 
mg/kg, on E9 or E17 (Meyer et al., 2007; Meyer et al., 2008d); 5mg/kg, E12-17 
(Ozawa et al., 2006)).  However, there is some inconsistency in the literature as 
some have reported that MIA resulted in decreased response to pharmaceuticals.  For 
example, reduced AMPH-induced locomotion was observed for adult rats exposed to 
Poly(I:C) (8mg/kg) on E14 (Richtand et al., 2011), and locomotion response to MK-
801 was reduced in pre-pubescent rat offspring following in utero Poly(I:C) 
(4mg/kg) exposure on E15 (Howland et al., 2012).  Interestingly, maternal starting 
weight predicted the weight change in response to Poly(I:C) administration (8mg/kg 
on E14), which was associated with differential progeny responses to dopaminergic 
and glutamatergic drug challenges (Bronson et al., 2011; Vorhees et al., 2012).  
Specifically, one study showed that maternal weight loss resulted in decreased 
locomotion response to AMPH and MK-801, whereas absence of maternal weight 
loss following Poly(I:C) injection resulted in increased locomotion response to MK-
801 and similar performance to controls following AMPH administration (Bronson 
et al., 2011).  However, another study demonstrated that the Poly(I:C)/maternal 
weight loss group exhibited exaggerated hyperactivity response to AMPH, and an 
attenuated hyperactivity response to MK-801 (Vorhees et al., 2012).  It is of note 
that these studies had opposite results with regards to AMPH responding even 
though the MIA and offspring behavior protocols were identical (same dose, timing, 
rout), suggesting there are more environmental or genetic factors which need to be 
elucidated in order to have replicable models across laboratories.  Even though the 
direction of response is unconfirmed for many of these pharmaceutical treatments, 
the evidence still clearly shows that MIA affects the responsiveness to drugs in 
affected offspring, and that in and of itself is of huge importance with regards to drug 
addiction and schizophrenia where altered response to drugs may play a role 
(Hambrecht & Häfner, 1996; Chambers et al., 2001).   
Along similar lines, serotonin and glutamate systems are hypothesized to be 
involved in schizophrenia etiology (Aghajanian & Marek, 2000; Rao et al., 2012; 
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Selvaraj et al., 2014), and are also required for anti-psychotic drug function (Jakab & 
Goldman-Rakic, 1998; Aghajanian & Marek, 1999; De Bartolomeis et al., 2013).  
While not applied in an OF paradigm, hallucinogens have also been administered to 
MIA offspring to investigate motor drug-response consequences of MIA.  In 
response to hallucinogens (which require the serotonin 5-HT(2A) receptor), mice 
exposed to the influenza virus on E9.5 had increased head-twitch responses, and this 
was associated with upregulated 5-HT(2A) receptor (Moreno et al., 2011).  This 
study also showed a diminished antipsychotic effect of metabotropic glutamate 
receptor (mGlu(2)) agonist with an associated down regulated mGlu(2) receptor in 
the same offspring (Moreno et al., 2011).  These data further suggest that MIA may 
affect the ability of the offspring to respond normally to pharmaceuticals due, at least 
in part, to differential receptor phenotypes.  The difference in these OF and 
pharmaceutical administration studies results emphasizes yet again the incongruent 
findings observed from different animal models. The need for more in depth studies 
that closely monitor and compare effects of experimental differences as well as 
studies that will help to elucidate which environmental factors exacerbate MIA 
effects on fetal outcome is becoming ever more important.    
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Reference 
Animal 
Model 
Immunogen, 
Dose, Rout 
Timing Key Findings 
Smith, 2007 Mouse 
Cytokine 
IL-6, 5 μg in 200 
μl 0.9% saline  
I.P.; or Poly IC, 
20 mg/kg, IP 
E12.5 IL-6: ↓ PPI, LI (adult offspring); Poly IC: ↓ PPI, LI, 
OF exploration, social interaction (adult age); Co-
administration of anti-IL-6 antibody with poly (I:C) 
prevents the deficits caused by poly I:C (adult) 
Moreno, 2011 Mouse 
Influenza 
Influenza 
(H1N1), 5*103 
pfu IN 
E9.5 ↓ locomotor activity, ↑ head-twitch after 
hallucinogen, ↓ antipsychotic effect of glutamate 
agonist (10-12 weeks) 
Shi, 2003 Mouse 
Influenza 
Influenza, IN; or 
Poly IC, 20 
mg/kg, IP 
E9.5 Flu: ↓ PPI, OF and NO exploration, social behavior 
(P28-56); Poly IC: ↓ PPI (P42-P56) 
Coyle, 2009 Mouse 
LPS 
LPS, 300 μg/kg 
SC 
E9 ↑ exploration of familiar vs novel object (P85) 
Depino, 2015 Mouse 
LPS 
LPS, 25μg/kg, 
SC 
E9 ↑ anxiety/depressive behaviors: avoided open arms in 
EPM, center of OF, and the light side of light/dark 
box; ↑ immobility in forced swim test and tail 
suspension (8-10 wks old at start) 
Golan, 2005, 
2006a,b 
Mouse 
LPS 
LPS, 120 μg/kg, 
IP 
E17 ↓ learning in cued water maze, ↑ novel object 
recognition, ↑ anxiety, ↓ passive avoidance (P240), ↑ 
OP exploration (P240, P600) 
Wang, 2010 Mouse 
LPS 
LPS, 8μg/kg, IP E8-E15, 
Daily  
↓ learning and retention radial arm maze, altered OF 
and burrowing/hoarding, impaired beam walking 
(P70, P200, P400, P600) 
Bitanihirwe, 2010 Mouse 
Poly IC 
Poly IC, 5 
mg/kg, IV 
E17 ↓ Social interaction, ↑ anhedonia in sucrose 
preference, ↑ LI, alterations in locomotor and 
stereotyped behaviors following APO treatment (8 + 
wks) 
Lipina, 2010, 2011, 
2012, 2013 
Mouse 
Poly IC 
Poly IC, 
2.5mg/kg or 
5mg/kg, IV 
E9 ↓ cognitive and social behavior; ↓ PPI (14-16wks); 
Disc1-L100P+/- mutants > sensitivity to MIA vs WT 
or Disc1-Q31L+/- (7-15 wks) 
Makinodan, 2008 Mouse 
Poly IC 
Poly IC, 
60mg/kg, IP 
E9.5 ↓ PPI (P63) 
Malkova, 2012, 
2014 
Mouse 
Poly IC 
Poly IC, 5mg/kg, 
IP 
E10.5, 
E12.5, and 
E14.5 
↓ USVs (P9 and adult), ↓ socializing and 
communicating behaviors, ↑ marble burying, ↑ self-
grooming, ↓ PPI of startle response, ↑ sensitivity to 
hallucinogenic drug DOI = similar to schizophrenia 
(8-10 weeks old) 
Meyer, 2006a,b, 
2008b,c,d 
Mouse 
Poly IC 
Poly IC, 2 or 5 
mg/kg, IV 
E9 or E17 E9: ↓ PPI, ↑ startle response, ↓LI, OF exploration, ↑ 
AMPH and/or MK801 induced locomotion (P35, 
P90-P120); E17: ↓ reversal learning of L-R 
discrimination; ↓ working memory in water maze; ↑ 
AMPH and MK801 induced locomotion (P98-P112) 
Ozawa, 2006 Mouse 
Poly IC 
Poly IC, 5 
mg/kg, IP 
E12-E17 ↓ PPI, thigmotaxix, NO recognition; ↑ MAP-induced 
locomotion (P63-P70) 
Soumiya 2011 Mouse 
Poly IC 
Poly IC, 
20mg/kg, IP 
E9.5 ↑ anxiety in OF, ↓ Social interaction (P56-63) 
Vuillermot 2010, 
2011, 2012 
Mouse 
Poly IC 
Poly IC, 5mg/kg 
or 2mg/kg, IV 
E9 or E17 ↑ OF locomotion, ↑ AMPH-induced locomotion, 
altered apomorphine-induced locomotion, ↓ PPI 
(adult), ↑ LI, visual discrimination task, ↓ working 
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memory in dry maze, (P30 and P70) 
Wolf, Susanne, 
2011 
Mouse 
Poly IC 
Poly IC, 5mg/kg, 
IP 
E15 Voluntary exercise (P50) rescues behavioral deficits 
in  PPI, OF (P90) 
Samuelsson, 2004, 
2005, 2006 
Rat 
Cytokine 
IL-6, 9 μg/kg IP E8, E10, 
&E12 OR 
E16, E18, 
&E20 
abnormal/extended stress responses to restraint and 
novel environment and CRF/ACTH stimulation in 
adulthood; ↓ special learning in Morris water maze 
(P140) 
Borrell, 2002 Rat LPS LPS, 1mg/kg, SC Alternate 
days whole 
pregnancy 
↓ PPI (P70, P100, P300) 
Fortier, 2004, 2007 Rat LPS LPS, 50 or 100 
μg/kg, IP 
E15 and E16 
or E18 and 
E19 
↓ PPI; just E18/E19: ↑ AMPH induced locomotion 
(P70) 
Girard, 2009, 2010 Rat LPS LPS, 200 μg/kg, 
IP 
2X/day from 
E17 to birth 
↓ latency to fall off rotarod (P30, P35, P40) 
Graciarena, 2010 Rat LPS LPS, 0.5mg/kg, 
SC 
Every other 
day E14-E20 
↓ NO recognition (>P60) 
Hao, 2010 Rat LPS LPS, 0.79mg/kg 
IP 
E8, 10 and 
12 
↓ spatial learning and memory (3, 10 and 20 month 
old) 
Kirsten, 2010, 
2012, 2015 
Rat LPS LPS, 100 μg/kg, 
IP 
E9.5 ↓ general activity in OF aft immune challenge; ↓ 
Social Interaction, T-maze learning and memory 
(adults); ↓ communication (P11); Treatment of zinc 
post LPS prevented USV impairment;  no difference: 
plus maze; normal OF, apomorphine stereotypy, nor 
haloperidol induced catalepsy 
Lanté, 2007, 2008 Rat LPS LPS, 500 μg/kg, 
IP 
E19 ↓ Spatial learning in water maze (P28) 
Ling, 2009 Rat LPS LPS, 1mg/kg, IP E10.5-E11 ↑ locomotor activity (P90), ↓ locomotor activity 
(P480) 
Liu, 2004 Rat LPS LPS, 1mg/kg, SC Alternate 
days whole 
pregnancy 
↑ ethanol intake and preference, ↓ rearing (P100-
P130) 
Romero, 2007, 
2010 
Rat LPS LPS, 2 mg/kg, 
SC 
Daily whole 
pregnancy 
↓ PPI (P35, P70, P170, P180, P400) 
Wijkstra, 1991 Rat LPS LPS, 0.2 or 2.0 
μg/ pregnant 
dam, IV 
E18 ↑ latency to initiate sexual behavior; ↓ intromission 
by males (P91) 
Bronson, 2011 Rat Poly 
IC 
Poly IC, 8mg/kg, 
IP 
E14 Maternal weight  loss = ↓ MK-801 and AMPH 
locomotion; no maternal weight loss =  ↑ MK-801 
locomotion, AMPH locomotion similar to control 
Dickerson, 2010 Rat Poly 
IC 
Poly IC, 4mg/kg, 
IV 
E15 ↓ PPI (3months) 
Howland, 2011; 
Zhang, 2012 
Rat Poly 
IC 
Poly IC, 4mg/kg, 
IV 
E15 ↓PPI, ↓ MK-801 induced locomotor activity (P35-36 
and P56-57); ↓ object-in-place memory (>P60); 
Impaired cognitive flexibility (males only) in operant 
paradigm (P53) 
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Mattei, 2014 Rat Poly 
IC 
Poly IC, 4mg/kg, 
IV 
E15 ↓ PPI and startle response (P90-98) 
Missault, 2014 Rat Poly 
IC 
Poly IC, 4mg/kg, 
SC 
E15 Mothers lost weight = deficits in: PPI; locomotor 
activity w/ AMPH, y w/out AMPH, w/ MK-801, 
w/out MK-801; ↓ sucrose preference; Mothers gained 
weight = no clear behavioral deficits (P76-104) 
Piontkewitz, 2011a, 
2011b 
Rat Poly 
IC 
Poly IC, 4mg/kg, 
IV 
E15 ↓ LI, ↑ AMPH induced activity (P35, 46, 56, 70, 90) 
Richtand, 2011 Rat Poly 
IC 
Poly IC, 8mg/kg, 
IP 
E14 ↓ response to AMPH in locomotion (P90) 
Van den Eynde, 
2014 
Rat Poly 
IC 
Poly IC, 4mg/kg, 
IV 
E15 No difference in  PPI; ↓ basal startle response and 
spontaneous locomotion (P56, 90,  and 180) 
Vorhees, 2012, 
2015 
Rat Poly 
IC 
Poly IC, 8mg/kg, 
IP 
E14 or E14-
E18 
Acute exposure: no effect on elevated zero maze, OF, 
object burying, light-dark test, swimming, MWM, 
cued fear, LI;  females of MIA+ mat weight gain 
group had ↓ cued water maze; MIA+ mat weight loss 
had ↑ hyperactivity to AMPH, ↓ hyperactivity to 
MK-801 (P65-70). Chronic exposure: NS outcomes 
w/= elevated zero maze, OF locomotion, marble 
burying, straight swimming channel, Cincinnati water 
maze, MWM, conditioned fear; ↑ PPI, ↓ time on dark 
side of light-dark test, ↓ Morris water maze 
acquisition,  ↑ OF AMPH, ↓ OF MK-801 (P65-92) 
Wolff, Amy 2008, 
2010, 2011 
Rat Poly 
IC 
Poly IC, 4 
mg/kg, IV 
E15 ↓ PPI, ↓NO memory (P56) 
Zuckerman, 2003; 
Zuckerman and 
Weiner, 2003, 2005 
Rat Poly 
IC 
Poly IC, 4 mg/kg 
IV 
E15 or E17 ↓ LI, ↑ reversal learning of L-R discrimination, ↑ 
AMPH and MK801 induced locomotion (P90) 
Table 1: Behavioral changes observed in offspring following MIA 
Table summarizing a wide sample of literature that has investigated the effects of 
MIA on behavioral characteristics of offspring.  In the “key findings” column the age 
at which offspring were tested is listed in parenthesis.  
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1.5 Effects of MIA on Brain Development 
In order to understand how or why the aforementioned behavioral alterations occur, 
researchers utilize animal models to better understand the morphological, molecular, 
and neurochemical changes resulting from in utero exposure to MIA.  Indeed, these 
investigations provide some of the most important evidence for determining the role 
of MIA in fetal programming and the neuroanatomical basis of the etiology of 
neurological impairments.   
 
1.5.1 Cytokine Profiles 
The first focus of many MIA studies includes analyzing the immune response in 
offspring by examining the expression of immune biomarkers in the brain and/or 
serum samples of the offspring.  This is because cytokines are important in cell 
signaling, they are produced by immune cells, and they have been implicated in 
neurodegenerative disease (Capuron & Miller, 2011; Smith et al., 2012).  Some 
researchers have reported acute (within 24h) increases in mRNA for IL-1β and TNF-
α in the fetal rat brain following MIA on E18 induced by LPS (4mg/kg (Cai et al., 
2000); 0.7 or 1mg/kg (Paintlia et al., 2004)).  However, inconsistent results have also 
demonstrated a decrease in TNF-α in whole fetal rat brain following LPS (2.5mg/kg) 
(Urakubo et al., 2001) or Poly(I:C), (10 or 20 mg/kg) (Gilmore et al., 2005) on E16.   
Furthermore, lower doses of LPS (100μg/kg (Gayle et al., 2004) or 50μg/kg 
(Ashdown et al., 2006)) on E18 resulted in no change in cytokine profiles in fetal rat 
brain for IL-1β, TNF-α, IL-6, and IL-10.  This has also been investigated in mouse 
models of MIA.  In this model, LPS (120 μg/kg (Golan et al., 2005); 500 μg/kg 
(Ning et al., 2008)) on E17 resulted in increased TNF-α and IL-6 in the fetal mouse 
brain.  Another study analyzed fetal brains 6h post administration of Poly(I:C) 
(20mg/kg) to pregnant mice on E16 and found increased levels of cytokines: IL-1β, 
IL-7, and IL-13; and chemokines: monocyte chemoattractant protein 1 (MCP-1), 
macrophage inflammatory protein (MIP)-1α, interferon gamma-induced protein (IP)-
10, and monokine induced by IFN-γ (MIG) (Arrode-Brusés & Brusés, 2012).  Also, 
Poly(I:C) administration (2 or 5 mg/kg) to pregnant mice on E9 increased fetal brain 
IL-1β, IL-6, and TNF-α levels, while it decreased IL-10 levels, and administration on 
E17 increased IL-1β and IL-6 (but not TNF-α) and also increased IL-10 (Meyer et 
al., 2006b; Meyer et al., 2008d), further implicating that the timing of MIA exposure 
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is critical to fetal outcome.  Therefore, even though the cytokine profiles of fetal 
brains can be quite different depending on dose, timing of immunogen exposure, as 
well as timing of cytokine measurement, it is clear that MIA alters this complex 
system.   
Importantly, cytokine alterations are not only apparent in fetal brains, but 
also characteristic of MIA offspring all the way through to adulthood.  For example, 
IL-2 and IL-6 serum levels were increased in adult rat offspring exposed to prenatal 
LPS (1mg/kg, alternate days whole pregnancy) (Borrell et al., 2002), and IL-1β and 
TNF-α were upregulated in adult rat brains that were exposed to maternal 
administration of Poly(I:C) (4mg/kg) on E15 (Mattei et al., 2014).  Furthermore, 
transforming growth factor beta (TGF-β) plays a role in proliferation and cellular 
differentiation and this cytokine was down regulated in the adult brains of rats 
exposed to in utero LPS (0.5mg/kg; every other day from E14-E20), suggesting a 
potential mechanistic role for TFG-β in the altered proliferation observed in MIA 
models (Graciarena et al., 2010).  Another, and more comprehensive study, looked at 
the effects of Poly(I:C) (20mg/kg) administration on E12.5 on mouse offspring 
levels of 23 different cytokines in the frontal cortex, cingulate cortex, hippocampus, 
and serum across the progeny lifespan (P0, P7, P14, P30, and P60), and found that 
most of the cytokines analyzed were altered in a region- and age-specific manner 
(Garay et al., 2013).  Specifically, several pro- and anti-inflammatory cytokines were 
elevated compared to controls in frontal and cingulate cortices at birth, decreased 
during adolescence, but then a few cytokines increased again in adulthood (Garay et 
al., 2013).  Interestingly, the hippocampus had distinct cytokine profile differences 
for MIA offspring, including both increased and decreased levels of different 
cytokines at every age except adult (Garay et al., 2013).  These data correspond with 
the knowledge that cytokines are part of intricate feedback loops which strive to 
maintain cytokine levels within a homeostatic range (Careaga et al., 2010).  As it is 
such a complex and dynamic system it makes sense that there will be increases in 
some cytokines while others are decreased, but again the key finding of importance 
is that MIA seems to substantially alter the cytokine profiles of its offspring during 
development and throughout the course of life.   
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1.5.2 Structural Alterations 
Work from Fatemi et al pioneered the investigation into structural consequences of 
in utero exposure to MIA.  They noted decreased neocortical and hippocampal 
thickness following human influenza infection on E9 in mice (Fatemi et al., 1999), 
and later confirmed this idea when the same group showed significant brain atrophy 
(~4%) in numerous regions of P35 mice that had been exposed to MIA on E18 
(Fatemi et al., 2008).  Others have similarly demonstrated alterations in brain region 
size post MIA; for instance, Poly(I:C) (4mg/kg) on E15 in the rat resulted in progeny 
with decreased volume of the hippocampus, striatum, and prefrontal cortex, as well 
as an increased ventricular volume (Piontkewitz et al., 2011a; Piontkewitz et al., 
2011b).  In agreement with this, MRI scans of humans demonstrated decreased  
cerebral volume and increased ventricular volume in schizophrenia patients (Wright 
et al., 2000), suggesting that altered volume of brain regions may be a physiological 
characteristic for MIA associated disorders.  
Aside from the volume analysis, other generalized morphology studies have 
been conducted in MIA models.  For example, animal studies have investigated 
MIA-induced lesions and altered white matter development following MIA as 
neonatal brain lesions are associated with CP (Dammann & Leviton, 1998; Bangash 
et al., 2014).  MIA (LPS, 300μg/kg, E19 and E20) lead to significant white matter 
injury in young rat pups (P1 or P7), consistent with the proposed pathophysiology of 
CP in humans (Rousset et al., 2006).  Interestingly, MIA has also been associated 
with cerebral cortical lesions, characterized by shrunken neuronal cell bodies and 
nuclei, described in rat pups (P3, P8) following maternal administration of LPS (200 
μg/kg) twice per day E17 through to birth (Larouche et al., 2005).  PVL was shown 
to be followed by impaired cerebral cortical development (Inder et al., 1999) and 
gray matter lesions occurred in a third or more of PVL cases in premature infants, 
suggesting that white matter lesions may not occur in isolation, implicating more 
adverse outcomes of MIA as well as a more complex pathophysiology for CP 
(Pierson et al., 2007).  Because white matter is largely made up of myelinated axons, 
this has also been studied with regards to MIA.  For example, delayed postnatal 
myelination has been observed in the whole brains of adult mouse offspring (P84) 
exposed to Poly(I:C) (5mg/kg) on E9 or E17 (Li et al., 2010), and also decreased 
myelin basic protein staining and decreased myelin thickness was observed in the 
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hippocampus of juvenile mouse offspring (P14) exposed to Poly(I:C) (60mg/kg) on 
E9.5 (Makinodan et al., 2008).  MIA appears to promote a decrease in brain 
complexity as seen by this myelin data, and also because prenatal LPS exposure 
(0.79mg/kg) promoted synaptic loss, shown by decreased synaptophysin (integral 
regulator of synaptic vesicle function and neurotransmitter release) staining in the 
hippocampus of 3-,10-, or 20-month old rat offspring (Hao et al., 2010).  
Furthermore, MIA resulted in decreased hippocampal neurogenesis in rats following 
LPS (50 or 100 μg/kg, E18 and E19, (Cui et al., 2009)) or Poly(I:C) exposure 
(4mg/kg on E15 (Mattei et al., 2014)).  In agreement with these findings, diminished 
hippocampal neurogenesis was found in adult mice exposed to Poly(I:C) (5mg/kg) 
on E9, E17(Meyer et al., 2006b), or E15 (Wolf et al., 2011).  However, others did 
not find differences in adult hippocampal neurogenesis of MIA exposed mice (LPS, 
25μg/kg, on E9) (Depino, 2015), though the dose of LPS in this later study may have 
been too low to produce the same results as the larger doses of LPS or Poly(I:C).  
Taken together, these studies provide evidence that hippocampal alterations are 
apparent across the lifespan of affected offspring.  Furthermore, it is evident that 
MIA can result in large structural and developmental alterations in the developing 
brain. 
 
1.5.3 Cellular Discrepancies 
The structural differences discussed presumably stem from developmental 
disturbances affecting specific cell types.  Indeed, a decrease in total proliferating 
cells and numbers of immature neurons has been observed in the dentate gyrus 
following MIA in later pregnancy (LPS; 0.5mg/kg; every other day E14-E20) 
(Graciarena et al., 2010).  More specifically, hippocampal γ-Aminobutyric (GABA) 
neurons seem to be affected by MIA.  Indeed, numbers of glutamic acid 
decarboxylase 67 (GAD67)- and reelin- (markers for GABA neurons) 
immunoreactive neurons were counted in the hippocampus from pre-adolescent 
brains following MIA exposure on E15 and E16 (LPS, 100 μg/kg), and they found 
decreased numbers of GAD67 and reelin immunoreactive cells in the dentate gyrus 
on P14, and decreased GAD67 positive cells in the dentate gyrus and CA1 on P28 
(Nouel et al., 2012).  This is consistent with findings in mice exposed to MIA on E9, 
as those offspring demonstrated reduced reelin-positive cells in the hippocampus at 
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P24 (Poly-I:C, 5mg/kg, (Meyer et al., 2006b)) as well as specifically in the dentate 
gyrus in adult offspring (LPS, 25μg/kg, (Depino, 2015)).  The hippocampus is not 
the only brain region with these neurons, though, and indeed MIA leads to 
alterations in other areas.  For example, alterations in Purkinje neuron (a GABA 
neuron) number, size, and density have been demonstrated in the cerebellums of 
offspring exposed to Poly-I:C (20mg/kg) on E12.5 (Shi et al., 2009) as well as 
prenatal influenza in early (E9) or later (E16) pregnancy (Fatemi et al., 1999; 2002c; 
2009).   
Along similar lines, one group investigated the morphological consequences 
of MIA on cortical neurons, as inhibitory neurons of the cerebral cortex commonly 
signal via GABA (Ascoli et al., 2008), and in this study, pregnant mice received an 
injection of Poly(I:C) (20mg/kg) on E9.5 and offspring brains were analyzed with 
BrdU labeling to determine the fraction of proliferating cells within the entire cell 
population as well as information on the cell cycle one week post MIA (Soumiya et 
al., 2011b).  The later stages of corticogenesis were affected following MIA, in that 
cell-cycle parameters and gene expression of daughter neurons were altered 
(Soumiya et al., 2011b).  They hypothesized that this altered corticogenesis lead to 
the altered synaptic development of upper-layer neurons (but not deeper layer) found 
in the cerebral cortex following MIA they found in a previous paper (Soumiya et al., 
2011a).   
Along with GABA neurons, DA neurons are also a specific neuron type 
investigated in MIA studies.  Cultures of rat mesencephalic neurons from rat 
offspring at E14.5 and P21 that were exposed to maternal LPS (1mg/kg) on E12.5 
demonstrated decreased numbers of tyrosine hydroxylase (TH; a marker for DA 
neurons) immunoreactive cells in the E14.5 cultures and in P21 SN and ventral 
tegmental area (VTA) (Ling et al., 2002), findings which were confirmed in 
numerous follow up studies by the same group (Ling et al., 2004; Ling et al., 2006; 
Ling et al., 2009).  In agreement with this, cultures from rat offspring exposed to 
LPS on E10, E14 or E18 demonstrated an accelerated loss of DA cells in the cultures 
over time compared to the control cultures, and the E10 exposure also resulted in 
impaired dopaminergic innervation into the striatum (Snyder-Keller & Stark, 2008).  
In vivo assessments further demonstrated the toxic effects of LPS (1mg/kg, on 
E10.5) because SN slices examined from numerous ages showed a persistent loss in 
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DA neurons across the lifespan (P21, up to 16 months), as measured by stereological 
cell counts of TH immune-positive cells (Carvey et al., 2003), and this was 
replicated in other papers from the same lab (Ling et al., 2006; Ling et al., 2009), 
Importantly, this study also showed that there was not an accelerated rate of DA 
neuron loss in the LPS animals, as researchers hypothesized, suggesting that MIA 
does not alter the normal rate of DA neuron loss with age (Ling et al., 2009).  
However, there were Lewy body like inclusions in the older adult animals along 
which may suggest a role for MIA in the morphological characteristics associated 
with PD symptomology.  Other groups have found conflicting results regarding the 
effects of MIA on DA neurons, however. For example, some have demonstrated an 
increase in DA cell numbers, measured by TH and dopamine transporter (DAT) 
positive neurons in the mouse fetal mesencephalic flexure at E11, E13, and E17 as 
well as increased TH immunoreactivity in adult striatum and nucleus accumbens 
(DA innervated regions), following Poly(I:C) (5mg/kg) administration to the mothers 
on E9 (Meyer et al., 2008a; Winter et al., 2008).  Furthermore, an increase in TH 
immunoreactivity in the shell of the nucleus accumbens and in the bed nucleus of the 
stria terminalis was observed from rats exposed to prenatal LPS (1mg/kg) every 
other day throughout the entire pregnancy (Borrell et al., 2002).  Importantly, these 
groups were interested in different regions brain and this may explain the 
discrepancy in results.  Indeed, the effects of MIA on DA neurons may be locally 
specific, with MIA exposure resulting in decreased DA neuron numbers in the SN, 
and increased numbers in the nucleus accumbens.   
MIA does not only affect the neuronal population within the brain, but also 
glial cell types.  For example, studies that investigated more specific disturbances in 
white matter development resulting from MIA, found decreased numbers of 
oligodendrocyte precursor cells, immature oligodendrocytes, as well as increased 
cell death and decreased myelin basic protein staining following administration of 
LPS to mothers in late pregnancy (E18-20) in the rat (700 μg/kg or 1mg/kg (Paintlia 
et al., 2004; Paintlia et al., 2008); 300 or 400 μg/kg (Rousset et al., 2008).  Hence, 
the previously mentioned disturbances in myelination are a possible consequence of 
the disrupted oligodendrocyte development as these are the main myelin producing 
cells.  Subsequent studies have also investigated astrocytes and microglia.  In one 
such example, immunohistochemistry of P8 hippocampus and cortex from rat pups 
following exposure to MIA (500μg/kg LPS) on E18 and E19 demonstrated increased 
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glial fibrillary acidic protein (GFAP) positive astrocytes, decreased OX-42 (type 3 
complement receptor) positive microglia, however there was no change in tomato 
lectin staining of amoeboid and ramified microglia in compared to control group, 
providing somewhat inconclusive glial morphological information (Cai et al., 2000).  
Following this, other groups have conclusively determined increased microglial 
activity and astrogliosis following MIA.  For example, one group found increases in 
hippocampal microglia at birth in mouse offspring exposed to prenatal LPS (120 
μg/kg on E15) (Roumier et al., 2008).  Another group showed astrogliosis, 
associated with elevated IL-1β, postnatal cell death, and hypomyelination in 1 week 
old pups following LPS (300 μg/kg) on E19 and E20 (Rousset et al., 2006).  A 
subsequent study later related these findings to CP symptoms in that rats exposed to 
LPS in utero displayed exacerbated responses to intracerebroventricular injections of 
ibotenate (a CP model) with a noted increase in microglial markers, astrogliosis, and 
reduced white matter myelination (Rousset et al., 2008).   
Others have demonstrated similar findings across the lifespan.  For example, 
Ling and colleagues administered LPS (1mg/kg) on E11 and analyzed the 
morphology of rat offspring whole brains 4, 14, and 17 months after birth; their 
results showed an increase in total microglia numbers as well as greater than normal 
amounts of these cells in their active or amoeboid form (OX-6ir positive) (Ling et 
al., 2009).  Subsequent studies have looked into specific brain regions and results 
from these studies suggest that the changes following MIA are age and region 
dependent.  For example, one study stained sections of frontal cortex, cingulate 
cortex, and hippocampus, from mouse offspring exposed to Poly(I:C) (20mg/kg) on 
E12.5, at P0, P7, P14, P30, and P60 and found no differences in microglial 
morphology compared to controls in any region or at any age (Garay et al., 2013).  
Then, at around 4 months of age (~P120), microglial density in rat brains does not 
differ from that of controls in the hippocampus, medial prefrontal cortex, ventral 
striatum, cingulate cortex, and cerebellum, but the microglial density was increased 
in the nucleus accumbens at this age, following in utero exposure to Poly(I:C) 
(4mg/kg) on E15 (Mattei et al., 2014).  Finally, in aged rat offspring (>P180) that 
were exposed to Poly(I:C) (4mg/kg) on E15, microglia density was increased in the 
hippocampus, corpus callosum, pons and thalamus (Van den Eynde et al., 2014).  
Persistent microglial activation in the adult hippocampus of affected offspring has 
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been reported by others, including rats exposed to LPS (0.5mg/kg) every other day 
from E14-E20 (Graciarena et al., 2010).  Furthermore, Hao et al subjected pregnant 
rats to LPS (0.79mg/kg) on E8, 10, and 12 and demonstrated an increase in GFAP 
expression in the CA1 region of hippocampus in the affected offspring compared to 
controls and this difference increased with age (measured at 3, 10, and 20 months) 
(Hao et al., 2010).  Taken together, these data suggest that glial abnormalities, and in 
particular microglial density differences become more pronounced at different ages, 
depending on brain region.  There are also other possible explanations for the 
difference in results, though, as some studies used rats versus mice, and furthermore, 
as noted by Mattei et al, different studies use different markers for microglia 
including Iba1 (Garay et al., 2013; Mattei et al., 2014), OX42 and ED-1 (Van den 
Eynde et al., 2014) which may also account for the difference in results.   
 
1.5.4 Neurochemical and Electrophysiological Changes 
As alterations in neurotransmitter systems are implicated in numerous diseases 
associated with MIA (Howes & Kapur, 2009; Volkow et al., 2009; Brunelin et al., 
2013), studies have also used animal models to investigate the specific consequences 
of MIA on neurotransmitter systems and electrophysiological function.  First of all, 
MIA (LPS, 1mg/kg, on E 10.5) has been shown to decrease serotonin in multiple rat 
brain regions as measured by tryptophan hydroxylase- (enzyme involved in serotonin 
synthesis) and 5-HT (serotonin receptor) levels (Wang et al., 2009).  In agreement 
with this, mouse models of MIA also demonstrated deficits in serotonin and/or 5-
hydroxyindoleacetic acid (5-HIAA, the main metabolite of serotonin) in multiple 
brain regions, including the hippocampus and nucleus accumbens, following LPS 
(25μg/kg) (Depino, 2015) or Poly(I:C) (5mg/kg) on E9 (Winter et al., 2009), or 
influenza on E16 or E18 (Fatemi et al., 2008; Winter et al., 2008).   
Secondly, prenatal exposure to LPS (1mg/kg) on E10.5 also resulted in 
decreased striatal dopamine in adult (4, 14, and 17 months) offspring (Ling et al., 
2009).  This result was replicated with a lower dose of LPS (100μg/kg) which was 
administered to pregnant rats on E9.5 and subsequently offspring demonstrated 
decreased striatal DA and DA metabolite levels at P60 (Kirsten et al., 2010a).  
Numerous others have also demonstrated a decrease in DA along with decreased 
innervation in nucleus accumbens or striatum of offspring exposed to MIA via LPS 
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in the rat (100 μg/kg, E10, E14, or E18, (Snyder-Keller & Stark, 2008); 1mg/kg, 
E10.5, (Ling et al., 2006; Ling et al., 2009); 20-80 μg/kg increasing daily, E15-E19, 
(Bakos et al., 2004)).  This has also been confirmed in the mouse Poly(I:C) model 
(5mg/kg, on E17) in that DA levels were reduced in the medial prefrontal cortex and 
hippocampus from adult (P140) offspring (Bitanihirwe et al., 2010).  However, 
results are inconsistent with regards to MIA effects on offspring DA because some 
have observed increased DA levels in adult brains following maternal administration 
of Poly(I:C) (5mg/kg) to pregnant mice on E9 (Meyer et al., 2008c; 2008d).  More 
specifically, chronic MIA exposure (Poly(I:C), 5mg/kg, once daily, E12-E17) 
increased striatal DA with reduced binding of D2 receptors in young adult mice 
(Ozawa et al., 2006).  Furthermore, an increase in DA activity in the rat fetal 
midbrain was shown following in utero LPS exposure (1mg/kg, on E12.5), however 
this was hypothesized to be a compensatory response to the decrease in DA neurons 
also observed in this study (Ling et al., 2002).  The discrepancy in DA results is 
most certainly due to differences in animals used, the immunogen, as well as timing 
of administration as all of these factors produce differing results (Meyer et al., 2007; 
2009; Boksa, 2010; Harvey & Boksa, 2012; Meyer, 2014), but they may also depend 
on other factors as well.  For example, results depend on the age at which offspring 
brains are analyzed as one group showed decreased DA levels in the nucleus 
accumbens in adolescence (P39), while they found an increase in DA in the same 
region at later ages (P170, P120, P210, P420, P510) for rats exposed to LPS 
(2mg/kg) daily for the duration of pregnancy (Romero et al., 2007; Romero et al., 
2010).  Thus, the effects of MIA on DA activity are multifactorial, and further 
research is needed to fully understand the specific alterations resulting from the 
numerous variables.   
Finally, glutamate and GABA were not affected by MIA in one mouse 
Poly(I:C) model (5mg/kg, on E9) (Winter et al., 2009).  However, basal levels of 
extracellular glutamate were elevated in the prefrontal cortex of post-pubertal (~P55) 
rats exposed to Poly(I:C) (8mg/kg) on E14 (Roenker et al., 2011).  Furthermore, 
MK-801-induced glutamate increases were blunted in the MIA exposed offspring 
(Roenker et al., 2011), suggesting decreased NMDA receptor function.  Similarly, 
mice that were exposed to Poly(I:C) (5mg/kg) on P2-P6 demonstrated elevated basil 
hippocampal extracellular glutamate levels when tested at 10-12 weeks of age (Ibi et 
al., 2009).  Importantly, NMDA receptor-dependent synaptic current and plasticity 
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are decreased following LPS (500 μg/kg) on E19 (Lanté et al., 2007).  These data are 
consistent with the NMDA glutamate receptor hypofunction theory of schizophrenia, 
which postulates that decreased activity of NMDA receptors, leading to decreased 
stimulation of GABAergic inhibitory neurons, resulting in increased glutamate 
release from glutamatergic efferent neurons (especially in the prefrontal cortex) 
accounts for many symptoms of schizophrenia (Olney et al., 1999; Carlsson et al., 
2000; Moghaddam & Javitt, 2012).   
While looking at specific neurotransmitters provides some insight into which 
pathways MIA affects, researchers need other means to investigate functionality 
within these pathways.  To this end, electrophysiological studies have provided 
evidence for altered electrical properties of brain cells following MIA.  For example, 
one group investigated whether MIA affected the synchrony of neural firing from the 
medial prefrontal cortex and the hippocampus and found that Poly(I:C) (4mg/kg) 
exposure in utero (E15) resulted in reductions in the EEG coherence of those 
regions, suggesting mechanistic disturbances in long range neuronal communication 
in brains of affected offspring (Dickerson et al., 2010).  This is similar to the 
abnormal synchronization of neural avidity thought to be at the core of schizophrenic 
symptomology (Spencer et al., 2009; Uhlhaas & Singer, 2010).  Furthermore, when 
the two main glutamate receptors were investigated, Lante et al found that MIA 
(LPS,500 μg/kg, on E19) exposure resulted in increased ratio of α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) / NMDA currents in the hippocampi of 
affected offspring (Lanté et al., 2008).  In agreement with these studies, CA1 
pyramidal cells from juvenile offspring (P28) exposed to in utero LPS (100 μg/kg) 
on E15 and E16 showed decreased presynaptic transmission associated with a 
compensatory increase in postsynaptic excitability (Lowe et al., 2008).  Taken 
together, these studies indicated disturbances in overall synaptic function in MIA 
exposed offspring.  In agreement with this, Lowe demonstrated reduction in short 
term plasticity but no difference in long term potentiation (LTP) (Lowe et al., 2008).  
However another study did find a decrease in LTP in the hippocampus of juvenile 
offspring following LPS (500 μg/kg) on E19 (Lanté et al., 2008), though the 
difference in dosage and timing presumably accounts for the discrepancy in results.  
As the mechanisms responsible for synaptic plasticity include changes in 
neurotransmitter quality, rate of neurotransmitter release, as well as effectiveness of 
cell response to those neurotransmitters (Gaiarsa et al., 2002; Citri & Malenka, 
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2007), these MIA-induced alterations in synaptic plasticity may result from the 
aforementioned neurotransmitter alterations, possibly in combination with the 
numerous cellular differences seen in affected offspring exposed to MIA.   
 
1.5.5 Molecular Consequences  
Aside from the cytokine alterations, other molecular differences have been observed 
in MIA offspring and of key importance are the observations of MIA genetic 
structure and function.  Interest in genetic modifications resulting from MIA has 
increased because it has been demonstrated that morphological and behavioral 
consequences of MIA are exacerbated by genetic alterations.  One example of this is 
the heterozygous deletion of nuclear receptor related 1 protein (Nurr1) in mice 
(Vuillermot et al., 2012).  This genetic alteration in combination with MIA 
(Poly(I:C), 2mkg/kg, E17) resulted in additive effects of behavioral consequences as 
well as triggering improper development of prefrontal cortical and ventral striatal 
DA systems (Vuillermot et al., 2012).  In agreement with this, another group 
investigated effects of MIA on mice with two different point mutations (L100P and 
Q31L) in the Disc1 gene, which regulates progenitor cell proliferation, migration and 
differentiation, thus acting as an important susceptibility gene for schizophrenia 
(Chubb et al., 2008; Jaaro-Peled et al., 2009; Brandon & Sawa, 2011; Lipina et al., 
2013).  The Disc1- L100P
-/-
 mutant mice demonstrated schizophrenia related 
behaviors previously (Lipina et al., 2010; Lipina et al., 2011; Lipina et al., 2012).  
Then, Disc1- L100P
+/-
 mice were found to be more sensitive to MIA (Poly(I:C) , 
5mg/kg at E9), which exacerbated schizophrenia phenotypic behaviors in offspring 
(Lipina et al., 2013).  These studies exemplify the theory that MIA is a key risk 
factor for, and plays a role in, the progression of mental disorders.  Hence, these 
findings have huge implications for the study of neuropsychiatric diseases, and in 
particular schizophrenia, which has a complex etiology combining numerous gene 
and environmental interactions (Cannon et al., 2003; Meyer et al., 2005; Meyer, 
2013).   
One group in particular was interested in the effects of MIA on expression of 
genes that have been associated with schizophrenia and ASD, and in this study, 
pregnant mice were inoculated with human influenza virus (H1N1) at E18 (Fatemi et 
al., 2008).  They found elevation of numerous genes in the brains of MIA offspring: 
Arhgef9 in the frontal cortex; Efnb2, Erbb4, Vldlr, and Sema3a in the hippocampus; 
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and Trfr2 and Sox2 in the cerebellum at P0; and Dby was elevated seven fold in 
frontal cortex at P56 (Fatemi et al., 2008).  Most of these genes that were increased 
in the MIA offspring have developmental roles.  Sox2, for example, is required for 
neural stem cell maintenance, having the potential to act as the “master regulator” in 
programming neural precursor cells (Maucksch et al., 2013), and deletion of this 
gene in mice resulted extreme developmental disturbances including hypoplasia of 
the dentate gyrus (Favaro et al., 2009).  Furthermore, Erbb4 is involved in 
proliferation, differentiation, and migration of neurons and glia cells (Jaaro-Peled et 
al., 2009), and Sema3a plays a role in axonal extension, synaptogenesis, and 
synaptic pruning (Tillo et al., 2012).  Efnb2 is a member of the ephrin (EPH) family 
and as such this gene is involved in dendritic development, cell adhesion, and 
migration (Irie & Yamaguchi, 2004; Senturk et al., 2011), and it is also an essential 
member of the Reelin receptor/signaling pathway that controls neuronal migration 
and positioning (Senturk et al., 2011).  Playing similar roles in the developmental 
process, Vldlr is a Reelin receptor and a regulator of PPI in mice (Barr et al., 2007), 
which is deficient in MIA models (Boksa, 2010) as well as in schizophrenia patients 
(Braff & Geyer, 1990; Wynn et al., 2005).  Indeed, many of these genes are 
associated with schizophrenia and/or ASD and are shown to be elevated in these 
patients, including Sema3a which is known to be increased in cerebella of 
schizophrenia patients (Eastwood et al., 2003), Tfr2 levels are elevated in plasma of 
schizophrenia (Maes et al., 1995), and Vldlr which is upregulated in ASD (Fatemi et 
al., 2005).  Importantly, the Fatemi group was able to conclude that MIA in later 
pregnancy (E18) altered more genes than in mid pregnancy (E9) suggesting that 
effects of influenza infection are more pronounced later in gestation (Fatemi et al., 
2008).  While influenza may have exacerbated effects in later pregnancy, others have 
shown that Poly(I:C) in earlier pregnancy leads to genetic alterations in offspring.  
Indeed, maternal administration of Poly(I:C) (5 mg/kg on E9) resulted changes in 
fetal brains 2, 4, or 8 days post MIA (E11, E13, or E17) consisting of altered 
transcription factors Nurr1 and Pitx3 and inductive signals Sonic hedgehog (Shh) 
and fibroblast growth factor (FGF8) (Meyer et al., 2008a), all of which are required 
for the development of dopaminergic neurons (Hegarty et al., 2013).  A subsequent 
longitudinal study showed increased expression of Nurr1 in ventral midbrain areas 
found in adult mice from the same MIA animal model (Poly(I:C, 5mg/kg, on E9) 
(Vuillermot et al., 2010).  Nurr1 plays an important role in differentiation as well as 
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survival of midbrain dopaminergic precursor neurons (Saucedo-Cardenas et al., 
1998) and it helps to regulate important proteins, including TH in mature midbrain 
DA neurons (Iwawaki et al., 2000; Kim et al., 2003).  Taken together, these studies 
emphasize the association of MIA to genetic abnormalities, and the implicated 
subsequent developmental alterations related to the specific genes, which may result 
in disease later in life.   
MIA effects on genes are not all detrimental, however and some evidence of 
compensatory genetic alterations exists, for example one study demonstrated three 
different MIA treatments, influenza, Poly(I:C) (20mg/kg), and IL-6, all upregulated 
α, β, and γ crystalline family genes in the embryonic brain (Garbett et al., 2012).  
Crystallin proteins are proposed to serve a neuroprotective role, as pretreatment with 
α-crystallin protected against experimentally induced neuroinflammation 
(Masilamoni et al., 2006) and in agreement with this, αβ-crystallin down regulated 
TNF-α and nitric oxide synthase in activated microglia (Wu et al., 2009).  As altered 
levels of αβ-crystallin protein levels were detected in ASD frontal cortices (Pickett, 
2001), these data may suggest that the up-regulation of crystallins observed by 
Garbett may be a mechanism for the brain to protect itself from the 
neuroinflammation pathology characteristic of ASD (Vargas et al., 2005; Prandota, 
2010). 
There is evidence to show that MIA affects the physical makeup of DNA 
itself, for example, following MIA on E15 (Poly(I:C), 5mg/kg) mice offspring had 
decreased activity of telomerase (an enzyme with important roles in DNA 
sequencing which adds the sequence repeats to the 3’ end of DNA strands) and 
associated shortened telomeres in hippocampal NPCs (Wolf et al., 2011).  
Furthermore, as telomere shortening has been shown to disrupt neuronal 
differentiation (Ferrón et al., 2009), this effect resulting from MIA presumably leads 
to impairment in proper neuronal development by limiting proliferation and 
differentiation of NPCs in offspring.  It has been proposed that epigenetic 
mechanisms regulate telomere length (Blasco, 2007), implicating a possible 
mechanism through which MIA exerts its effects on the developing brain.  Indeed, 
abnormalities in epigenetic modifications such as DNA methylation have been 
linked to complex neurodevelopmental disorders including schizophrenia and ASD 
(Dempster et al., 2011; Wong et al., 2014).  For example, one study demonstrated 
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that prenatal exposure to Poly(I:C) (5mg/kg) on E9 resulted in significant global 
DNA hypomethylation in the hypothalamus and a similar trend in the striatum of 
adolescent offspring (Basil et al., 2014).  In particular, the Methyl CpG-binding 
protein2 (Mecp2), which plays a key role in activation and repression of gene 
expression, was significantly hypomethylated in the hypothalamus (Basil et al., 
2014).  This evidence should be further investigated as gene modifications have the 
potential to be modified by therapeutic targets, and as Basil et al point out, Mecp2 
could be utilized as a potential biomarker for alterations associated with prenatal 
immune exposure (Basil et al., 2014).   
 
 
  
69 
 
Reference Animal Model 
Immunogen, 
Dose, Rout 
Timing Key Findings 
Fatemi, 1999, 
2002, 2008, 
2009 
Mouse Influenza Influenza IN E9, E16, or 
E18 
E9: ↑ pyramidal cell density in hippocampus 
(P0, P98); ↓ thickness of cerebral cortex, ↓ total 
area of brain hemisphere (P0), ↑ brain weight 
and size, ↓ VBR (P98).  E16: ↓ ventricular area 
(P0), ↓ total brain area and cerebellar area 
(P14), ↓hippocampal area (P35); altered white 
matter anisotropy by DTI (P0, P14, P56).  E18: 
↓ anisotropy in corpus callosum; ↓ brain by DTI 
volume by MRI (P35) 
Depino, 2015 Mouse LPS LPS, 25μg/kg, 
SC 
E9 ↓ reelin pos cells in dentate gyrus; adult 
neurogenesis not affected (>P60) 
Golan, 2005 Mouse LPS LPS, 120 μg/kg, 
IP 
E17 ↓hippocampal CA1 width (P7), ↑ hippocampal 
CA1 width and ↓ dentate length (P14); ↑ dentate 
width (P240); ↑ cell density in hippocampal 
CA1 (P240) 
Roumier, 
2008 
Mouse LPS LPS, 120 μg/kg, 
IP 
E15 ↑ microglial density in hippocampus (P0) 
Garay, 2013 Mouse Poly IC Poly IC, 
20mg/kg, IP 
E12.5 no change in microglia density of frontal cortex, 
cingulate cortex, and hippocampus (P0, P7, P14, 
P30, and P60) 
Li, 2009, 
2010 
Mouse Poly IC Poly IC, 5 
mg/kg, IV 
E9 or E17 Delayed postnatal myelination; ↓ purkinje cell 
density; ↑ lateral and 4th ventricle volumes by 
MRI (P84) 
Makinodan, 
2008 
Mouse Poly IC Poly IC, 60 
mg/kg, IV 
E9.5 ↓ axonal size and myelin thickness in 
hippocampal CA1; ↓ MBP staining in 
hippocampal CA1 and CA3 (P14) 
Meyer, 
2006a,b, 
2008 
Mouse Poly IC Poly IC, 5 
mg/kg, IV 
E9 or E17 ↓ neurogenesis in hippocampus (P24). E9: ↓ 
reelin-ir cells in hippocampus (P24) and in 
mPFC (P180); ↓ paravalbumin-ir cells in mPFC 
(P180). E17: ↓ reelin-ir cells in mPFC, ↓ 
paravalbumin-ir cells in mPFC and ventral 
hippocampus (P180) 
Shi, 2009 Mouse Poly IC Poly IC, 20 
mg/kg, IP 
E12.5 ↓ cerebellar Purkinje cells (P120) 
Soumiya 
2011a, 2011b 
Mouse Poly IC Poly IC, 
20mg/kg, IP 
E9.5 Abnormalities in cortical progenitor cells; ↓ 
synaptic development of upper-layer neurons; ↓ 
synaptophysin, ↓ glutamic acid decarboxylase-
67 positive puncta surrounding neural cell 
bodies; ↑ dendritic spine density (P56) 
Wolf, 
Susanne, 
2011 
Mouse Poly IC Poly IC, 5mg/kg, 
IP 
E15 ↓ adult hippocampal neurogenesis 
Samuelsson, 
2006 
Rat Cytokine IL-6, 9μg/kg, IP E8, E10 and 
E12; or E16, 
E18, and E20 
↓ neurons and ↑ astrocytes in hippocampus 
(P168) 
Baharnoori, 
2009 
Rat LPS LPS, 100 μg/kg, 
IP 
E15 and E16 ↓ dendritic arborization in mPFC and 
hippocampal CA1 (P10, P35, P60); ↓ dendritic 
length in mPFC (P10, P35) and CA1 (P60); ↓ 
spine density in mPFC (P60) 
Cai, 2000 Rat LPS LPS, 500 μg/kg 
IP 
E18 ↑ GFAP-astrocytes, ↓ OX-42-microglia, no 
change in tomato lectin-microglia in 
hippocampus and cortex (P8) 
Cui, 2009 Rat LPS LPS, 50 or 100 
μg/kg, IP 
E15 and E16, 
or E18 and 
E19 
↓ neurogenesis in hippocampal dentate gyrus 
(E18, P14) 
Graciarena, 
2010 
Rat LPS LPS, 0.5mg/kg, 
SC 
Every other 
day E14-E20 
↓ proliferating cells and immature neurons of 
dentate gyrus; persistent microglial activation 
(>P60) 
Hao, 2010 Rat LPS LPS, 0.79mg/kg 
IP 
E8, 10 and 
12 
↓ neuron, ↓ SYP expression, ↑ GFAP in 
hippocampal CA1 (3, 10, 20 month-old) 
Larouche, 
2005 and 
Girard, 2010 
Rat LPS LPS, 200 μg/kg, 
IP 
2X day from 
E17 to birth 
↑ cerebral cortical lesions in form of shrunken 
neuronal cell bodies and nuclei (P3, P8); ↑ 
proliferating and total microglia in forebrain 
white matter (P9) 
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Ling, 2002, 
2006, 2009 
Rat LPS LPS, 1 mg/kg, IP E14.5 and 
P21; E10.5-
11 
Morph: ↓ DA neurons in SN and VTA + inc in 
DA activity; ↑ microglia cells that were also 
larger cell body and thicker processes (i.e. 
activated microglia), ↓ DA cell counts, LPS 
animals exhibited Lewy body like inclusions 
after 14months (4, 14, 17 months) 
Nouel, 2011 Rat LPS LPS, 100 μg/kg, 
IP 
E15 and E16 ↓ GAD67 cell count in dentate gyrus (P14); ↓ 
GAD67 cell count in dentate gyrus and CA1 
(P28); ↓ reelin cells in dentate gyrus (P14) 
Paintlia, 
2004, 2008 
Rat LPS LPS, 700 μg/kg 
or 1mg/kg, IP 
E18 ↓ OPCs and immature oligodendrocytes in 
corpus callosum and lateral ventricles with ↓ 
MBP and PLP mRNA in brain; ↓ MBP 
immunostaining in corpus callosum and 
cingulum (P9, P16, P23, P30) 
Rousset, 
2006, 2008 
Rat LPS LPS, 300 or 400 
μg/kg, IP 
E19 and E20 ↑ apoptosis in striatum, PWM and germinative 
ventricular zone (P1, P7); ↓ MBP 
immunostaining in external and internal capsule 
(P7); ↑ ibotenate-induced cortical lesions and 
PWM cysts (P9); ↑ ibotenate-induced microglial 
activation and astrogliosis in various regions 
(P9) 
Snyder-
Keller, 2008 
Rat LPS LPS, 100 μg/kg 
IP 
E10, E14, or 
E18 
Accelerated loss of DA neurons in culture 
Mattei, 2014 Rat Poly IC Poly IC, 4mg/kg, 
IV 
E15 ↓ net-neurogenesis; minocycline for 10 weeks 
rescued neurogenesis (adult); no change in 
microglia density in hippocampus, medial 
prefrontal cortex, ventral striatum, cingulate 
cortex, nor cerebellum; ↑ in microglia in 
nucleus accumbens (4months) 
Piontkewitz, 
2011a, 2011b 
Rat Poly IC Poly IC, 4mg/kg, 
IV 
E15 ↓ volume of hippocampus, striatum, and 
prefrontal cortex; ↑ ventricular volume (P35, 46, 
56, 70, 90) 
Van den 
Eynde, 2014 
Rat Poly IC Poly IC, 4mg/kg, 
IV 
E15 ↑ microglia density in hippocampus, corpus 
callosum, pons and thalamus (P180) 
Table 2: Morphological changes observed in offspring following MIA 
Table summarizing a wide literature sample of the effects of MIA on brain 
morphology from affected offspring.  In the “key findings” column the age at which 
offspring samples were tested is listed in parenthesis. 
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Reference Animal Model 
Immunogen, 
Dose, Rout 
Timing Key Findings 
Asp 2005 Mouse Influenza Influenza IN E14 ↑ mRNA neuroleukin, FGF5, ring finger 
protein 1B, Akv MuLV in whole brain (P90 
and/or P280); ↑ neuroleukin in whole brain 
(P90) 
Fatemi, 1999, 
2002, 2005, 
2008, 2009 
Mouse Influenza Influenza IN E9, E16, or 
E18 
E9: 7 genes altered in whole brain (P0); ↓ 
reelin-ir cells in hippocampus, cortex, (P0); 
altered SNAP-25 immunoreactivity in 
hippocampus (P0); ↑ GFAP immunostaining 
in cortex (P14) and hippocampus (P35); 
altered nucleolin, microcephalin, connexin 43 
and aquaporin 4 protein in various regions 
(P35, P65). E16: Microarray/PCR- 13 genes 
altered (P0), 4 genes altered (P14), 3 genes 
altered (P56) in hippocampus ; ↓MBP, ↓ MA, 
↑ splice variant of PLP1 in cerebellum (P14, 
P35, P56). E18: microarray/PCR: 12 genes 
altered (P0), 2 genes in various brain regions 
(P56); ↑ Foxp2 in cerebellum (P0, P35) 
Moreno, 2011 Mouse Influenza H1N1 
(influenza), IN 
E9.5 ↑ 5-HT(2A) receptor, ↓ mGlu2 receptor in 
frontal cortex (10-12 weeks) 
Golan, 2005 Mouse LPS LPS, 120 
μg/kg, IP 
E17 ↑ IL-6 (3h), ↑ BDNF (9 h) in brain; ↓ BDNF 
in cortex, hippocampus (P21); ↑ BDNF in 
thalamus (P270); ↓ NGF in hippocampus 
(P21); ↑ NGF in thalamus (P7, P270) 
Liverman, 
2006 
Mouse LPS LPS, 50μg, IP E18 ↑ mRNA for IL-1β, IL-6, mCP-1, needin, 
VEGF, YB-1 (1-12 h); ↓ mRNA for groucho, 
semaphoring 5b (6h) 
Ning, 2008 Mouse LPS LPS, 500 
μg/kg, IP 
E17 ↑ TNF in brain, liver an amniotic fluid (1.5h) 
Garbett, 2012 Mouse Multiple Influenza, IN; 
Poly IC, 
20mg/kg, IP; 
IL-6, 5μg/150μl 
saline, IP 
E9.5 or E12.5 Upregulation of crystallin gene family (3h) 
Basil, 2014 Mouse Poly IC Poly IC, 
5mg/kg, IV 
E9 global DNA hypomethylation in 
hypothalamus (6wk old) 
Bruses, 2012 Mouse Poly IC Poly IC, 
20mg/kg, IP 
E16 ↑ IL-1β, IL-7, IL-13, MCP-1, MIP-1α, IP-10, 
MIG (6h and 24h post injection) 
Garay, 2013 Mouse Poly IC Poly IC, 
20mg/kg, IP 
E12.5 23 cytokine  measurements from frontal 
cortex, cingulate cortex, hippocampus, and 
serum (P0, P7, P14, P30, and P60) 
Lipina, 2012 Mouse Poly IC Poly IC, 
2.5mg/kg or 
5mg/kg, IV 
E9 Disc1-L100P+/- mutants > sensitivity to MIA 
vs WT or Disc1-Q31L+/-; Anti-IL6 co-admin 
w/ Poly IC reversed adverse effects 
Makinodan, 
2008 
Mouse Poly IC Poly IC, 60 
mg/kg, IV 
E9.5 ↓ MBP, ↓ mRNA for MBP, ↓ pAkt in 
hippocampus (P14) 
Malkova, 
2014 
Mouse Poly IC Poly IC, 
5mg/kg, IP 
E10.5, E12.5, 
and E14.5 
↑ DOI-induced egr-1, COX-2 and BDNF 
mRNA in PFC; ↑ 5-HT2AR, phospholipase C 
β1, and regulator of G protein signaling 4 
mRNA in PFC (adult) 
Meyer, 
2006a,b, 2008 
Mouse Poly IC Poly IC, 5 
mg/kg, IV 
E9 or E17 ↑ TH pos cells in region ventral to fetal 
mesencephalic flexure in E13 and VM for 
E17; DAT expression ↓ at E13 but ↑ at E17. 
E9: altered mRNA for genes involved in DA 
development: Shh, Fgf8, Nurr1, Pitx3 (E11, 
E17); ↓ IL-1β, ↑ IL-6m, ↓ IL10 in brain (3h); 
↑IL-1β, IL-6, TNF in brain (5 or 6h). E17: ↑ 
IL-1β, IL10 (3h); ↑ IL-6 (6h)  
Vuillermot 
2010, 2011, 
2012 
Mouse Poly IC Poly IC, 
5mg/kg or 
2mg/kg, IV 
E9 or E17 ↑ Nurr1 positive cells in SN at E19 & P70, no 
difference at P35; ↑ VTA Nurr-1 positive 
cells at P70, no difference at E19 or P35 
Wolf, 
Susanne, 2011 
Mouse Poly IC Poly IC, 
5mg/kg, IP 
E15 ↓ telomerase activity in NPCs, telomere 
shortening (P1, P3, P10, P60) 
Samuelsson, 
2006 
Rat Cytokine IL-6, 9μg/kg, IP E16, E18, and 
E20 
↑ procaspase-3, active caspase-3; ↑ mRNA for 
GFAP, IL-6, and caspase-3 in hippocampus 
(P28, P168) 
Ashdown, 
2006 
Rat LPS LPS, 50 μg/kg, 
IP 
E18 ↑ IL-1β, IL-6, TNF-α in placenta (2-8h); no 
change in fetal brain IL-1β, IL-6, TNF 
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Cai, 2000 Rat LPS LPS, 500 μg/kg 
IP 
E18 ↑ IL-1β (1h), TNF-α (4-24h); ↑ GFAP in 
various brain regions (P8) 
Gayle, 2004 Rat LPS LPS, 100 
μg/kg, IP 
E18 ↑ CRH mRNA (6, 12h), no change in IL-1β, 
TNF-α, IL-6, and IL-10 
Gilmore, 2005 Rat LPS LPS, 100 
μg/kg, IP 
E14, E15, and 
E16 
↓ TNF-α in brain (24h) and in FC (P7) 
Kumral, 2007 
and 
Yesilirmak 
2007 
Rat LPS LPS, 500 
μg/kg, IP 
E18 and E19 ↑ IL-1β, IL-6, TNF-α mRNA in whole brain 
(P7) 
Lanté, 2007, 
2008 
Rat LPS LPS, 500 
μg/kg, IP 
E19 ↑ protein carbonylation (1-4 h), 
↓reduced/oxidized glutathione (16 h), ↓ α-
tocopherol in hippocampus (4h) 
Ling, 2002, 
2004a,b, 2006; 
Zhu 2007 
Rat LPS LPS, 1 mg/kg, 
IP 
E10.5-11 ↑TNF-α in striatum (P21, P120, P210, P510) 
and SN (P210); ↓ reduced/ oxidized GSH 
(P120, P210, P510) ↓ enzyme activity for 
GSH synthesis, ↑ GSH redox recycling 
enzyme activities, ↑ lipid peroxidation (P120, 
P510) and protein oxidation (P480) in many 
brain regions 
Nilsson, 2001 Rat LPS LPS, 790 
μg/kg, IP 
E8, E10, and 
E12 
↑ GR in hippocampus after euglycemic 
hyperinsulinemia (P84) 
Paintlia, 2004, 
2008 
Rat LPS LPS, 700 μg/kg 
or 1 mg/kg, IP 
E18 ↓ peroxisome markers : DHAP-AT, PMP70, 
PPAR-α mRNA and protein; ↑ GFAP 
immunostaining in corpus callosum and/or 
cingulum (P9, P16, P23, P30); ↑ IL-1β 
mRNA (1-48h), TNF (1-24h), iNOS (24-48); 
↑apoptosis in subventricular zone, ↓ OPCs 
and ↑ microglial activation (48h); ↑ oxidative 
stress, ↓ glutathione, ↓ peroxisomal function 
(24h, 48h) 
Romero, 2007, 
2010 
Rat LPS LPS, 2 mg/kg, 
SC 
Daily whole 
pregnancy 
↓ synaptophysin in FC (P21, P400), ↑ 
synaptophysin in FC, hippocampus (P170, 
P180), ↓ DARPP-32 in FC (P180), ↓ GSK-3β 
(P400) 
Rousset, 2006 Rat LPS LPS, 300 
μg/kg, IP 
E19 and E20 ↑ IL-1β mRNA (P1), ↓ TNF-α whole brain 
(P7) 
Urakubo, 2001 Rat LPS LPS, 2.5 mg/kg 
IP 
E16 ↓ TNF fetal brain (2h) 
Mattei, 2014 Rat Poly IC Poly IC, 
4mg/kg, IV 
E15  ↑ microglia IL-1β and TNF-α in 
hippocampus, not cerebellum (P128) 
Table 3: Molecular and genetic changes observed in offspring following MIA 
Table summarizing research investigating effects of MIA on molecular and genetic 
characteristics of offspring brains.  In the “key findings” column the timing at which 
offspring samples were tested is listed in parenthesis. 
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Reference Animal Model 
Immunogen, 
Dose, Rout 
Timing Key Findings 
Fatemi, 2008 
and Winter 
2008 
Mouse Influenza Influenza IN E16, or E18 ↓ 5-HT, ↓ 5-HIAA in cerebellum (P14); ↓ 5-
HT, ↓ taurine in cerebellum (P35) 
Depino, 2015 Mouse LPS LPS, 25μg/kg, 
SC 
E9 ↓ serotonin and noradrenaline in hippocampus 
(>P60) 
Roumier, 2008 Mouse LPS LPS, 120 μg/kg, 
IP 
E15 ↑ ratio of AMPAR/NMDAR currents in 
hippocampus (P28) 
Bitanihirwe, 
2010 
Mouse Poly IC Poly IC, 5 
mg/kg, IV 
E17 Changes in mult systems/depends on brain 
region, but main results: ↓ DA and glutamate 
in PFC and hippocampus, ↑ serotonin in 
amygdala females only, ↑ 5-HIAA in amygdala 
(~P140) 
Meyer, 
2008a,c,e and 
Winter 2008 
Mouse Poly IC Poly IC, 5 
mg/kg, IV 
E9 or E17 E9: ↑THir cell (E13, E17), ↑ DATir cells (E17) 
in mesencephalon; ↑ TH immunoreactivity in 
striatum and NAc, ↓ immunoreactivity for Glu-
R1 subunit of AMPA receptor in NAc (P120); 
↑ DA, DOPAC in PFC and globus pallidus, ↓ 
serotonin and metabolite in hippocampus, 
nucleus accumbens and lateral globus pallidus, 
↓ taurine in hippocampus, no effect on 
glutamate nor GABA (P84); ↓ D1 receptor 
immunoreactivity in medial PFC (P180). E17: 
↓ NR1 receptor subunit immunoreactivity in 
dorsal hippocampus (P180) 
Nyffeler, 2006 Mouse Poly IC Poly IC, 5 mg/kg 
IV 
E9 ↑ GABAAα5 receptor subunit immunoreactivity 
in ventral dentate and basolateral amygdala 
(P180) 
Ozawa, 2006 Mouse Poly IC Poly IC, 5 
mg/kg, IP 
E12-E17 ↑DOPAC, ↑HVA, ↓ D2 receptor binding in 
striatum (P63-P70) 
Samuelsson, 
2006 
Rat Cytokine IL-6, 9μg/kg, IP E16, E18, and 
E20 
↑ mRNA for NR1 and GABAAα5 receptor 
subunits in hippocampus (P28, P168) 
Bakos, 2004 Rat LPS LPS, 20-80 
μg/kg increasing 
daily, SC 
E15-19 ↓ DA in NAc (P83) 
Borrell, 2002 Rat LPS LPS, 1 mg/kg, 
SC 
Alternate Days 
whole 
pregnancy 
↑ TH immunoreactivity in NAc and bed 
nucleus of striaterminals (P100, P300) 
Cambonie, 
2004 
Rat LPS LPS, 300 μg/kg, 
IP 
E19 ↑Glu-induced hydroxyl radical release (mGlu I 
mediated) in striatum (P14) 
Kirsten, 
2010a,b, 2012, 
2015 
Rat LPS LPS, 100 μg/kg, 
IP 
E9.5 ↓ striatal DA and metabolite levels (P60) 
Lanté, 2007, 
2008 
Rat LPS LPS, 500 μg/kg, 
IP 
E19 ↑ ratio of AMPAR/NMDAR currents in 
hippocampus, ↓ LTP in hippocampus (P28) 
Ling, 2002, 
2004a,b, 2006, 
2009, and 
Wang, 2009 
Rat LPS LPS, 1 mg/kg, IP 10.5 ↓ THir cells in SN (P21, P120, P210, P420, 
P510); ↑↑ DA neuron loss in SN after postnatal 
rotenone, 6-OHDA or intranigral LPS; ↓ DA in 
SN, ↑ HVA/DA in striatum (P120, P510) and 
other brain regions (P120) 
Lowe, 2008 Rat LPS LPS, 100 μg/kg, 
IP 
E15 and E16 ↑ hippocampal CA1 synaptic transmission and 
↑ CA1 pyramidal cell excitability; ↓ 
presynaptic excitability in CA1 (P20-P25) 
Romero, 2007, 
2010 
Rat LPS LPS, 2 mg/kg, 
SC 
Daily for whole 
pregnancy 
↓ DA in NAc (P39), ↑ DA in NAc (P170, 
P120, P210, P420, P510), ↑ DOPAC in 
striatum (P180) 
Snyder-Keller, 
2008 
Rat LPS LPS, 100 μg/kg, 
IP 
E10, E14, or 
E18 
↓ THir cells in SN/VTA and ↓ DA innervation 
of striatum in organotypic cultures 
Wang, 2009 Rat LPS LPS, 1 mg/kg, IP E10.5 ↓ TPHir cells in dorsal raphe, ↓ 5-HT and ↑ 5-
HIAA/5-HT in various brain regions (P120) 
Dickerson, 
2010 
Rat Poly IC Poly IC, 4mg/kg, 
IV 
E15 Electrophysiological recordings = ↓ in mPFC-
HPC EEG coherence (5months of age)  
Roenker, 2011 Rat Poly IC Poly IC, 8mg/kg, 
IP 
E14 ↑ PFC glutamate; blunted MK-801 induced 
increase in glutamate (P55-58) 
Zuckerman, 
2003 
Rat Poly IC Poly IC, 4 
mg/kg, IV 
E15 ↑KCL-induced DA release from striatal slices 
(P100) 
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Table 4: Neurochemical and electrophysiological alterations in offspring 
following MIA 
Table with summarized literature detailing the neurochemical characteristics and 
electrophysiological functioning in brains of offspring exposed to MIA.  In the “key 
findings” column the timing at which offspring samples were tested is listed in 
parenthesis. 
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1.6 Mechanisms 
Even though infections during pregnancy are fairly common, (Petersen, 1992; 
Longman & Johnson, 2007; Parveen et al., 2012), most offspring exposed to MIA do 
not develop disorders (Selten & Slaets, 1994).  This suggests that there are multiple 
factors at play, including genetic vulnerability and environmental insults that work 
with the effects of MIA to result in disease onset for a subset of affected individuals.  
Therefore, elucidating the mechanisms through which MIA evokes developmental 
changes leading to disease susceptibility is of huge importance.  As mentioned 
previously, numerous infections are associated with increased risk of offspring 
development of neurological disease, such as CP, or neuropsychological disorders, 
like schizophrenia, ADHD or ASD (see “Epidemiological and Clinical Evidence” 
section), and there is increasing evidence indicating that many of these disorders 
share numerous risk factors (including MIA) and brain dysfunctions (Cheung et al., 
2010; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; 
Moreno-De-Luca et al., 2013; Meyer, 2014).  Furthermore, most of our information 
comes from animal models, and as none of these could ever presume to encompass 
one human disease in its entirety, the data are often applicable to numerous disease 
pathologies.  As such, the mechanistic factors are usually associated with MIA only, 
as opposed to a specific disease etiology.  Hence, researchers have begun to 
elucidate possible mechanistic factors that potentially apply to the development of 
many diseases and to determine how MIA may result in future neurobiological and 
behavioral alterations in affected offspring.  The current factors that are hypothesized 
to play a mechanistic role in the effects of MIA in offspring neuropathology are 
herein reviewed. 
 
1.6.1 Cytokines 
One of the first reactions of the innate immune response during an infection, tissue 
damage, stress or other physiological insults, is to induce inflammation (Gallin et al., 
1999).  Inflammation is characterized by the secretion of numerous inflammatory 
factors, including prostaglandins, chemokines, and cytokines.  Immunological 
factors, and specifically cytokines are the most widely hypothesized mediator of the 
aversive outcomes associated with MIA because MIA in the absence of an infectious 
agent is sufficient to induce neurodevelopmental alterations and behavioral 
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impairments in affected offspring (Kneeland & Fatemi, 2013; Meyer, 2013; Knuesel 
et al., 2014).  Indeed cytokines are implicated in all of the other mechanistic players 
in MIA, which is evident throughout this section.   
Cytokines are primarily produced by microglia, but astrocytes and neurons 
are also sources (Breder et al., 1994; Smith et al., 2012; Sofroniew, 2013).  They 
function in many processes within the immune system, including immune cell 
differentiation, maintenance, and homeostasis (Huang & August, 2015) as well as 
inducing cell death (Curfs et al., 1997).  More importantly for our purposes, many 
cytokines and their receptors are expressed in fetal brain development (Mehler & 
Kessler, 1997; Mousa et al., 1999), and therefore also affect neurodevelopmental 
processes (Meyer, 2013).  Indeed, it has been noted that cytokines serve numerous 
essential functions in normal neurodevelopment, including neurogenesis, migration, 
and survival (Bauer et al., 2007; Deverman & Patterson, 2009; Meyer, 2013), and 
cells (including neurons and microglia) use cytokines for paracrine and autocrine 
signaling within the developing CNS (Deverman & Patterson, 2009).  Cytokines 
have also been shown to influence synthesis and reuptake of neurotransmitters, 
including dopamine and serotonin (Capuron & Miller, 2011); altered functioning of 
both of these neurotransmitters are implicated in neuropsychological diseases, most 
notably schizophrenia (Winter et al., 2008; Howes & Kapur, 2009; Lau et al., 2013; 
Selvaraj et al., 2014).  Clearly, cytokines have important roles to play in normal 
brain functioning, and as such, discrepancies in the proper protein levels could lead 
to devastating developmental alterations.  
Animal models have demonstrated significant increases in protein and 
mRNA levels of IL-1β, IL-6, IL-10, and TNF-α in the fetal brain following MIA, 
suggesting that these may be of particular interest in MIA mechanisms (Meyer et al., 
2005; Patterson, 2009).  Our group has demonstrated that high amounts of IL-1β 
limited proliferation and altered differentiation of neural progenitor cells and altered 
fetal neuron development in vitro (Nolan et al., 2011; Crampton et al., 2012).  
Furthermore, IL-1β, IL-6 and TNF-α were toxic to fetal midbrain DA neuron in 
some in vitro studies (Jarskog et al., 1997; McGuire et al., 2001), however they 
promoted cell survival when at higher concentrations in another (Akaneya et al., 
1995).  Furthermore, TNF-α had neurotrophic effects on DA neurons cultured from 
mice in early fetal development (E12.5), but neurotoxic effects in later 
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developmental phases (E14 or E16) (Doherty, 2007).  This suggests the ultimate 
effect of MIA induced cytokine alterations on DA neuron development is highly 
dependent upon developmental stage.  
Importantly, in vivo studies confirm the potential mechanistic role of 
cytokines.  The main cytokine implicated in MIA animal model studies seems to be 
IL-6, with IL-1 and TNF-α closely behind.  Indeed, studies investigating the 
potential roles of IL-6 and IL-1 have demonstrated that blocking the cytokine action 
following MIA eliminated aversive outcomes, including behavioral deficits as well 
as brain and placental phenotypical alterations, which previously resulted from 
immunogen induced MIA or cytokine administration (Smith et al., 2007; Girard et 
al., 2010).     
 
1.6.2 Microglia Function 
Microglia are the major immune cells and resident macrophages of the CNS, 
regulating induction and inhibition of inflammatory processes and helping maintain 
homeostasis through crosstalk with neurons, astrocytes, oligodendrocytes, and 
circulating immune cells (Ransohoff & Perry, 2009; Ransohoff & Cardona, 2010; 
Aguzzi et al., 2013).  These cells accomplish their immune regulatory functions by 
up- or down- regulating cytokines and associated receptors, as well as other immune-
related cell surface receptors (Meyer, 2013), and interestingly, cytokines also 
regulate microglia, as do chemokines, neurotrophic factors, complement factors, and 
neurotransmitters (Glass et al., 2010; Hagberg et al., 2012).  Aside from the immune 
roles, microglia cells also have key roles in developmental processes: they help 
astrocytes regulate neuronal differentiation and maturation and they play key roles in 
synaptic pruning and neural circuit formation (Boulanger & Shatz, 2004; Glass et al., 
2010; Schafer et al., 2012; Ueno & Yamashita, 2014).  Therefore, while microglia 
cells do play necessary roles in neuroprotection and development, they are also 
potentially problematic if their functionality in these roles becomes disrupted as 
result of MIA.  For instance, chronic microglial activation leads to heightened 
release of pro-inflammatory factors and this process is linked to neurodegenerative 
processes (Block et al., 2007; Knuesel et al., 2014).  Indeed, chronic microglia 
activation is a characteristic of PD brains, first noted in the SN (McGeer et al., 1988) 
and then subsequently noted in the hippocampus, putamen, and cortex of patients 
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with PD (Imamura et al., 2003).  Furthermore, chronic microglial activation has been 
implicated as a potential mechanism in neuropsychiatric disorders, including those 
with increased risk following MIA (Smith et al., 2012; Knuesel et al., 2014). Also 
numerous MIA associated diseases are characterized by chronic immune 
abnormalities, including ASD (Pardo et al., 2005; Careaga et al., 2010; Gesundheit 
et al., 2013) and schizophrenia (Strous & Shoenfeld, 2006; Müller & Schwarz, 
2010), further implicating a role for chronic changes in the immune system of 
affected individuals.   
Microglia can be primed following an initial inflammatory stimulus to 
respond more strongly to subsequent stimuli (Cunningham et al., 2009; Meyer, 
2013; Knuesel et al., 2014; Perry & Holmes, 2014).  This microglial priming state is 
associated with alterations in microglial morphology, increased microglia cell 
number, as well as elevated cytokine / immune mediator levels (Knuesel et al., 2014; 
Perry & Holmes, 2014).  MIA models have shown that exposure to LPS or Poly(I:C) 
in utero resulted in increased microglial activation.  For example, increased levels of 
microglial IL-1β and TNF-α were observed in rats exposed to Poly(I:C) (4 mg/kg) 
on E15(Mattei et al., 2014).  This increase in microglia cytokine output was 
associated with decreased neurogenesis and PPI because when microglial cytokine 
production was normalized through minocycline treatment, neurogenesis and the 
behavioral deficit were rescued (Mattei et al., 2014).  Interestingly, though, when a 
second hit of Poly(I:C) was administered in adulthood to MIA exposed offspring, the 
inflammatory response was significantly heightened with increased numbers of 
active microglia and cytokine expression (Krstic et al., 2012).  Similar indications of 
microglial priming were found following a secondary insult of stress in puberty (as 
opposed to another immune specific insult) in MIA exposed mice (Giovanoli et al., 
2013).  These findings demonstrate the ability of MIA to prime microglia for 
heightened response later in life.  It has been proposed that this priming action is 
what mediates the improper neuromodulatory and immune functions of microglia in 
MIA offspring, resulting in susceptibility to disease later in life (Knuesel et al., 
2014).   
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1.6.3 Placental Roles 
The placenta is a key regulator of maternal-fetal interactions, regulating fetal growth 
and development (Huppertz, 2008), and as such a proper intrauterine environment is 
imperative for normal placental functioning in protecting fetal development (Hsiao 
& Patterson, 2012).  The LPS and Poly(I:C) MIA models have been shown to 
increase pro-inflammatory cytokine levels in all of the maternal-fetal environments: 
the placenta, amniotic fluid and the fetus itself (Cai et al., 2000; Urakubo et al., 
2001; Paintlia et al., 2004; Ashdown et al., 2006; Meyer et al., 2006b; Boksa, 2010).  
In the placenta, signaling of cytokines along with growth factors and hormones play 
important roles in maternal and fetal cell cross talk (Hsiao & Patterson, 2012).  
Hence, placental alterations may lead to important deviations in developmental 
processes, and indeed placental health may even predict neurodevelopmental 
outcome (O’Keeffe & Kenny, 2014).  Therefore, it is likely that the placenta plays a 
role in the mechanisms underlying MIA induced changes in fetal development.    
Initially, researchers investigated if maternal immune factors or the 
immunogens themselves are able to cross the placenta and directly affect fetal 
development.  Interestingly, neither influenza (Shi et al., 2005) nor LPS were shown 
to cross the placenta in animal models (Ashdown et al., 2006).  This is consistent 
with findings that LPS does not cross chorioamniotic membranes in vitro in humans 
(Romero et al., 1987), possibly due to antimicrobial proteins found on fetal 
membrane epithelium (Kim et al., 2002).  However, cytokines, and in particular IL-
6, have been shown to cross the placental barriers.  Indeed, radioactive IL-6 was 
observed in the fetus 30 min after its administration to the pregnant rat (Dahlgren et 
al., 2006).  Importantly, this group also demonstrated a significant difference in the 
fetal levels of IL-6 depending on gestational age, with mid gestation (E11-E13) 
allowing for higher concentration of cytokine transfer compared to later gestation 
(E17-E19) (Dahlgren et al., 2006), suggesting that placental permeability changes 
throughout the course of pregnancy allowing for different levels of potentially 
harmful agents to reach the fetus depending on timing. 
 Animal models have also demonstrated structural and molecular 
abnormalities in the placenta and subsequent adverse fetal outcomes following MIA 
(Koga & Mor, 2010; Kneeland & Fatemi, 2013).  For example, after pregnant mice 
were infected with influenza on E7, placenta that were harvested on E16 displayed 
cytoarchitectural disorganization and an increased number of immune cells and there 
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was major genetic variation with upregulation of 77 genes and downregulation of 93 
others (Fatemi et al., 2012).  Furthermore, our group demonstrated that infection-
induced placental changes occurred, followed by altered development of neurons 
isolated from affected offspring, following late pregnancy MIA exposure in the rat 
(Straley et al., 2014).  The placental changes included increased levels of IL-1β, 
reduced placental weight, and down regulation of the enzyme 11β-hydroxysteroid 
dehydrogenase type 2 (HSD11β2) (Straley et al., 2014), which is an enzyme that 
plays an important role protecting the fetus from excessive maternal cortisol 
exposure (Togher et al., 2014).  Other placental differences, including massive 
necrosis and edema, and subsequent neurodevelopmental and behavioral deficits in 
affected offspring have also been reported (Girard et al., 2010; Carpentier et al., 
2011).  Importantly, the negative effects of these studies were attributed to cytokine 
signaling because targeting TNF-α (Carpentier et al., 2011) or IL-1 (Girard et al., 
2010) with receptor agonists prevented the placental pathology and alterations in 
progeny.  Furthermore, increases in IL-6 mRNA and protein levels in placenta were 
observed 3, 6, or 24h following Poly(I:C) (20mg/kg) exposure on E12.5, and IL-6 
mediated numerous endocrine changes in these placenta samples, including 
increased infiltration of uterine natural killer (uNK) cells and macrophages (Hsiao & 
Patterson, 2012).  We know from previous findings that IL-6 is a key mediator of 
MIA-induced behavioral deficits observed in affected offspring (Smith et al., 2007).  
Furthermore, evidence has shown that insult to the placenta itself (as opposed to a 
maternal systemic infection, etc.) is sufficient to induce many of the same 
neuropathological changes observed in MIA studies (Hutton et al., 2008; Bassan et 
al., 2010), suggesting that the placental consequences of MIA may mediate the 
unfavorable effects on the progeny.  Taken together, these data may implicate IL-6 at 
the heart of an indirect mechanism through which MIA alters fetal development. 
 
1.6.4 Oxidative Stress 
Oxidative stress is the imbalance that occurs when the body is not able to eliminate 
excessive levels of reactive oxygen species (ROS) in the body, and so the amount of 
free radicals in the body remains above a tolerable level (Di Carlo et al., 2012).  
When levels are maintained well, ROS are important in immune processes and are 
secreted by innate immune cells to help rid the body of invading pathogens (Nathan 
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& Shiloh, 2000), but when oxidative stress occurs it can lead to devastating 
outcomes.  Indeed, oxidative stress can lead to major cell damage (Sies, 2013), 
including neurodegeneration, apoptosis, and reduced neuroprotection (Sayre et al., 
2007; Niizuma et al., 2009) as well as mitochondrial dysfunction (Yan et al., 2012).  
Hence, oxidative stress has been implicated in neurodegenerative diseases (Sayre et 
al., 2007), specifically including PD (Jenner, 2003) and Alzheimer’s disease (AD) 
(Wang et al., 2014).   
In terms of MIA, the offspring from mice infected with influenza on E9 
demonstrated altered levels of nitric oxide (a common ROS) with increases in 
adolescence (P35) and decreases in early adulthood (P56) compared to control 
offspring (Fatemi et al., 1998; Fatemi et al., 2000a).  Similarly, maternal 
administration of LPS (700μg/kg or 1mg/kg) on E18 resulted in immediate (several 
hours) increase in oxidative stress markers in fetal rat brains (Paintlia et al., 2004; 
Paintlia et al., 2008).  This increase in oxidative stress in offspring brains following 
exposure to LPS in utero was shown consistently across the rat lifespan, from P9 
through P510 by multiple groups (1mg/kg on E10.5-E11, (Ling et al., 2004; Ling et 
al., 2006) and (700μg/kg on E18, (Paintlia et al., 2008).  Even more compelling is 
the finding that maternal treatment with the anti-oxidant N-acetylcysteine prevented 
fetal brain oxidative stress as well as some of the spatial learning deficits observed in 
adolescent offspring that had been exposed to LPS (500μg/kg) on E19 (Lanté et al., 
2008).  Therefore, oxidative stress may play a key mechanistic role in MIA 
associated disturbances, accounting for some of the detrimental outcomes that occur 
because of MIA (Meyer, 2013).   
Interestingly, it has been shown that IFN-γ, a type 11 interferon cytokine, 
mediates neuronal oxidative stress and apoptosis (Vartanian et al., 1995; Kneeland & 
Fatemi, 2013), and it is released during a bacterial infection (Kim et al., 2011).  
Furthermore, IFN-γ is found at higher levels in normal pregnancy because it plays a 
key role in placental development, modifying decidual arteries (Croy et al., 2002).  
Indeed, mice lacking uNK cells (the main lymphocytes found at human and murine 
implantation sites) had inadequate levels of IFN-γ which resulted in improper 
modification of decidual arteries, and uNK cell maturation  (Ashkar et al., 2000).  
Interestingly, nitric oxide is released by microglia (Nakajima & Kohsaka, 2001; 
Smith et al., 2012) in response to high levels of IFN-γ (Meda et al., 1995).   Taken 
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together, these reports suggest that there may be a connection between microglia, 
cytokines, oxidative stress, and malfunctioning placenta, all of which are thought to 
play mechanistic roles in MIA.   
  
83 
 
 
Figure 3: Key MIA Mechanisms 
The current mechanisms though to mediate the adverse effects of MIA on offspring 
neurodevelopmental outcome.  Altered cytokines (and in particular IL-6) in the 
maternal system, placenta and fetal brain, are thought to be the most potent factors in 
terms of MIA as they are able to alter the placenta as well as act directly on 
neurodevelopmental processes.  Oxidative stress is implicated in similar roles, and 
can be promoted by cytokines or active microglia.  Incidentally, altered functionality 
of microglia is another key mechanistic factor to MIA as microglia can alter any 
number of immunological factors within the CNS.  Finally, the placenta, which itself 
can be adversely affected by MIA as well as associated alterations in systemic 
cytokines and oxidative stress, is a contributor to detrimental outcomes following 
MIA exposure due to its roles in fetal protection and developmental regulation.    
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1.7 Relevance to Midbrain/ Dopaminergic System Development 
As described earlier, epidemiological and preclinical data have associated MIA with 
increased risk for a range of neurodevelopmental and neuropsychiatric disorders in 
affected offspring.  Many of these MIA-associated diseases are related to 
malfunctions in dopaminergic systems, including PD (Toulouse & Sullivan, 2008; 
Lees et al., 2009), schizophrenia (Brown et al., 2004a; Brown, 2006; Howes & 
Kapur, 2009; Brown & Patterson, 2011; Canetta & Brown, 2012), and ADHD 
(Pineda et al., 2007; Gold et al., 2014; Silva et al., 2014).  While the causative 
molecular basis of these conditions is an area of on-going investigation, it has been 
hypothesized that “fetal programming” as a result of MIA may alter the development 
of fetal dopaminergic neurons and associated dopamine (DA) pathways, and those 
alterations in combination with other genetic and environmental risk factors may 
converge into a final disease phenotype later in life (Howes & Kapur, 2009).  Thus, 
investigations into the effects of MIA on midbrain specific development and DA 
related behaviors are imperative for elucidating the role of MIA in DA-related 
disorders.   
 
1.7.1 Normal Development/ Anatomical Description 
Development of ventral mesencephalon (VM) DA neurons begins early in 
mammalian development in the floor plate of the mesencephalon.  Indeed, VM DA 
neurogenesis begins at E10 in the rat, induced by signaling factors FGF8, Shh, and 
Wnt1 (Hegarty et al., 2013).  These factors induce expression of FoxA2, Lmx1a/b, 
and Msx1, indicating the presence of VM DA NPCs (Ono et al., 2007).  The peak of 
proliferation of these DA NPCs occurs at E12 in the rat (Gates et al., 2006).  From 
about E12 to E16, the NPCs differentiate toward DA phenotype which is promoted 
by Nurr1 and Pitx3 expression (Smidt & Burbach, 2007; Deng, 2010).  Indeed, 
Nurr1 levels peak from E13-E15 in the rat, which is indecently when most VM DA 
neurons undergo differentiation (Volpicelli et al., 2004).  Then, the cells begin to 
migrate and extend axons at E13 in the rat, and their projections begin to reach the 
striatum by E14 and the cortex by E16 (Hegarty et al., 2013).  These projections 
ultimately result in the main dopaminergic pathways, which continue to be refined 
throughout postnatal development (Levitt, 2003; Tau & Peterson, 2010). 
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In the adult mammal, three quarters of all dopaminergic neurons are located 
in the midbrain, specifically in the SN and VTA (German et al., 1983; Pakkenberg et 
al., 1991; Blum, 1998; Hegarty et al., 2013).  The A9 DA cells of the SN primarily 
project to the dorsal striatum, forming the nigrostriatal pathway (Hegarty et al., 
2013).  Nigrostriatal dopaminergic function is crucial for voluntary motor control, 
and dopaminergic neuronal loss results in PD (Toulouse & Sullivan, 2008; Lees et 
al., 2009).  A10 and A8 DA neuron clusters from the VTA and retrorubal field 
(RRF), respectively, innervate the ventral striatum and prefrontal cortex (PFC), 
forming the mesocorticolimbic DA system (Björklund & Dunnett, 2007; Van den 
Heuvel & Pasterkamp, 2008).  Mesocorticolimbic dopaminergic function is crucial 
for the regulation of emotion and reward (Tzschentke & Schmidt, 2000), and 
alterations in this system have been implicated in schizophrenia (Meyer-Lindenberg 
et al., 2002; Howes & Kapur, 2009), drug addiction (Robinson & Berridge, 1993; 
White, 1996), depression (Martin-Soelch, 2009), and ADHD (Volkow et al., 2009). 
Importantly, the mesocorticolimbic system consists of two distinct subset pathways, 
the mesolimbic pathway which consists of A10 DA neurons that project from the 
VTA to the nucleus accumbens (NAc) (Joel & Weiner, 2000; Björklund & Dunnett, 
2007), and the mesocortical pathway in which the VTA DA neurons project to the 
PFC (Van den Heuvel & Pasterkamp, 2008).  The mesolimbic pathway functions are 
primarily concerned with reward processes, including emotional and motivational 
aspects of reward seeking along with goal-directed behavior (Van den Heuvel & 
Pasterkamp, 2008; Salamone & Correa, 2012); whereas the mesocortical pathway 
deals more with cognitive control and behavioral inhibition related to reward, 
emotion, and motivation (Tzschentke, 2001), and as such, these two pathways 
function synergistically for proper regulation of those processes.  
 
1.7.2 Developmental Effects of MIA 
VM DA neuron development is regulated by various well characterized genetic 
pathways and subsequent molecular pathways (Smidt & Burbach, 2007; Hegarty et 
al., 2013).  Interestingly, MIA (Poly(I:C), 5mg/kg, E9), altered gene expression of 
genes that have critical roles in DA neuron development including Shh and FGF8 as 
well as transcription factors Pitx3 and Nurr1 (Meyer et al., 2008a).  Indeed, 
Nurr1has been subjected to numerous investigations recently because of its 
important roles in the final differentiation, migration, and survival of DA neurons 
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(Hegarty et al., 2013) as well as regulation of TH and DAT in maturing and adult 
DA neurons (Saucedo-Cardenas et al., 1998; Kadkhodaei et al., 2009).  Furthermore, 
Nurr1 abnormalities have been observed in relation to PD (Jankovic et al., 2005), 
schizophrenia (Buervenich et al., 2000), and ADHD (Smith et al., 2005) implicating 
a role for this nuclear receptor transcription factor in MIA-induced alterations.  
Indeed, Nurr1
+/−
 mice demonstrated more of behavioral consequences along with 
improper development of prefrontal cortical and ventral striatal DA systems 
following Poly(I:C) (2mkg/kg) on E17 (Vuillermot et al., 2012).   
These genetic alterations are associated with structural and functional 
changes.  Indeed, Poly(I:C) (5mg/kg) administered on E9 to pregnant mice lead to a 
significant increase in TH-positive cells of affected offspring compared to controls in 
the SN at E19 and P70 and VTA at E70, and this increase was associated with an 
increase in Nurr1 protein expression (Vuillermot et al., 2010).  These results suggest 
that MIA has the ability to affect DA neuron development, possibly through 
alterations in Nurr1.  In contrast, however, other studies have found loss of DA 
neurons in the midbrain in rats following intracerebral injection of LPS at P5 
followed by analysis of DA neuron numbers in the midbrain P21 (Fan et al., 2005) 
as well as following in utero (E10.5) maternal LPS injection and offspring rat brains 
analyzed at P21, P120, P210, P420, and P510 (Ling et al., 2002; Ling et al., 2004; 
Ling et al., 2006; Ling et al., 2009).  While the difference in immunogen and species 
may make these studies less than ideal candidates for comparison, the recognition 
that MIA is able to alter DA neuron development is not trivial.   
Importantly, the ability of MIA to affect DA neuron development expands to 
include the regions of dopaminergic projection.  For instance, exposure to in utero 
Poly(I:C) (5mg/kg) on E9 resulted in a decrease in TH density in the nucleus 
accumbens of mouse adolescent offspring (P35), followed by an increase in TH 
density adulthood (P70) (Vuillermot et al., 2010).  These cellular differences are in 
parallel with neurochemical findings of decreased striatal DA levels in adolescence 
(P39), but increased in adulthood following LPS exposure (2mg/kg) every day 
throughout pregnancy (Romero et al., 2007).  Consistently, Poly(I:C) exposure 
(5mg/kg) daily from E12-E17 resulted in hyperfunction of striatal DA in adulthood 
for mice (Ozawa et al., 2006).  Cortical projections are also affected by MIA, as 
decreased expression of dopamine receptor (DR) 1 and DR2 (Meyer et al., 2008c; 
Meyer et al., 2008d), along with significantly increase basal DA levels (Winter et al., 
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2008) were observed in PFC of adult offspring following exposure to Poly(I:C) 
(5mg/kg) in utero (E9). 
 
1.7.3 Behavioral Effects of MIA 
Given that MIA can lead to altered neurodevelopment and subsequent neurochemical 
alterations, and because DA is required for proper functioning of motor control 
(Volkow et al., 1998; Jenkinson & Brown, 2011) and regulation of emotion and 
reward (Tzschentke & Schmidt, 2000), subsequent studies have investigated the 
behavioral consequences in affected offspring behavior following MIA in animal 
models.   
A number of studies have focused on the nigrostriatal dopaminergic pathway 
by measuring motor behavior (Girault & Greengard, 2004).  Some have shown 
delayed achievement of certain developmental milestones (Toso et al., 2005; Xu et 
al., 2013), while other studies report no difference following MIA (Golan et al., 
2005; Kirsten et al., 2010a).  Rotarod and open field have been used to test motor 
coordination following MIA, but results are again conflicting with some studies 
reporting differences (Roberson et al., 2006; Girard et al., 2009), and others none in 
affected offspring (Zager et al., 2012).  One of the most common ways of studying 
the motor system has been with the use of amphetamine (AMPH) challenges 
(Bernardi et al., 1986; Robinson & Becker, 1986; Jackson et al., 1994; Rodríguez et 
al., 2013) because of the ability of the drug to induce locomotion through promotion 
of increased DA release (Pijnenburg et al., 1976; Ikemoto, 2002; Zager et al., 2012; 
Shim et al., 2014).  Furthermore, enhanced susceptibility to AMPH-induced DA 
stimulation has been observed in disorders affecting the DA system, including 
schizophrenia (Laruelle et al., 1996; Laruelle et al., 1999).  This is consistent in 
some animal models of MIA.  For example, the locomotion response to AMPH was 
enhanced for animals exposed to prenatal Poly(I:C) (2 or 5 mg/kg, on E9 or E17) 
(Meyer et al., 2007). However, inconsistent findings have also been reported as 
reduced response to AMPH in locomotion behavior was observed for adult rat 
offspring that had been exposed to Poly(I:C) in utero (on E14) (Richtand et al., 
2011).   
Due to the contribution of DA imbalance in schizophrenia (Laruelle et al., 
1999; Howes & Kapur, 2009; Brunelin et al., 2013; Lau et al., 2013) and ADHD 
(Levy, 1991; Swanson et al., 2000; Volkow et al., 2009; Volkow et al., 2011) 
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pathology, other studies have utilized motivation or goal directed behavior assays in 
order to investigate functionality of the mesocorticolimbic DA system following 
MIA.  Adult rats that had been exposed to Poly(I:C) (4mg/kg) on E15 did not differ 
in discrimination learning, motivation, nor gross locomotor behavior compared to the 
saline exposed controls in a basic operant conditioning task with food restriction 
(Zhang et al., 2012).  However, another study administered betamethasone, an anti-
inflammatory and immunosuppressive glucocorticoid, to pregnant baboons and 
subsequently tested juvenile offspring in progressive ratio task, among other learning 
and motivation behaviors, in which they found a decrease in motivation for affected 
juveniles, suggesting that alterations to the fetal environment have the ability to alter 
later motivation and reward behaviors (Rodriguez et al., 2011).  Furthermore, 
maternal malnutrition resulted in restricted learning and motivation of offspring as 
demonstrated by operant conditioning scenarios in rats (Reyes-Castro et al., 2011; 
Reyes-Castro et al., 2012; Rodriguez et al., 2012b) and baboons (Rodriguez et al., 
2012a; Keenan et al., 2013).  Poor maternal nutrition has resulted in a number of 
detrimental effects on offspring neurodevelopment including poor neuronal circuit 
formation, down regulation of growth factors, increased cell death, and inability for 
normal developmental maturation and organization of certain cell types (for reviews 
see (Morgane et al., 1993; Monk et al., 2013)), and is associated with fetal origins of 
adult diseases similarly to MIA (Barker & Osmond, 1986; Barker, 2002; Armitage et 
al., 2004).   
As pointed out by Meyer, these findings have not provided us with a direct 
causal link from MIA to the DA-associated structural and functional alterations 
observed throughout the life span of affected offspring, because MIA may result in 
any number of neurodevelopmental sequelae, but they have demonstrated that DA 
abnormalities begin in utero following MIA and they are developmentally regulated 
(Meyer, 2013).  As such, MIA-induced atypical fetal midbrain development is the 
potential starting point on a trajectory which, in combination with genetic factors and 
other environmental insults, could lead to malfunctioning nigrostriatal or 
mesocorticolimbic pathways and the eventuality of related disorders.  However, 
before we can put all of the pieces of this multifaceted story together, we must 
understand each stage in its entirety.  In order to do this, more comprehensive 
analysis of MIA effects using standardized animal models will need to occur.  This is 
because the current literature is varied and conflicting due to differences in 
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experimental designs and animal models, which makes it hard to draw conclusions 
between lab groups or even between studies.    
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1.8 Aims and Objectives of the Thesis 
This thesis aims to comprehensively investigate the effects of MIA on offspring 
midbrain development and function, and in particular to gain a better understanding 
of how and why the developing brain is more susceptible to the effects of MIA at 
different gestational ages.  There is currently a great deal of conflicting information 
regarding the behavioral effects of MIA exposure, and the cellular and molecular 
consequences of MIA on the developing midbrain remain to be fully elucidated.  
Thus, the overall objective of my project is to establish the consequences of acute 
and mild MIA on offspring dopamine-related behaviors, as well as the associated 
cellular and molecular disturbances of MIA on the midbrain of the offspring.    
 
1.8.1 Establish an animal model of acute and mild maternal infection 
While there are currently a wide variety of animal models of MIA, they are 
paralleled with inconsistent findings in developmental and behavioral outcomes 
(Boksa, 2010; Harvey & Boksa, 2012).  Thus we initially sought to validate our own 
model of acute and mild MIA with which we could reproduce and compare across 
studies.  Our low dose of LPS aimed to represent an animal model of 
chorioamnionitis, a bacterial infection of the fetal membranes which is often 
subclinical and associated with negative fetal outcomes (De Felice et al., 2005; 
Miyazaki et al., 2007).   
 
1.8.2 Determine the effects of MIA on placenta 
As the placenta is a key regulator of fetal development (Huppertz, 2008; Togher et 
al., 2014), and placental health is a great indicator of neurodevelopmental outcome 
(O’Keeffe & Kenny, 2014), determining the effects of our model of MIA on the 
placenta was extremely important.  In particular, investigating changes in placental 
cytokine levels as well as expression of HSD11B2 would help to understand the 
MIA-induced, placenta-mediated alterations in neurodevelopment because cytokines 
are known to alter neuron development (Deverman & Patterson, 2009; Stolp, 2013) 
and HSD11B2 is a critical regulator of fetal neurodevelopment (Togher et al., 2014). 
 
91 
 
1.8.3 Investigate any changes in offspring dopamine-related behaviors in the MIA 
model 
There is a large body of literature relating to behavioral consequences of MIA 
(Meyer et al., 2007; Meyer et al., 2008d; Meyer et al., 2009; Boksa, 2010; Harvey & 
Boksa, 2012; Meyer, 2014), however inconsistency in results plagues the research 
field.  Differences in experimental methods are widely attributed as the reason for 
this.  Therefore, there was a need for a comprehensive study that would elucidate the 
lifelong behavioral consequences following MIA exposure at different time points 
during pregnancy, using one validated animal model.  Furthermore, we are most 
interested in midbrain development and associated functioning as it relates to 
numerous disease etiologies, including PD (Toulouse & Sullivan, 2008), 
schizophrenia (Meyer-Lindenberg et al., 2002; Howes & Kapur, 2009), drug 
addiction (Robinson & Berridge, 1993; White, 1996), depression (Martin-Soelch, 
2009) and ADHD (Volkow et al., 2009). Therefore, we utilized a wide array of 
behavioral assays which would provide information into the functionality of 
dopaminergic systems across the lifespan of affected offspring. 
 
1.8.4 Establish molecular and cellular effects of MIA on midbrains of affected 
offspring 
The final aim of the thesis was to investigate possible factors that could lead to 
behavioral deficits.  As MIA results in increased levels of pro-inflammatory 
cytokines, including IL-1β and TNF-α, in the fetal brain (Urakubo et al., 2001), and 
we have demonstrated that IL-1β impairs proliferation and alter differentiation of 
VM NPCs in vitro (Crampton et al., 2012), it was important to determine the 
cytokine profiles of offspring subjected to our MIA model.  Following from this, we 
then needed to establish if MIA resulted in any alteration to VM NPC proliferation, 
as well as determine how inflammatory mediators affected differentiation in culture.  
Due to the different age of onset for MIA associated disorders, it was also important 
to identify the cytoarchitecture of the midbrain across the lifespan.  Importantly, as 
timing of MIA determines fetal outcome due to the different developmental 
processes that occur at different gestational stages (Andersen, 2003), we sought to 
determine these characteristics following MIA at different time points to establish 
critical windows for our model.    
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Chapter 2: 
 
LPS alters placental inflammatory and 
endocrine mediators and inhibits fetal neurite 
growth in affected offspring during late 
gestation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Straley ME, Togher KL, Nolan AM, Kenny LC, O'Keeffe GW.  LPS alters 
placental inflammatory and endocrine mediators and inhibits fetal neurite growth in 
affected offspring during late gestation.  Placenta. 2014 Aug;35(8):533-8. doi: 
10.1016/j.placenta.2014.06.001. Epub 2014 Jun 12.     
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Abstract 
Introduction 
During pregnancy, maternal infection at different stages of gestation increases the 
risk of developing several psychiatric and neurological disorders later in life for 
affected offspring.  As placental health is intrinsically linked to neurodevelopmental 
outcome, maternal infection may adversely affect the placenta at or before the 
gestational stages it affects fetal neurodevelopment.  Here we examined this premise.      
Methods 
Pregnant-Sprague Dawley rats were administered saline or lipopolysaccharide (LPS) 
by intraperitoneal injection on embryonic days 12 – 18.  We then examined a 
number of key placental inflammatory and endocrine mediators, along with fetal, 
birth and neuronal characteristics at different stages of development.   
Results 
Maternal exposure to LPS at later gestational ages significantly increased pro-
inflammatory IL-1β expression and reduced placental HSD11β2 expression.  This 
was accompanied by a reduction in placental weight and embryo number without an 
effect on embryo weight or crown rump length.  In utero LPS exposure at later 
gestational ages also impaired the growth of neurons from affected offspring.    
Discussion 
These data show that maternal infection at later gestational ages modifies placental 
inflammatory and endocrine mediators that may adversely affect the growth of 
developing neurons in affected offspring.   
 
 
Key words:  Maternal infection, placenta, pregnancy, LPSneuron. 
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2.1 Introduction 
Fetal programming describes how in utero adversity influences developmental 
trajectories and disease risk in affected offspring (Schlotz & Phillips, 2009).  Many 
epidemiological studies have now provided evidence that maternal infection during 
pregnancy, increases the risk for neurodevelopmental and neuropsychiatric disorders 
in affected offspring that include schizophrenia (Brown et al., 2004a; Brown et al., 
2005), autism spectrum disorders (Zerbo et al., 2013a) and cerebral palsy (Shatrov et 
al., 2010) (for recent excellent reviews see (Boksa, 2010; Canetta & Brown, 2012)).  
Critical to these outcomes, is the role of the placenta at the maternal-fetal interface in 
regulating fetal growth and development (Huppertz, 2008).  There is increasing 
evidence that placental health plays a key role in determining fetal 
neurodevelopmental outcome (for review see (Baker & Sibley, 2006; von Beckerath 
et al., 2013; O’Keeffe & Kenny, 2014)).  This was directly assessed in a recent 
retrospective cohort study which showed that neurodevelopmental impairment was 
significantly more frequent in infants with distinct signs of placenta dysfunction 
compared to those with normal placental function (von Beckerath et al., 2013).  
These data show that placental health during pregnancy is likely to be intrinsically 
linked to neurodevelopmental outcome, thus infection-induced changes in the 
placenta may contribute to the molecular sequale of how these affect the developing 
fetal nervous system.   
Important to the protective functions of the placenta is the enzyme 11β-
hydroxysteroid dehydrogenase type-2 (HSD11β2) which protects the fetus from the 
much higher levels of maternal glucocorticoids seen in pregnancy (Demey-Ponsart et 
al., 1982; D'Anna-Hernandez et al., 2011; Jung et al., 2011), by converting active 
cortisol into inactive cortisone (Sun et al., 1997; Cuffe et al., 2012).  This enzyme is 
critical in protecting the developing fetus from potential adverse fetal programming 
due to heightened cortisol exposure (Holmes et al., 2006; Cottrell et al., 2014; 
Togher et al., 2014).  Interestingly, the pro-inflammatory cytokines tumor necrosis 
factor (TNF)-α and interleukin (IL)-1β have been shown reduce HSD11β2 
expression in vitro (Chisaka et al., 2005; Suzuki et al., 2005; Kossintseva et al., 
2006).  Despite this, whether maternal infection reduces placental HSD11β2 
expression in vivo is unknown. 
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The increase in risk for adverse neurodevelopmental outcome for affected 
offspring following maternal infection has been shown to be dependent on the stage 
at which the infection occurs during pregnancy.  For example, bacterial infection in 
the second, but not the first trimester of human pregnancy was found to increase the 
risk for autism spectrum disorders and schizophrenia in the offspring (Sørensen et 
al., 2009; Atladóttir et al., 2010; Patterson, 2011b).  This has been confirmed by a 
large body of work in pre-clinical models that have confirmed the presence of 
“critical developmental periods” during which the developing nervous system is 
susceptible to the effects of maternal immune activation (Boksa, 2010; Harvey & 
Boksa, 2012).  In agreement with this, we have recently shown, using the well-
characterized superior cervical ganglion (SCG) in vitro model (Glebova & Ginty, 
2005), that the growth of fetal neurons can be inhibited by the pro-inflammatory 
cytokine, interleukin (IL)-1β, at late embryonic and early postnatal stages of 
development, but not before or after this developmental window of sensitivity 
(Nolan et al., 2011).  This suggests that maternal infection during this window of 
sensitivity may impair fetal neurite growth and/or affect the placenta.  Here we use 
the lipopolysaccharide (LPS) rat model to examine the effects of maternal infection 
on placental expression of proinflammatory cytokines and HSD11β2 which plays a 
critical role in protecting the fetus against excessive exposure to maternal cortisol 
(Holmes et al., 2006; Cottrell et al., 2014; Togher et al., 2014), and determine its 
effects on the developing fetus and the growth of fetal neurons at different stages of 
gestation. 
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2.2 Materials and Methods 
2.2.1 LPS injections and sample collection 
The study carried out under license with full ethical approval from the Ethics 
Committee of UCC.  Time mated Sprague-Dawley rats (Biological Services Unit, 
UCC) were maintained in a controlled environment on a 12 hour light/dark cycle 
with ad libitum access to food and water.  Pregnant dams (n=4/group/time point) 
received an intraperitoneal (I.P.) injection of LPS (Sigma: 50μg/kg) or normal saline 
on embryonic day (E)12, E14, E16, or E18.  48 h post injection, dams were 
anesthetized with inhaled Isoflurane (Abbeville Veterinary hospital, Cork) and culled 
by decapitation.  Embryonic sacs were removed via laparotomy, and washed in ice-
cold Hank’s Balanced Salt Solution (HBSS).  Embryos were removed from the yolk 
sac and transferred to fresh HBSS where then they were weighed and crown-to-rump 
length (CRL) was measured.  Placentae were cleaned of all membranes, quickly 
weighed, and either snap frozen in liquid nitrogen or fixed in 4% PFA for 24h, then 
cryoprotected for 48h.  SCG samples were dissected as previously described (Zareen 
& Greene, 2009).  Briefly, the head was faced ventral side up in order to identify the 
trachea.  Then forceps were used to clear away skin and fat around the trachea in 
order to expose parallel muscles that run alongside the trachea.  The muscle was 
removed from one side first to expose the carotid artery, which runs along the 
trachea as well before it branches into a “Y” shape.  The carotid artery was severed 
at the most caudal end and then lifted up to locate the almond-shaped mass of glossy 
tissue that is the SCG just at the point of the “Y”. The SCG was gently detached, and 
the same method was used to obtain the SCG tissue from the other side of the 
trachea.  
 
2.2.2 Real-time PCR 
A motorized pestle and mortar were used to disrupt the placenta and total RNA was 
extracted using an RNeasy tissue mini kit (Qiagen).  RNA concentration was 
determined using a Spectrophotometer (NanoDrop Technologies).  500ng of RNA 
was reverse transcribed using a high capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) in a 20μl reaction mixture consisting of 2.0μl 10X RT Buffer, 
0.8μl 25X dNTP mix (100mM), 2.0μl 10X RT Random Primers, 1.0μl Reverse 
Transcriptase, and 4.2μl Nuclease-free H2O, using the following parameters: 25°C 
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for 10 min; 37°C for 120 min; 85°C for 5 min; 4°C for at least 10 minutes.  The 
cDNA was stored at -80°C prior to use.  For real time PCR, all samples were run in 
triplicate, with the reaction mix for a single reaction consisting of 1.0 μl 20X 
TaqMan® Gene Expression Assays (Applied Biosystems), 10 μl 2X TaqMan® Gene 
Expression Master Mix (Applied Biosystems), and 8.0 μl RNase-free H2O (Applied 
Biosystems).  19 μl of the mix was added to each well of a 96 well PCR reaction 
plate (Applied Biosystems) as well as 1.0 μl of the relevant cDNA.  The plate was 
centrifuged briefly and then loaded into the qRT-PCR system (StepOne Real-Time 
PCRY System, Applied Biosystems) and run using the following cycling parameters; 
50°C for 2 minutes; 95°C for 10 minutes; and 50 repetitions of 95°C for 15 seconds 
and 60°C for 1 min.  Analysis was carried out using the 2-CT method (Livak & 
Schmittgen, 2001).   
 
2.2.3 Immunohistochemistry 
Post-mortem immunohistochemistry for HSD11β2 was performed on 20μm 
cryosections of the fixed placentae.  To block endogenous peroxidase, sections were 
treated with 10% H2O2 for 5 min, washed in 10mM PBS and blocked for 1 h in 10% 
normal goat serum in 10mM PBS with 0.4% Triton-X.  Sections were then incubated 
in primary antibody to HSD11β2 (1:250; Sigma) in 1% normal goat serum in 10mM 
PBS with 0.4% Triton-X overnight at 4°C.  Following a 3 x 10 min wash in 10mM 
PBS, sections were incubated with a biotinylated secondary antibody (1:200, goat 
anti rabbit, Vector Labs) for 2 h at room temperature.  Following another 3 x 10 min 
wash in 10mM PBS, sections were incubated in ABC solution (1:200; Vector Labs) 
for 45 minutes at room temperature followed by immersion in diaminobenzidine 
substrate/chromogen reagent for 2-3 min at room temperature.  Sections were 
dehydrated, cleared, mounted and imaged using an Olympus AX70 Provis upright 
microscope.  Negative controls received the same treatment except PBS was 
substituted for the primary antibody.   
 
2.2.4 Corticosterone ELISA 
Pregnant dams were culled by rapid decapitation between 10:00am and 12:00pm and 
trunk blood was collected, centrifuged for 15 min at 4°C to isolate serum, which was 
stored at -80°C.  Serum corticosterone concentration was determined using a 
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commercial ELISA assay kit (Enzo Life Sciences, NY, USA) according to the 
manufacturer's instructions.  The corticosterone concentration was calculated via 
reference to the standard curve. 
 
2.2.5 Cell culture and quantification 
Study 1: JEG-3 cells treated with IL-1β 
JEG-3 human choriocarcinoma cells were grown and maintained in 
Dulbecco's Modified Eagle Medium Nutrient Mixture F-12 (Sigma), supplemented 
with 10% fetal calf serum (Sigma), 100 nM L-Glutamine (Sigma), 100 U/ml 
Penicillin (Sigma) and 10 μg/ml Streptomycin (Sigma), in a humidified atmosphere 
containing 5% CO2 at 37 °C.  Cultures were treated with 10ng/mL IL-1β for 24h.   
Cultures were fixed in ice-cold methanol for 5 min at room temperature, 
blocked with 5% bovine serum albumin (BSA; Sigma) in PBS before incubation 
with rabbit anti-11HSDB2 (1:250; Santa Cruz Biotech) in 1% BSA in 10mM PBS at 
4°C overnight.  Cultures were washed in 10mM PBS and incubated for 2h at room 
temperature with an appropriate secondary antibody (Alexa Fluor; Invitrogen; 1:500) 
in 1% BSA in PBS in the dark.  The fluorescence intensity of HSD11β2 expressing 
JEG-3 cells was measured using the Image J analysis software. The relative 
fluorescence intensity was calculated per individual cell after subtraction of the 
background. 
 
Study 2: SCG investigation 
Following in utero LPS exposure on E16 or E18, dissociated neurons from 
the superior cervical ganglia (SCG) of embryonic (E18) and postnatal (P1) Sprague-
Dawley rats were plated at a low density on poly-ornithine/laminin-coated 4 well 
35mm tissue culture dishes (Sigma; Greiner Bio-One) and cultured in a humidified 
atmosphere containing 5% CO2 at 37°C for 24 h as previously described (Nolan et 
al., 2011).   
All cultures were fixed in ice-cold methanol for 5 min at room temperature, 
blocked with 5% bovine serum albumin (BSA; Sigma) in PBS before incubation 
with mouse anti-β-III tubulin (to visualize neurons and quantify neuronal survival) 
(1:250; Promega) in 1% BSA in 10mM PBS at 4°C overnight.  Cultures were 
washed in 10mM PBS and incubated for 2h at room temperature with an appropriate 
99 
 
secondary antibody (Alexa Fluor; Invitrogen; 1:500) in 1% BSA in PBS in the dark.  
Neuronal survival and the total neurite length and number of branch points of 
neurons was measured using Sholl analysis as previously described (Gutierrez & 
Davies, 2007; Nolan et al., 2011).   
 
2.2.6 Data analysis 
In this study we were interested in how the LPS exposed group compared to the 
corresponding control for each variable investigated, therefore all data were analyzed 
using student’s T-tests.    
100 
 
2.3 Results 
2.3.1 Effect of maternal LPS exposure on placental, fetal and birth characteristics 
Firstly, we carried out a morphometric analysis of the placenta and fetal birth 
characteristics to determine if LPS induced any overt change in these parameters.  
I.P. administration of LPS to the pregnant dams on E16 resulted in a significant 
decrease in placental weight by E18 (Fig. 1a), but we found no significant change in 
placental weight when LPS was administered on E12 or E14 (Fig. 1a).  I.P. 
administration of LPS on E12 did not result in any significant difference in the 
number of embryos per dam on E14, however LPS administration on E14 and E16, 
resulted in a significant reduction in the number of embryos per dam on E16 and E18 
respectively (Fig. 1b).  We next examined the crown-rump length (CRL) and fetal 
weight at these time points and found that LPS exposure did not significantly change 
these parameters irrespective of when LPS was administered (Fig. 1c-e).  I.P. 
administration of LPS on E16, which reduces placental weight at E18 (Fig. 1a), had 
no effect on birth weight, however repeated exposure to LPS on E12, E14, E16 
significantly reduced birth weight (data not shown). These data suggest that the 
duration of LPS exposure may dictate its effects on birth weight, despite that shorter 
term LPS exposures can affect the placenta. 
 
2.3.2 The effects of maternal LPS on placental cytokine and HSD11B2 expression 
vary by developmental age. 
We next sought to determine the mRNA expression profile of TNFα and IL-1β in the 
placenta following maternal exposure to LPS at different stages of gestation.  I.P. 
administration of LPS to the pregnant dams on E14 and E16 resulted in a significant 
increase in placental IL-1β mRNA expression on E16 and E18 respectively (Fig. 2a), 
but we found no significant change in TNF-α expression at these time points (Fig. 
2b).  The greatest increase in IL-1β mRNA expression was observed at E18 (Fig. 
2a).   
To determine if maternal exposure to LPS altered the expression of placental 
HSD11B2, which is a critical regulator of fetal development (Togher et al., 2014), 
we next examined the expression of placental HSD11β2 using real-time PCR and 
immunocytochemistry at each of these time points.  HSD11β2 protein (Fig. 2c) and 
mRNA (Fig. 2d) were expressed in the placenta at all gestational ages studied. Using 
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quantitative real-time PCR, we found that levels of HSD11β2 mRNA significantly 
increased from E14 to E16 and from E16 to E18 (Fig. 2d).  I.P. administration of 
LPS to pregnant dams on E12 induced a significant up-regulation of HSD11β2 
mRNA expression in the placenta (Fig. 2e).  In contrast, I.P. administration of LPS 
on E14 or E16 resulted in a significant decrease in HSD11β2 expression at E16 and 
E18 respectively (Fig. 2e).   
As cortisol/corticosterone levels are known to regulate HSD11β2 expression 
(Togher et al., 2014), we next examined maternal corticosterone levels at E18 in 
pregnant dams that received I.P LPS or saline on E16.  We found that maternal 
corticosterone levels were significantly lower in the LPS group compared to saline 
treated controls using an ELISA on maternal plasma samples (Fig. 2f), suggesting 
that the decrease in HSD11β2 expression is not due to an increase in maternal 
cortisol levels.  Given that we found a significant up-regulation of placental IL-1β at 
E18, we next examined if IL-1β could reduce the expression of HSD11β2 in the 
placental JEG3 cell line.  Treatment of JEG3 cells with 10ng/ml IL-1β for 24h 
resulted in a significant down regulation in HSD11β2 expression (Fig. 2g, h) 
suggesting that LPS-induced increase in placental IL-1β at E18 may mediate the 
observed decrease in placental HSD11β2 expression. 
 
2.3.3 Effect of maternal LPS exposure on fetal neurite growth  
Maternal infection is a known risk factor for a neurological dysfunction later in life 
(Boksa, 2010).  We have previously shown that IL-1 exerts a growth inhibitory 
effect on developing fetal neurons that becomes apparent on E18, but not at 
developmental stages preceding this (Nolan et al., 2011).  Given that maternal 
exposure to LPS increases placental IL-1β mRNA in late but not early stages of 
pregnancy (Fig. 2), we next examined if developing neurons in LPS exposed 
offspring were affected at specific stages of pregnancy.  To explore this further, we 
cultured neurons isolated from the SCG of rat pups or embryos that were exposed to 
maternal inflammation in utero. The SCG model system is a well characterized and 
experimentally tractable population of neurons extensively used to analyze the 
molecular basis of neuronal survival and axonal growth (Nolan et al., 2011).  Neuron 
cultures from P1 pups of pregnant dams that were exposed to LPS at E18 displayed a 
significant reduction in neurite length (Fig. 3a-c), whereas those neurons from pups 
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of dams exposed to LPS on gestational day 16 and grown at E18 or P1 grew 
normally (Fig. 3a). There was no effect on neuronal survival at any stage (data not 
shown).  To confirm these findings, we used Sholl analysis, which provides a 
graphic illustration of neurite length and branching with distance from the cell body. 
Neurons from pups exposed in utero to LPS at E18 displayed a significant reduction 
in their Sholl profile (Fig. 3b) indicating a decrease in neuronal arbor elongation and 
complexity, whereas neurons from pups exposed in utero to LPS at E16 grew 
normally (Fig. 3b).  This affect was not due to a direct effect of LPS, as neurons 
cultured in the presence of LPS were not adversely impacted in terms of axonal 
length (Fig. 3d), Sholl profile (Fig. 3e) and survival (Fig. 3f).    
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2.4 Figures and Figure Legends: 
 
 
Figure 1: Maternal LPS exposure in late stages of pregnancy reduces placenta 
weight and fetal number. 
(a) Graphical representation of placental weight, and (b) number of embryos, in 
pregnant dams at E14, E16 and E18 that received an I.P. injection of saline (control) 
or 50µg/kg LPS at E12, E14, or E16 respectively. (c) Representative examples of 
embryos (d) crown rump length (CRL) and (e) average fetal weight at each age from 
pregnant dams that received an I.P. injection of saline (control) or 50µg/kg LPS at 
E12, E14 or E16 with the embryos assessed following removal by laparotomy 48 h 
later.  All data are expressed as mean ±SEM. (* P < 0.05).       
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Figure 2: The effects of maternal LPS exposure on placental cytokine and 
HSD11β2 expression vary by developmental age. 
Graphical representations of (a) IL-1β and (b) TNF-α mRNA expression in the 
placentae of pregnant dams that received an I.P. injection of saline (control) or 
50µg/kg LPS at E12, E14, or E16.  (c) Immunohistochemistry and (d) real-time PCR 
data showing HSD11β2 expression in the placenta at each gestation studied.  (e) 
Graphical representation of real-time PCR data showing HSD11β2 mRNA 
expression in control and LPS exposed dams at E14, E16, and E18.  (f) Graphical 
representation of maternal corticosterone concentration in pg/ml at E18, 48h post 
LPS or saline exposure.  (g) Relative levels of HSD11β2 expression, and (h) 
representative photomicrographs of HSD11β2 expression in JEG3 cells treated with 
10ng/ml IL-1β for 24h.  All data are expressed as mean ± SEM. (* P < 0.05, ** P < 
0.01, *** P < 0.001, ### P < 0.001).       
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Figure 3: Maternal LPS exposure in late stages of pregnancy inhibits neurite 
growth. 
(a) Graphical representation of normalized total neurite length as percentage of 
control, and (b) Sholl profiles of SCG neurons from embryos or pups from dams that 
received an I.P. injection of saline (control) or 50µg/kg LPS at E16 or E18 with 
neurons cultured for 24h at E18 or P1 as indicated (day of I.P. injection  day of 
culture).  (c)  Representative photomicrographs of P1 SCG neurons after 24h in vitro 
from P1 pups that were exposed to either saline or 50µg/kg LPS on E18 in utero.  (d)  
Total neurite length, (e) Sholl profile and (f) survival of E18 SCG neurons directly 
treated with 50ng/ml LPS for 24h.  All data are expressed as mean ±SEM. (** P < 
0.01). 
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2.5 Discussion 
During this study, we found that placental HSD11β2 expression increased from E14 
to E18.  This progressive increase in HSD11β2 expression with advanced pregnancy 
has been demonstrated in the human (Benediktsson et al., 1993; Shams et al., 1998; 
Togher et al., 2014) and baboon (Pepe et al., 1996) placenta previously.  Conversely, 
HSD11B2 mRNA is abundantly expressed in the labyrinth zone and extra embryonic 
membranes of the mouse placenta until E15.5 but then halts at E16.5 (Brown et al., 
1996).  Contradictory trends have been previously observed in the rat with increasing 
enzymatic activity of rat placental HSD11β2 with advancing pregnancy (E16 to E22) 
has been demonstrated by some (Burton & Waddell, 1994) but not others (Staud et 
al., 2006).  However there may be zone specific effects, as HSD11β2 mRNA 
expression in the labyrinth zone and decidua decreases, while it increases in the basal 
zone with advancing gestation (Burton et al., 1996; Waddell et al., 1998).  
Interestingly we found that maternal exposure to LPS has a bi-phasic effect on 
placental HSD11β2 expression in that it increased placental HSD11β2 expression at 
mid-gestation (E14), but decreased it at later stages (E18).  These findings are 
supported by a study by Cottrell et al. that showed that a maternal low protein diet 
increased placental HSD11β2 expression at mid-gestation (E13.5), but reduced it at 
late gestation (E17.5) in the mouse (Cottrell et al., 2012).   
As we found that maternal exposure to LPS induced a down-regulation of 
HSD11β2 expression at later stages of pregnancy we next examined its effect on 
maternal corticosterone and found that at the same developmental stage, LPS 
induced a down-regulation of maternal corticosterone levels (Fig. 2).  These finding 
are supported by previous studies showing that cortisol infusion into pregnant mice 
between embryonic day E12 and E15 up-regulated HSD11β2 expression in the 
placenta two days later (Cuffe et al., 2012), indicating that LPS-induced decrease in 
cortisol levels post LPS, may lead to the observed decrease in HSD11β2 expression.  
However, we also observed an increase in placental IL-1expression and found that 
IL-1 treatment of the JEG3 placental cell line down-regulated HSD11β2 expression 
after 24h.  This is in agreement with previous studies showing that TNF-α reduced 
HSD11β2 expression in LLC-PK cells (Heiniger et al., 2001).   Similarly, TNF-α, 
and IL-1β have been shown to reduce HSD11β2 in term human placental villi 
explants (Kossintseva et al., 2006).  However IL-1β (but not TNF-α) decreased 
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HSD211β2 expression in primary cultures of term trophoblasts, indicating a 
predominant role for IL-1β in regulating placental HSD11β2 expression (Chisaka et 
al., 2005).  In agreement with this, we found that LPS induced placental IL-1 but 
not TNF- expression.  Collectively these data suggest that the down-regulation in 
placental HSD11β2 expression post LPS, may be mediated by a drop in maternal 
cortisol levels and an increase in placental IL-1 expression. 
Interestingly we also found that maternal LPS reduced placental weight 
without affecting fetal weight only at E18.  This is supported by a study showing that 
in the HSD11β2-/- mice at E15 (~E17 rat) there was a reduction in placental weight 
while fetal weight was maintained suggesting that compensatory changes occur in 
the placenta to maintain function (Wyrwoll et al., 2009).  What these changes mean 
for fetal exposure to cortisol remains to be determined. However as demonstrated by 
Cottrell et al. placental HSD11β2 expression in vivo protect the fetus from the effects 
of maternal cortisol overexposure, and a reduction in placental HSD11β2, increased 
fetal concentration of corticosterone (Cottrell et al., 2012). This suggests that in our 
study the significant decrease in placental HSD11β2 expression post LPS at late 
gestation may result in elevated fetal exposure to maternal corticosterone. However, 
we also observed a significant reduction in maternal corticosterone levels at this 
stage, but as corticosterone levels are many times higher in the maternal circulation, 
this may still result in elevated fetal exposure to maternal corticosterone as a result of 
decreased placental HSD11β2 expression, the exact scale of which will depend 
potentially on the change in the ratio between both parameters. The 
neurodevelopmental ramifications of this will likely depend on the degree of change 
in fetal cortisol levels (for excellent review see (Cottrell et al., 2014)), and may also 
be influenced and even exacerbated by corresponding changes pro-inflammatory 
cytokine levels, which have been shown to have many adverse effects on the 
developing brain (Boksa, 2010). 
 In agreement with this, we found that in utero LPS exposure, during the stage 
at which the placenta becomes sensitive to LPS (E18), inhibits the growth of neurons 
isolated from affected offspring.  This is entirely consistent with previous work 
showing that IL-1 exerts a growth inhibitory effect on these neurons during this 
developmental window from E18 to P1 (Nolan et al., 2011), and that IL-1 was the 
causative agent of behavioral change induced by maternal infection (Girard et al., 
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2012).  Though translating developmental dates between species in a linear manner 
is an over simplification, the first and second halves of rat gestation are often 
equated to the first and second trimesters of human pregnancy (Clancy et al., 2007).  
Thus these findings are consistent with the notion that second trimester maternal 
infection can increase the risk an adverse neurodevelopmental outcome (Sørensen et 
al., 2009; Atladóttir et al., 2010; Patterson, 2011b).  As maternal infection during 
specific periods may induce long lasting placental molecular change (O’Keeffe & 
Kenny, 2014), it is possible that these placental signatures may be useful in 
predicting subsequent risk for averse neurodevelopment. 
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Chapter 3: 
 
LPS-induced maternal immune activation 
results in differential neurobehavioral 
outcomes depending on gestational age of 
exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
Straley ME, Theze SA, Hegarty SV, Crampton SJ, Cyran JF, O’Mahony SM, 
O’Keeffe GW. LPS-induced maternal immune activation results in differential 
developmental and neurobehavioral outcomes depending on gestational age of 
exposure.  In preparation for submission to the Journal of Neuroscience.    
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Abstract 
Introduction 
The majority of DA neurons are found in the adult midbrain and they project 
outwards to form two of the major dopaminergic pathways: the nigrostriatal and 
mesocorticolimbic pathways.  Nigrostriatal dopaminergic function is needed for 
proper motor control and degeneration of these DA neurons leads to Parkinson’s 
disease.  Regulation of emotion and reward depends on the mesocorticolimbic 
pathway and dysfunction of this pathway has been implicated in disorders such as 
schizophrenia, drug addiction, depression, and ADHD.  While the full etiology of 
these diseases has yet to be fully elucidated, epidemiological and preclinical data 
suggest that fetal programming as a result of maternal immune activation (MIA) may 
alter neurodevelopment trajectories and leave affected offspring more susceptible to 
these diseases later in life.  Here we aim to assess the differential effects of MIA at 
multiple gestational ages on two major DA pathways and associated behaviors.   
Methods 
To do this, pregnant rats were administered a 50μg/kg dose of LPS or saline via I.P. 
injection on E12 or E16.  To determine if the timing of MIA altered neurobehavioral 
outcome, we performed an array of behavioral tests which target utilization of the 
dopaminergic system, including motor and reward behavior assays, across the 
lifespan of affected offspring.   
Results 
Our results show that motor differences can be seen in juvenile offspring following 
maternal infection at E16 only.  These differences are compensated for in 
adolescence, but subsequently there is a decline in motor function in adulthood.  
Furthermore, our results also demonstrate differential responses to amphetamine in 
reward seeking behaviors of adolescent and adult offspring that were exposed to 
maternal infection at E12.   
Conclusions 
Our data show that timing of MIA is important, and infection earlier in gestation 
(E12) may have greater consequences for the mesocorticolimbic pathway whereas 
infection in later pregnancy (E16) may have greater consequences for the function of 
the nigrostriatal pathway.    
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3.1 Introduction 
Three quarters of all dopaminergic neurons found in the adult brain are located in the 
midbrain (German et al., 1983; Pakkenberg et al., 1991; Blum, 1998; Hegarty et al., 
2013).  These neurons form two major output projections as the nigrostriatal 
pathway and the mesocorticolimbic pathway.  Nigrostriatal dopaminergic function is 
crucial for voluntary motor control, and dopaminergic neuronal loss results in 
Parkinson’s disease (PD), which is a neurodegenerative disorder characterized by 
impaired motor function (Toulouse & Sullivan, 2008; Lees et al., 2009).  
Mesocorticolimbic dopaminergic function is crucial for the regulation of emotion 
and reward (Tzschentke & Schmidt, 2000), and alterations in this system have been 
implicated in schizophrenia (Meyer-Lindenberg et al., 2002; Howes & Kapur, 2009), 
drug addiction (Robinson & Berridge, 1993; White, 1996), depression (Martin-
Soelch, 2009) and ADHD (Volkow et al., 2009).   
While the causative basis of these disorders is an area of intensive 
investigation, it has been suggested that “fetal programming” as a result of maternal 
immune activation (MIA) may alter the development of the fetal dopaminergic 
circuitry leaving the offspring more susceptible to these disorders later in life 
(Howes & Kapur, 2009; Knuesel et al., 2014).  In agreement with this, 
epidemiological and pre-clinical data show in utero exposure to an inflammatory 
stimulus increases the risk for a range of neurodevelopmental and neuropsychiatric 
disorders including schizophrenia (Brown et al., 2004a; Brown et al., 2005), autism 
spectrum disorders (ASD) (Zerbo et al., 2013a; Zerbo et al., 2013b; Lee et al., 2015) 
and cerebral palsy (Shatrov et al., 2010) in affected offspring.   
One of the most widely used pre-clinical models of MIA is intraperitoneal 
administration of the bacterial endotoxin lipopolysaccharide (LPS) to pregnant dams 
(Boksa, 2010; Knuesel et al., 2014). Observations of a causal link between LPS-
exposure and loss of dopamine (DA) neurons in the midbrain have been reported in 
rats following intracerebral injection of LPS at P5 followed by analysis of DA 
neuron numbers in the midbrain P21 (Fan et al., 2005) as well as following in utero 
(E10.5) maternal LPS injection and offspring rat brains analyzed at P21, P120, P210, 
P420, and P510 (Ling et al., 2002; Ling et al., 2004; Ling et al., 2006; Ling et al., 
2009).  Subsequently, as relative function of DA neurons can be measured using 
behavior analysis (Girault & Greengard, 2004; Goldberg et al., 2011), a number of 
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studies have focused on the impact of prenatal LPS exposure on the development 
and subsequent functioning of the nigrostriatal system utilizing motor behavior 
assays.  Some studies have shown delayed achievement of certain developmental 
milestones (Toso et al., 2005; Xu et al., 2013), while other studies report no 
difference following maternal infection (Golan et al., 2005; Kirsten et al., 2010a).  
Similarly, other studies have examined motor coordination following MIA, but 
results are conflicting with some studies reporting differences in juvenile or adult 
motor activity (Girard et al., 2009), and others finding none in affected offspring 
(Zager et al., 2012).   
To the best of our knowledge, there has only been one study examining the 
effects of MIA on basic motivation based behaviors in affected offspring.  These 
adult rats, which were exposed to Poly(I:C) (4mg/kg) on E15 did not show marked 
differences in discrimination learning, motivation, nor gross locomotor behavior 
compared to the saline exposed controls in a basic operant conditioning task with 
food restriction (Zhang et al., 2012).  In contrast, maternal malnutrition resulted in 
restricted learning and motivation of affected offspring as demonstrated by operant 
conditioning scenarios in rats (Reyes-Castro et al., 2011; Reyes-Castro et al., 2012; 
Rodriguez et al., 2012b), which suggests a potential for in utero exposure to LPS to 
alter motivation and reward behaviors in affected offspring later in life (Rodriguez et 
al., 2011).  Interestingly, Poly-I:C exposure at E17 resulted in a significant reduction 
in the sucrose preference test for adult mice, indicating that late prenatal MIA may 
lead to anhedonia in adulthood (Bitanihirwe et al., 2010), a symptom which is 
commonly associated with reward deficits as well as anxiety and depressive 
behaviors (Der-Avakian & Markou, 2012).  Many studies have also analyzed 
anxiety-like behaviors as another indicator of the functionality of the 
mesocorticolimbic dopaminergic pathway; behavior tests measuring anxiety include 
ultrasonic vocalization, open field, and elevated plus maze (EPM), among others 
(Kalinichev et al., 2002; Schmidt & Müller, 2006; Baharnoori et al., 2012; Solati et 
al., 2015).  Prenatal influenza exposure in mice during mid-gestation (Shi et al., 
2003) or prenatal exposure to LPS in mid or late gestation increased anxiety levels 
and depression in male rat (Enayati et al., 2012; Lin et al., 2012) and mouse 
offspring (Hava et al., 2006; Babri et al., 2014).  However, in contrast, adult male 
rats that were exposed to LPS at E15 and E16, demonstrated no difference in anxiety 
behavior (Wischhof et al., 2015).   
113 
 
Here, we use a LPS, Sprague-Dawley rat model of MIA (Straley et al., 2014), 
to examine the impact of in utero exposure to MIA on both nigrostriatal and 
mesocorticolimbic-mediated behaviors in affected offspring in the neonatal period, 
adolescence and adulthood.  Throughout the study we utilize amphetamine (AMPH) 
administration in the behavioral experiments due to its role in increasing 
extracellular DA which can result in heightened locomotor behavior (Jackson et al., 
1994; Pontieri et al., 1995; Underhill et al., 2014) as well as increased reward 
responding in operant conditioning (Fletcher et al., 1998; Schmidt et al., 2013).  As 
rat midbrain dopaminergic neurons extend axons at E12/E13 to establish functional 
circuitry and these projections begin to reach the striatum by E14, and the cortex by 
E16 (Hegarty et al., 2013), we administered LPS on E12 or E16 to determine the 
impact of the timing of exposure to MIA on dopaminergic-mediated behavior in 
affected offspring.    
 
  
114 
 
3.2 Materials and Methods 
3.2.1 Animals/LPS injections 
All experimental animal work was carried out under license with ethical approval 
from the Ethics Committee of UCC.  Sprague-Dawley rats (Biological Services Unit, 
UCC) were maintained in a controlled environment on a 12 hour light/dark cycle 
with ad libitum access to food and water.  As the timing of infection during 
pregnancy is often a critical determinant of fetal outcome, we administered LPS at 
different time points (E12 or E16).  For analysis of behavior, pregnant dams (n=6 or 
7/group/time point) received an intraperitoneal (I.P.) injection of LPS (Sigma: 
50μg/kg) or normal saline on E12 or E16.  Pregnancies continued without 
disturbance and post-partum the offspring were randomly assigned for future 
behavior testing at P9, P30 or P60
+
.  Once the animals reached weaning age 
(21days), female offspring were culled and male offspring received ear punches and 
tail marks for identification and were randomly assigned to groups with which they 
were housed.  This was done to ensure that no animal was disrupted until it was time 
to perform behavior testing and so that treatment groups remained caged together.  
Every experimental group consisted of male offspring from multiple litters with no 
more than 3 rats from the same litter.  In all cases, experimenters were blinded to the 
cage codes for the duration of the study in order to prevent experimental bias.  Upon 
completion of assigned behaviors, animals were culled by rapid decapitation (see 
Figure 1 for a timeline of the experiment).   
 
3.2.2 Maternal care behavior 
To determine if LPS administration adversely affected maternal care behavior in the 
post-partum period, which may confound the behavioral results, maternal behavior in 
all the saline and LPS groups was scored daily for the first 4 days postpartum, at the 
same time every day (beginning at 8am), and each trial lasted for 30 minutes.  The 
animals habituated to the testing room for 10 minutes prior to scoring.  During this 
time, nests were observed and scored as follows: 1 = nesting material was untouched 
or nest had no form; 2 = nesting material was in one section, flat, but nest could be 
distinguished; 3 = nesting material was loosely gathered into a definite shape of 
moderate height; 4 = nest was symmetrical, tightly packed and high walls or in a 
spherical shape (Capone et al., 2005).  Then the camera was started and scoring 
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began.  For each session, 4 dams were under inspection at a time, and the observer 
examined dam #1 for 20 sec, #2 for 20 sec, #3 for 20 sec, #4 for 20 sec, and so on 
until the 30 minutes finished.  With this method each dam was observed 22 times 
over the course of a trial. During each observation, the dam was scored for care 
behaviors, including: gathering pups, licking/grooming any pup, nursing pups as 
well as other behaviors such as exploring or remaining stationary (Francis et al., 
1999; Liu et al., 2000; Franks et al., 2011).  Nursing behaviors were broken down 
into sub-categories as follows: blanket posture was defined as the dam lying flat over 
the pups, passive posture was defined as the dam allowing feeding while either 
laying on her back or side, and arched-back nursing was defined as a tense posture 
where the dam remained upright with the back strained (Liu et al., 2000).  The 
frequency of each behavior was calculated. 
 
3.2.3 Reflex behaviors (P9 rat pups) 
Three natural reflex behaviors were observed, with methods described by Heyser 
(2004).  To score the righting reflex, the P9 rat pup was placed in a supine position 
on a flat surface and latency for the pup to turn itself to its belly was recorded.  This 
test was repeated three times per animal and average time was calculated.  The cliff 
test was next performed whereby the pup was placed on the edge of a platform with 
its nose and forefeet hung over the edge.  The aim was to determine if the pup moved 
away from the cliff by backing up or turning sideways which was scored as a “pass” 
or “fail”.  Finally, the grasp reflex was examined by using a wooden toothpick to 
lightly stroke the paw of each individual pup.  The reflex was confirmed as present if 
the animal grasped at the probe.  
 
3.2.4 Ultrasonic vocalization (P9 only) 
Neonatal rat pups produce alarm calls that can be measured at 40Hz by a bat detector 
(Walker et al., 2003).  P9 pups were subjected to USV at the beginning (pre test) and 
the end (post test) of the juvenile test battery (which included reflex testing, bar hold, 
and open field).  The equipment was tested before each trial to ensure the detector 
was not picking up extraneous noise within an empty cage to ensure it would only 
register noise made by pups. Pups were placed individually into the Plexiglas 
isolator box which was cleaned with 70% EtOH before each animal and 
vocalizations were recorded using a mimi-3 bat detector for 3 minutes.   
116 
 
 
3.2.5 Bar hold (all ages) 
The animal was lifted by the trunk and brought within reaching distance of a thin 
metal bar.  The animal was allowed to grab hold with its front paws, and once it had 
grasped the bar it was released, the duration the animal held on was recorded, with a 
maximum cut off of 10s for pups and 180s for adolescent/adult animals (Heyser, 
2004).   
 
3.2.6 Rotarod (adolescent and adult offspring) 
Adolescent (P30) and adult (>P60) animals were tested on a rotarod every day for 3 
days, with the same 4 trial pattern as follows.  Animals were firstly trained for 5 min 
at a fixed rate (4RPM) (trial 1).  Then rats completed 3 trials on a rod that 
accelerated smoothly from 4 to 40 RPM over 5 min. There was at least 15 min break 
between each of the trials. The length of time that each animal was able to stay on 
the rod was recorded as the latency to fall, registered automatically by a trip switch 
under the floor of each rotating drum.   
 
3.2.7 Open field (all ages) 
An open field was conducted at each age: juvenile (P9), adolescent (P30) and adult 
(>P60).  The apparatus was cleaned with 70% EtOH before each individual trial as to 
prevent any location bias due to smell.  Rats were placed in the middle of the arena, 
always facing the same direction, and then the experimenter left the room while 
locomotion was recorded.  P9 pups underwent open field for 5 min in a small arena 
(40cm x 32 cm rectangular arena), and the P30/P60 animals had trials which lasted 
10 minutes in a larger arena (90cm diameter circular arena).  Ethovision software 
was used to analyze locomotion behaviors (Noldus Information Technology, The 
Netherlands).  For open field tests, locomotion was assessed using distance traveled 
and velocity measurements.  Immobile frequency was an additional variable 
investigated to understand the number of times the animal froze during the test and 
was identified using controlled parameters with the Ethovision software. 
 
3.2.8 Open field amphetamine challenge 
Animals were habituated to the testing room and the open field chamber as described 
previously for 10 min (see ‘open field’ protocol).  Following this, they were 
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habituated to injections by receiving I.P. injections of saline (10ul/kg).  Two days 
following the habituating injections, they were subjected to an AMPH challenge in 
order to flood the system with extracellular DA which could exacerbate functional 
differences in the MIA offspring. Firstly, normal saline (10ul/kg) was injected I.P. in 
the left quadrant and the animal was immediately placed in the center of the open 
field apparatus for 15 minutes as previously described (Eisenstein et al., 2009).  
After this point, the animal received an I.P. injection of amphetamine in the right 
quadrant (1mg/kg) and was placed back into the chamber undisturbed for 20 
minutes.  Locomotion behaviors were again recorded and subsequently analyzed 
using Ethovision software (Noldus Information Technology, The Netherlands).   
 
3.2.9 Food reward operant conditioning (adolescent and adult) 
Food reward operant conditioning test was performed to examine the effects of MIA 
at different gestational ages (E12 or E16) on the reward seeking behavior of food 
restricted animals.  Furthermore, as we were interested in the possible adverse 
outcomes following maternal infection upon the dopaminergic system we utilized the 
reward-potentiating effect of d-amphetamine to fully elucidate any potential 
differences in the mesocorticolimbic dopaminergic pathways of our saline or LPS 
exposed groups.  In a progressive ratio (PR) schedule, the number of lever presses 
required for the animal to obtain 1 sweetened pellet was arithmetically increased 
over a 1hr long test session.  Reinforcer efficacy was expressed as the “break point” 
and is herein defined as the highest ratio completed before responding ceased or the 
session ended.  
A food reward protocol was adapted from (Richardson & Roberts, 1996; 
Mobini et al., 2000; Levin et al., 2003; Hanlon et al., 2010).  Every day, starting 1 
week before conditioning, rats were habituated to the sweet pellets (45mg, Sandown 
Scientific, UK).  48 hours before training, 4 weeks old rats were food restricted to 5g 
food / rat /day, and 24 hours before training rats received no food in order to create 
optimal reward seeking behavior.  During the experiments, animals were kept food 
restricted at 12g food/ rat/day in order to maintain 90% of free-feeding body weight.  
Rats were placed in dual lever test chambers (Med Associates, USA) which were 
equipped with a house light and cue light above each lever.  During food reward 
sessions, only one lever was active and the cue light over said active lever would be 
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illuminated indicating the active one.  MED-PC software was used to program 
experiments and control data collection.   
Rats were put initially on a fixed ratio (FR) training schedule FR1 to FR2 to 
FR5, receiving one training session of 1 h duration per day and progressed forward 
only once they were able to receive 30 rewards (food pellets) in 30 minutes, or 60 in 
an hour.  Following training, rats were put on a PR schedule for 3 consecutive days 
in order to get the average number of rewards obtained from PR in 1 h (the average 
of the three days is reported as “baseline”).  The next day, animals received an 
injection of saline (10μl/kg) and underwent PR test in order to establish a vehicle 
control for each animal.  Finally on the last day, animals received an injection of 
0.25 mg/kg d-amphetamine sulfate (Sigma, UK), which has been previously reported 
as the breaking point dose of amphetamine to use on PR (Richardson & Roberts, 
1996), 10 minutes prior to being put in the operant chamber for a final session of PR 
(Mobini et al., 2000).  Animals were then returned to ad libitum food and water and 
went undisturbed from this point until they were grown into adults (week 10).  Then 
they were again food restricted for 2 days (5g food / rat /day the first day and 0g the 
second) and maintained at 90% of free-feeding body weight during the experiment.  
On the first day of adult food reward they had one session of FR training confirm 
they all remembered the rules.  All 47 animals progressed from FR1 to FR5 within 
the 1 h training session.  Following this, the animals went through 3 consecutive 
days of PR again to reach a valid average (baseline) for each animal.  As we were 
not under time constraints for this stage of the study (as the animals were full grown) 
we were able to perform a full dose response using 0.10, 0.25, and 2.5 mg/kg doses 
of d-amphetamine sulfate (Sigma, UK) and normal saline as vehicle control.  Using a 
within-subject study design, animals were randomly assigned to a drug schedule, 
with two days between sessions, as two days has been shown previously to allow for 
amphetamine wash out (Gentry et al., 2004; Milesi-Hallé et al., 2005).    
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Helpful definitions for operant conditioning with food reward experiments 
Fixed Ratio (FR) When the number of lever presses required for 1 food 
reward remains the same for the entire session (e.g. 1 lever 
press for 1 pellet = FR1; 5 lever presses for 1 pellet = FR5) 
Progressive Ratio (PR) When the number of lever presses required to obtain 1 
reward exponentially increases throughout the session. For 
example, to get the first pellet, the animal must press the 
lever 5 times. Then, to receive the second food reward they 
must press it 11 times, and so on. 
Baseline The average of 3 PR trials, indicating the baseline reward 
responding. 
Break Point The highest level of PR the animal was able to reach before 
they stopped responding or the session timed out. 
Rewards Sweet food pellets 
Active Lever The lever the animal needs to press to obtain a reward 
Inactive Lever  The lever which does not connect to the food pellet 
Time Out There is an interval following a successful production of a 
food reward where a light turns on in the operant box 
indicating to the animal that any lever presses during the 
“time out” will not result in a reward. 
Time out active lever 
presses 
The number of times the animal presses the active lever 
when the house light indicating a ‘time out’ was on. 
 
3.2.10 Statistics 
For multiple variable situations, statistics were calculated using multi-way ANOVA 
in statistica software program.  Following the ANOVA, Fisher’s Least Significant 
difference (LSD) post hoc test was conducted where appropriate.  As we were only 
interested in how E12 control compared to E12 LPS, and how E16 control compared 
to E16 LPS and we were not interested in how E12 compared to E16 overall, the 
cohorts were kept separate for ease of statistical calculations.  In many instances, we 
were specifically interested to see if the saline control group had a better behavioral 
performance compared to the relative LPS group at a single time point, and in these 
cases, graph pad prism statistical software was used to conduct one-tailed student t-
tests.   
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3.3 Results 
3.3.1 In utero exposure to LPS does not affect maternal care behavior in the 
postnatal period 
Firstly, we sought to investigate maternal care behavior  towards the offspring post 
LPS, as it has been shown previously that alterations in maternal care can have a 
significant effect on offspring behavior (Weaver et al., 2006).  We investigated a 
multitude of maternal behaviors, including nesting abilities, nursing, maternal 
activity, grooming behavior, and pup location (grouped or scattered) over the first 4 
days post-partum.  Overall, there were no significant differences in the maternal 
behaviors, save for a decrease in frequency of blanket nursing in the E12 LPS group 
compared to the E12 control group on the first 3 days only.  However, when all 
nursing behavior was analyzed together there were no significant differences (Table 
1). Collectively these data show that all the pups received maternal care that was 
overall similar in nature, meaning any differences in offspring behavior are not due 
to differences in maternal care.   
 
3.3.2 Effect of in utero LPS exposure on primitive reflexes in early life 
Primitive reflexes are highly stereotypical automatic responses elicited in very early 
life, and weak reflexes are indicative of poor neurodevelopment (Zafeiriou, 2004).  
We first examined primitive reflexes at P9, as this is the age when many primitive 
reflexes are prominent in the rodent (Heyser, 2004).  Firstly, to assess vestibular and 
proprioceptive skills, we examined the righting reflex (Roberts & Roberts, 1967), 
followed by the grasping reflex, which is often used for early detection of 
neurodevelopmental abnormalities including diagnosis of CP (Zafeiriou, 2004; Udo 
et al., 2014), and can demonstrate insufficient peripheral or spinal cord involvement 
(Futagi et al., 2012).  Finally, the cliff avoidance reflex was examined to assess the 
sensory and motor function of the pups (Xi et al., 2009).  Our results demonstrate no 
differences in these reflexes (Table 2), suggesting that there were no extensive 
developmental abnormalities following in utero exposure to LPS at the two 
gestational stages we examined.  
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3.3.3 In utero exposure to LPS on day 16 of gestation significantly reduces 
locomotion and alters juvenile adaptation to anxiety 
We next measured ultrasonic vocalization (USV) of rat pups (De Vry et al., 1993; 
Hofer et al., 2001; Wöhr & Schwarting, 2008) and examined open field behavior to 
look for characteristics widely associated with anxiety like behaviors (Prut & 
Belzung, 2003).  The USV pretest showed no significant differences between any of 
the groups suggesting that their anxiety levels were similar (Figure 2B,C).  However, 
in the post test differences were observed in the E16 cohort.  The E16 LPS group had 
a significantly shorter duration of calls compared to controls, while there were no 
differences in the overall number of calls (Figure 2B,C).  This suggests that the E16 
LPS group adapted differently than the E16 control group during the battery of tests.  
We also measured the time spent in center (Figure 2F) and time spent on edges (data 
not shown) of the open field to assess anxiety, and found no significant differences 
in any of the groups, suggesting no differences in anxiety levels during the open field 
test. 
We next investigated voluntary motor function at P9.  LPS exposure 
significantly reduced the bar holding time compared to the relative control group in 
both cohorts (Figure 2A).  Furthermore, there were significant differences in the 
open field as a result of in utero LPS exposure on E16 but not E12 (Figure 2D-G). 
Specifically, the E16 LPS group displayed decreased locomotor activity compared to 
E16 controls as there was a significant decrease in distance traveled (Figure 2D) and 
velocity (Figure 2E).  Taken together, these results suggest an impairment in motor 
skills at P9 following in utero LPS exposure later (E16) but not earlier (E12) in 
gestation. 
 
3.3.4 The detrimental effects of late gestation in utero exposure to LPS on 
motricity is resolved by adolescence 
To determine the life-long consequences of in utero LPS exposure on 
neurobehavioral function in affected offspring, we also carried out behavioral testing 
in adolescence (P30) and adulthood (>P60) and male rats were subjected to a battery 
of motor tests at each time point.  By P30, we observed no significant differences 
between any of the groups in the bar hold test (Figure 3A), rotarod (Figure 3B), or in 
the open field in the numerous motor variables measured (Figure 3C-I).  These data 
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suggest that the behavioral disturbances that we observed at P9 (Figure 2), have been 
eliminated or compensated for by the time these animals reach adolescence.   
Interestingly, when the open field experiment was used to analyze anxiety 
behaviors, unlike the P9 result, there was a significant increase in time spent in the 
center in the E16 LPS group compared to E16 controls while still no difference 
between the E12 groups (Figure 3H).  These data suggest that while the E12 groups 
were similar in anxiety level, the E16 groups differ in their anxiety response.  
However, the fecal pellet output, which is another indicator of anxiety levels used in 
open field assessments, was not significantly different between groups (Figure 3I).   
 
3.3.5 Age-related decline in motor function as a result of in utero exposure to LPS 
on E16 
We next conducted the same battery of tests once animals reached adulthood (over 
P60) including bar hold, rotarod, and open field.  Similarly to the adolescent 
behavior assay, the group that was exposed to LPS in utero on E12 had no 
statistically significant differences on any test (Figure 4).  In contrast, although the 
E16 cohort displayed no significant difference in the bar hold test (Figure 4A), there 
was a group difference observed with the rotarod test. Over the 3 days, the E16 LPS 
group remained on the apparatus for a shorter duration than the E16 control group, 
with statistically significant differences observed on days 1 and 3 specifically 
(Figure 4B).  In the open field, there were initial differences in locomotion behavior 
of the E16 animals as demonstrated by distance moved (Figure 4D) and velocity 
(Figure 4F); however after 5 minutes the animals were covering similar distances at 
similar speeds.  Furthermore, the number of times E16 LPS animals were reported as 
immobile, or the number of times the animals froze, was significantly higher 
compared to the E16 controls (Figure 4G).    
We next examined anxiety behavior again using the open field test.  There 
were no differences shown between the relative control vs LPS groups regarding 
time spend in the center (Figure 4H) or time spent on the edges (data not shown).  
While the E12 groups were not significantly different, the E16 LPS group had a 
higher fecal output compared to E16 control (Figure 4I).  While exploratory behavior 
demonstrates similar anxiety levels between groups, the fecal pellet output may 
suggest a subtle level of heightened anxiety in the E16 LPS group compared to E16 
controls.   
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3.3.6 MIA differentially affects amphetamine response in open field task 
depending on gestational age of exposure 
Drug challenges are extensively used to elucidate abnormal dopaminergic function, 
and one of the most common ways of studying the dopaminergic motor system has 
been with the use of amphetamine (AMPH) challenge in an open field test (Bernardi 
et al., 1986; Robinson & Becker, 1986; Jackson et al., 1994; Rodríguez et al., 2013).  
Amphetamine is an  indirect DA receptor agonist, and as such has been known to 
induce locomotion in a control animal by promoting significant increases in DA 
release (Pijnenburg et al., 1976; Carboni et al., 1989; Pontieri et al., 1995; Ikemoto, 
2002; Zager et al., 2012; Shim et al., 2014; Underhill et al., 2014).  Furthermore, 
enhanced susceptibility to the dopaminergic stimulation caused by amphetamine has 
been observed as a symptom of dopaminergic system disorders including 
schizophrenia (Laruelle et al., 1996; Laruelle et al., 1999).  This appears to hold true 
for certain models of maternal infection.  For example, in the Poly I:C mouse MIA 
model, the locomotion response to amphetamine was enhanced for the animals 
exposed to prenatal Poly I:C (Meyer et al., 2007).  Therefore, we sought to 
determine if prenatal exposure to LPS altered the locomotion response to 
amphetamine in affected offspring (Robinson & Becker, 1986; Laruelle et al., 1999).   
Interestingly, amphetamine affected motor behaviors in a similar manner 
between in the E16 groups, altering distance covered, time moved and velocity by 
statistically similar amounts (Figure 5D-F).  That is, the amphetamine response was 
the same for the E16 control and E16 LPS groups.  Surprisingly, there were 
significant differences observed within the E12 cohort.  The E12 LPS group reacted 
to the amphetamine differently than the E12 control as seen by the difference in 
locomotion distance (Figure 5A) and velocity (Figure 5B).   
We also used fecal pellet output during this paradigm to investigate anxiety 
related behaviors again, this time investigating how amphetamine might alter anxiety 
response.  Importantly, there was a significant increase in the control groups’ 
amphetamine trial fecal pellet output per minute compared to saline trials (i.e. E12 
control saline trial compared to E12 control AMPH trial), suggesting that the 
amphetamine increased anxiety in the control groups (Figure 5C,F).  However this 
difference was not seen with the LPS groups; there was not a statistically different 
fecal pellet output from the saline trial to the AMPH (Figure 5C,F).  Interestingly, 
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the LPS groups both had significantly higher fecal pellet output than their respective 
control during the saline trial, suggesting a heightened anxiety response following 
saline injection for the LPS animals (Figure 5C,D). Finally, only the E16 cohort 
showed significant differences in the AMPH trial, with the E16 LPS group having a 
significantly lower fecal pellet output compared to E16 control (Figure 5F). 
 
3.3.7 Adolescent and adult offspring demonstrate differential amphetamine 
response in food reward paradigm following maternal LPS exposure at E12 
We next investigated motivation behaviors in affected offspring using food reward 
operant conditioning.  Using baseline active lever press and inactive lever press 
during progressive ratio (PR) to rate the ability of animals to understand the test, E12 
LPS animals performed similarly to E12 control and E16 LPS also compared 
comparably to E16 control (Figure 6C,F,H,J).  These data suggest that all groups of 
animals were able to understand that the active lever would result in a food reward 
while the inactive lever would not.  During the baseline trial where animals were not 
exposed to amphetamine, as well as saline vehicle control trials there was no 
difference seen between any of the groups, suggesting that the animals have similar 
functionality of reward behavior in normal circumstances.  This was consistent 
across both adolescent and adult testing time points.  
At the adolescent age (P30), we administered a moderate dose (0.25mg/kg) 
(Richardson & Roberts, 1996) of d-amphetamine sulfate via I.P. injection in order to 
investigate how this indirect dopamine agonist would affect reward seeking behavior 
in adolescent animals.  The goal directed behavior of the E12 LPS group was not 
altered by amphetamine exposure, unlike the other groups which saw a significant 
increase in reward responding as measured by break point (Figure 6A,D) and active 
lever presses (Figure 6C,F) following the amphetamine injection.  While there were 
difference between E12 control and E12 LPS groups, there were no difference 
between E16 control and E16 LPS, suggesting that the E12 cohort responded 
differently to the drug. 
Similarly, the groups did not differ in the baseline PR task nor following a 
saline injection in goal directed behaviors in adulthood (Figure 7A-F).  Using a 
within subject study design, we administered 3 different doses of d-amphetamine 
sulfate in order to determine a dose response.  Interestingly, for all animals reward 
seeking (as measured by break point, rewards obtained, and active lever presses) was 
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most heightened with the lowest dose (0.1mg/kg), whereas  as expected, the highest 
dose of 2.5mg/kg resulted in a complete lack of reward seeking behavior (Figure 7A-
F).  The E12 LPS exposed group differed from the E12 control group in numerous 
instances; rewards obtained (Figure 7B) and active lever presses (Figure 7C) with the 
0.1mg/kg dose; and break point (Figure 7A), rewards obtained (Figure 7B), and 
active lever presses (Figure 7C) with 0.25mg/kg dose.  There were no significant 
differences seen between the E16 groups in any measurement.  These data taken 
together suggest that MIA did not leave the dopaminergic system vulnerable to 
motivation or goal directed behavior dysfunction under normal food deprivation.  
However, the animals exposed to MIA at E12 responded differently to a dopamine 
specific pharmacological intervention compared to their saline controls suggesting 
that MIA at E12, but not E16, might reduce sensitization to amphetamine in reward 
behaviors. 
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3.4 Figures and Figure Legends 
 
 
 
 
 
Figure 1: Schema of experimental design. 
Schematic of the experimental design showing two cohorts of animals divided by 
gestational age of exposure: E12 or E16.  On the designated day (E12 or E16) these 
cohorts were then further divided into saline control or LPS group and mother was 
administered the randomly assigned vehicle/LPS via I.P. injection (n=6 or 7 mothers 
per group).  The four groups (E12 cont, E12 LPS, E16 cont, and E16 LPS) received 
no other differences throughout the study and experimenters were blind to the 
groups.  Maternal care behaviors were observed on days 1-4 post-natal. Following 
weaning, offspring were caged according to treatment group and assigned behavior 
(i.e. E12 LPS offspring that were tested at P30 were grouped together).  Juvenile 
behaviors were assessed on P9. Adolescent behaviors were assessed at P30. Adult 
behaviors were assessed beginning when animals reached the age of P60 and testing 
took approx. 1 month for completion. 
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Category Behavior E12 E16 
Nesting Nest Score 
Control: 3.0 ± 0.4  
LPS: 3.4 ± 0.3 
Control: 3.2 ± 0.2 
LPS: 2.6 ± 0.4 
        
Nursing Passive Nursing 
Control: 24.7 ± 12.2 
LPS: 9.7 ± 4.9 
Control: 9.7 ± 4.5 
LPS: 10.58 ± 5.462 
  Blanket Nursing 
Control: 3.2 ± 1.3 
LPS: 9.7 ± 4.1  
Control: 18.8 ± 6.7 
LPS: 18.18 ± 6.6 
  
Arched Back 
Nursing 
Control: 33.8 ± 11.4 
LPS: 49.4 ± 7.3 
Control: 33.8 ± 7.1 
LPS: 50.8 ± 11.6 
  
Any Nursing 
Behavior 
Control: 61.7 ± 13.5 
LPS: 68.8 ± 9.0 
Control: 62.3 ± 7.7 
LPS: 79.6 ± 7.9 
        
Moving Pups Grouping 
Control: 3.9 ± 1.5 
LPS: 1.9 ± 1.9 
Control: 2.0 ± 0.9 
LPS: 1.5 ± 1.0 
  Scattering 
Control: 0 ± 0 
LPS: 1.3 ± 1.3 
Control: 1.4 ± 0.9 
LPS: 0 ± 0 
        
Maternal 
Activity 
Stationary 
Control: 85.7 ± 3.0 
LPS: 92.2 ± 2.6 
Control: 89.0 ± 1.9 
LPS: 93.94 ± 3.3 
  Active 
Control: 21.4 ± 3.7 
LPS: 16.2 ± 4.2 
Control: 16.2 ± 4.9 
LPS: 5.3 ± 1.4 
  Exploring 
Control: 11.7 ± 1.7 
LPS: 11.7 ± 2.6 
Control: 6.5 ± 1.7 
LPS: 5.3 ± 1.8 
        
Grooming Groom Pup 
Control: 24.7 ± 3.6 
LPS: 18.8 ± 6.1 
Control: 17.5 ± 3.5 
LPS: 17.4 ± 3.4 
  Groom Self  
Control: 11.0 ± 4.2 
LPS: 5.2 ± 1.8 
Control: 5.2 ± 1.8 
LPS: 2.3 ± 1.0 
        
Pup Location Grouped 
Control: 90.3 ± 8.4 
LPS: 99.4 ± 1.5 
Control: 78.6 ± 15.3 
LPS: 103.8 ± 1.4 
  Scattered 
Control: 9.7 ± 9.0 
LPS: 0.7 ± 0.7 
Control: 23.4 ± 15.2 
LPS: 0.0 ± 0.0 
Table 1:  Exposure to LPS at the two gestational ages studied does not affect 
maternal care behavior in the postnatal period.   
Table showing results of maternal care behaviors on Day 4.  Nest score was marked 
on a scale of 1-4. All other variables are reported as frequency (the number of times 
the behavior was observed per the 22 viewings of that mother in this 30 minute 
session).  Results compare E12 control group to E12 LPS, and E16 control group to 
E16 LPS.  Analyzed using 2way ANOVA, data expressed as mean ±SEM (n=6-7 
mothers per group). 
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Reflex E12 E16 
Righting Reflex Control: 1.3 ± 0.08 
LPS: 1.1 ± 0.08 
Control: 1.2 ± 0.04 
LPS: 1.4 ± 0.2 
Cliff Test # Failures Control: 2 / 13 
LPS: 2 / 8 
Control: 1 / 10 
LPS: 0 / 8 
Grasping Reflex # 
Failures 
Control: 0 / 13 
LPS: 0 / 8 
Control: 1 / 10 
LPS: 0 / 8 
Table 2: Prenatal injection of LPS does not affect normal reflexes in pups. 
Table showing results of reflex behavior testing on P9 rat pups.  Righting reflex 
mean and SEM scores.  Cliff test and Grasping are reported as pass/fail.  Student 
one-tailed t-test was used to analyze data (n=8-13). 
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Figure 2:  Exposure to in utero LPS on day 16 of gestation significantly reduces 
locomotion and alters juvenile adaptation to anxiety.   
(A) Bar hold test, (B-C) ultrasonic vocalization (USV), and (D-G) open field 
behavioral assessment was performed at P9 for offspring that were exposed in utero 
to saline (Cont) or LPS at E12 (blue bars) or E16 (red bars) as indicated.  (B-C) 
Ultrasonic vocalization was measured pre and post behavioral test battery conducted 
in P9 rat pups.  (B) Number of calls and (C) duration of calls during each 3 minute 
session are reported. In Open Field assessment, (D) total distance moved, (E) 
velocity, (F) the total amount of time spent in the “center” and (G) frequency animal 
was immobile are shown. Data expressed as mean +SEM (n=7-12 per group; * = P < 
0.05, ** = P < 0.01; compared to corresponding saline treated control).    
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Figure 3:  The detrimental effects of late gestation in utero LPS exposure on 
motricity is resolved by adolescence.   
(A) Bar hold test and (B) Rotarod test and (C-I) open field test was performed at P30 
for offspring that were exposed in utero to saline (Cont) or LPS at E12 (blue bars) or 
E16 (red bars) as indicated.  (C) Total distance moved, (D) breakdown of distance 
covered over the duration of the open field test, (E) overall velocity, (F) breakdown 
of velocity over the duration of the open field test, (G) immobile frequency, (H) the 
total amount of time spent in the center of the arena, and (I) number of fecal pellets 
produced. Data expressed as mean +SEM (n = 8-14 rats per group; *** = P < 0.001 
in utero exposed LPS group compared to relative saline control group).      
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Figure 4:  Age-related decline in motor function as a result of late gestation in 
utero  LPS exposure.   
(A) Bar hold test and (B) latency to fall from an accelerating rotarod that were 
performed after P60 for offspring that were exposed in utero to saline (Cont) or LPS 
at E12 (blue bars) or E16 (red bars) as indicated.  (C-I) Open field behavioral 
assessment was performed after P60 as indicated.  (C) The total distance moved, (D) 
distance moved at four 150s intervals, (E) velocity, (F) velocity moved at four 150s 
intervals, (G) Frequency Immobile, (H) total time spent in the center of the arena, 
and (I) fecal pellet output during the open field. Data expressed as mean +SEM (n = 
9-11 rats per group; * = P <0.05; ** = P <0.01; in utero exposed LPS group 
compared to relative saline control group).    
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Figure 5: MIA at E12 results in differential response to AMPH in open field test 
of adult offspring 
Open field behavioral assessment with amphetamine challenge was performed on 
adult offspring that were exposed in utero to saline (Cont) or LPS at (A-C) E12 (blue 
bars) or (E-F) E16 (red bars). The total distance moved (A,D), velocity (B,E), and 
fecal pellet output (C,F) are indicated. Data expressed as mean +SEM  (n = 6-10 rats 
per group; *P < 0.05, **P < 0.01 in utero exposed LPS group compared to relative 
saline control group; ### = P < 0.001 OF saline trial compared to OF AMPH trial 
within same group)  
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Figure 6: Altered amphetamine response in goal directed and impulsivity 
behaviors of adolescent offspring following maternal LPS at E12  
Motivation behavior was assessed using an operant conditioning task with food 
restricted animals in adolescence offspring following exposure to MIA or saline in 
utero at either E12 (Blue Bars) or E16 (Red Bars).  Goal directed behavior for 
animals exposed at (A-C) E12 or (D-F) E16 as measured by (A,D) Break point, 
(B,E) Rewards Obtained, and (C,F) Active Lever presses.  Impulsive behavior for 
offspring exposed at (G-H) E12 or (I-J) E16 as measured by (G,I) Time Out Active 
Lever Presses and (H,J) Inactive Lever Presses.  Amphetamine dose = 0.25 mg/kg. 
Data expressed as mean +SEM (n=7-13 per group; * = P < 0.05). 
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Figure 7: Maternal LPS at E12 results in reduced responsiveness to 
amphetamine in food reward paradigm, altering reward seeking behavior of 
adult offspring injected with AMPH 
An operant conditioning paradigm utilizing food reward with systemic amphetamine 
challenges was used to assess motivation behavior in adult offspring who had 
exposure to systemic maternal LPS or saline at either E12 (Blue Bars) or E16 (Red 
Bars).  Goal directed behavior for animals exposed at  (A-C) E12 or (D-F) E16 as 
measured by (A,D) Break point, (B,E) Rewards Obtained, and (C,F) Active Lever 
presses.  Impulsive behavior for offspring exposed at (G-H) E12 or (I-J) E16 as 
measured by (G,I) Time Out Active Lever Presses and (H,J) Inactive Lever Presses. 
Data expressed as mean +SEM (n=7-13 per group; * = P < 0.05, ** =  P < 0.01). 
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3.5 Discussion 
The two major dopaminergic pathways begin to develop at E12 in the rat as midbrain 
dopaminergic neurons extend projections that reach the striatum to form the 
nigrostriatal pathway, and the prefrontal cortex and nucleus accumbens to form the 
mesocorticolimbic pathway (Tzschentke & Schmidt, 2000; Janhunen & Ahtee, 2007; 
Hegarty et al., 2013).  This work investigated the impact of MIA as a result of in 
utero exposure to LPS at E12 (earlier) or at E16 (later) on relevant behavior 
mediated by these circuits in affected offspring during three stages of postnatal life.  
We used a number of behavioral tests associated with motor and motivation/reward 
behavior when the rats reached different ages including P9, P30, and P60+ in order 
to determine the effects of MIA on the dopaminergic system of the offspring across 
the lifespan.  The overall results of this study demonstrate that MIA at different time 
points during pregnancy differentially affects behavioral outcome, with exposure at 
E12 altering the response to amphetamine in motivation/reward behavior of 
adolescent or adult offspring, and LPS exposure at E16 affecting motor behaviors in 
juvenile and adult offspring.   
In agreement with a previous study, which administered a 100μg/kg dose of 
LPS at E11 we found no differences in maternal care as a result of in utero LPS 
exposure (Connors et al., 2014).  Therefore it is important to note that any behavioral 
changes seen in offspring are not due to differences in maternal care, which is a 
known determinant of the neurobehavioral outcome of neonates (Weaver et al., 
2006).   
Due to the fact that weak primitive reflexes are indicative of poor neuro-
development (Zafeiriou, 2004), and an MIA study reported delays in several 
neurological reflexes following an in utero exposure to a high dose of LPS 
(300μg/kg) at E19-20 in the rat (Rousset et al., 2013), we next examined primitive 
reflexes including righting reflex, cliff test, and grasp reflex at P9 in our 
experimental paradigm.  We found no differences in these reflexes, which is 
consistent with previous findings that have also shown no effect on pup reflex 
development following in utero exposure to LPS (120g/kg) at E17 in mice (Golan 
et al., 2005), at E9.5 in rats (100μg/kg) (Kirsten et al., 2010a), and also in rats 
exposed to LPS (200μg/kg) at E10-15 and P5-10 (Xu et al., 2013).  These data 
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suggest that MIA, in numerous animal models, does not adversely affect overall 
CNS integrity in affected offspring.   
We next found impaired performance in the bar hold test as a result of in 
utero LPS exposure at both gestational ages, in affected offspring at P9.  In 
agreement with this, in utero exposure to 300μg/kg LPS on E19 and 20 in rats was 
found to decrease motor coordination in affected juvenile offspring (Rousset et al., 
2013).  Consistent with this, offspring exposure to maternal LPS at E16 had impaired 
locomotion behavior in the open field test, in contrast to those exposed at E12, 
although these differences were no longer apparent by P30.  In agreement with this, 
others have reported no difference in juvenile rat offspring motor behavior 
(measured at P21), following MIA (100μg/kg LPS) in mid-gestation (E9.5) (Kirsten 
et al., 2010a).  This is consistent with our data from the E12 cohort, suggesting that 
this period is not a vulnerable window during which MIA affects the nigrostriatal 
pathway.  Also consistent with our findings, is a previous study showing a decrease 
in rat juvenile offspring motor performance from birth up to 3 weeks following 
exposure to 300μg/kg of LPS administered to pregnant dams at later pregnancy (E19 
and 20) (Rousset et al., 2013).  Furthermore, dams administered 50μg/kg LPS on 
E15 and E16 had offspring with no differences in rotarod performance at P35 
(Harvey & Boksa, 2014).  Taken together, these data indicate a critical window of 
later pregnancy during which MIA affects the motor behavior of young offspring, an 
impairment which is subsequently compensated for by adolescence.   
By the time offspring reached adulthood, we observed an age-related decline 
in complex motor functioning in the rotarod test in the group that was exposed to 
LPS at E16.  Along similar lines, our data demonstrated an initial decrease in 
locomotor activity in the open field for the E16 LPS group, which attenuated after 5 
minutes.  Previous work has shown a greater decline in motor skills including 
diminished rotarod performance and a more robust decline in spontaneous locomotor 
activity in offspring following a much higher dose of LPS (200ug/kg) administered 
every 12 h from E17 to birth (Stigger et al., 2013).  These results suggest a potential 
dose response associated with in utero LPS exposure whereby the degree of MIA 
can be related to extent of the neurobehavioral impairment in affected offspring later 
in life.  Our data also demonstrated an increase in frequency immobile, or frequency 
freezing in the group exposed to in utero LPS at E16 only.  Previous findings have 
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demonstrated increased immobility following MIA via LPS (500μg/kg on E17) in 
mouse offspring (Babri et al., 2014) as well as in rat offspring (66μg/kg on E10.5) 
(Lin & Wang, 2014) subjected to the forced swim test, however immobility 
frequency following MIA has not been reported in the open field test until now.  As 
immobility is a hallmark symptom of PD, a disease associated with a degeneration of 
dopaminergic neurons and subsequent functional decline of the nigrostriatal system 
(Xia & Mao, 2012; Winner & Winkler, 2015), these results taken together indicate 
that MIA at E16 may lead to adverse outcomes in offspring motor behavior later in 
life, which I discuss further in the final discussion.   
In the current study, we also conducted an amphetamine challenge in the 
open field to assess overall dopaminergic functioning, as amphetamine leads to 
increases in extracellular dopamine in numerous brain regions and pathways (Di 
Chiara & Imperato, 1988; Heuer et al., 2012; Bardo, 2013).  Our results demonstrate 
that MIA alters amphetamine response with regards to locomotion as seen by altered 
distance and velocity in the E12 LPS group, compared to the E12 control group.  We 
saw an initial decrease in locomotion following AMPH administration, consistent 
with some literature which has demonstrated decreased sensitivity to the locomotor 
enhancing effects of amphetamine in adult rat offspring following MIA (8mg/kg 
Poly-I:C at E14) (Bronson et al., 2011; Richtand et al., 2011).  Conversely, in the 
second half of the AMPH trial we saw a significant increase in locomotion behavior, 
which is similar to previous studies that have shown an exaggerated hyperactivity 
response to amphetamine following exposure to acute Poly-I:C (8mg/kg on E14 
(Vorhees et al., 2012) or 4.0mg/kg on E15 (Zuckerman & Weiner, 2005; Piontkewitz 
et al., 2011b)) or chronic Poly-I:C (E14-18, 8mg/kg/day) (Vorhees et al., 2015) in 
rats.  Importantly, many of these studies assessed the locomotion response to 
amphetamine for a longer duration than the present study, suggesting that a long 
testing period may provide more comprehensive insight into the effects of MIA on 
AMPH-induced locomotion and future studies should take this into consideration.  
However, it is still clear from our data that the animals exposed to MIA at E12 
responded to AMPH differently than the relevant control while the E16 cohort 
demonstrated no differences, indicating a possible critical window for differential 
responding to this indirect dopamine agonist.   
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We next analyzed anxiety behavior to investigate functionality of the 
mesocorticolimbic system in our MIA model, as previous work (using 
Grin1
Δ/loxP
;Slc6a3
crel+
 knockout mice to alter dopamine neuron activation) has 
indicated a role for proper mesolimbic dopamine functioning in normal anxiety 
behavior (Zweifel et al., 2011).  We found a decrease in the duration of USVs in the 
post test following MIA at E16, but not E12.  This is consistent with previous data 
which demonstrated reduced number and duration of USVs from P3 and P5 rat pups 
following in utero exposure to LPS (100μg/kg LPS at E15 and E16) (Baharnoori et 
al., 2012).  Impairment in the generation of USVs in isolation is an indicator of 
aversive affective states in young rodents (Hofer et al., 2001).  This suggests our E16 
LPS group experienced increased feelings of anxiety, depression and/or anhedonia 
by the end of the test battery in comparison to the relative saline control.  The USV 
tests in young rodents can predict anxiety response in adult age (Hofer et al., 2001); 
this finding suggests that the E16 LPS group may have heightened anxiety later in 
life and therefore we assessed anxiety behaviors again at P30 and after P60. 
Adolescent offspring exposed to MIA at E16 spent significantly more time in 
the center of the open field arena compared to E16 controls, and again there were no 
differences in the E12 cohort.  Greater duration in the center of the open field arena 
is usually indicative of anxiolysis as the open field test exploits the natural aversion 
rats have to exposed areas (Prut & Belzung, 2003), which would suggest that the E16 
LPS group demonstrated decreased anxiety behaviors compared to E16 control.  In 
agreement with this, exposure to LPS in early life (10μg/kg every 24h P5-P8) has 
been shown to decrease anxiety in adolescence (Fan et al., 2005), while 
administration of LPS to pregnant mice (50μg/kg on E15, E16 and E17) resulted in 
no significant differences in adolescent (P40) anxiety behavior (Enayati et al., 2012).  
However, high LPS exposure in utero (300 and 500μg/kg on E16; 500μg/kg on E17) 
resulted in heightened levels of adolescent anxiety in the EMP (Enayati et al., 2012).  
This suggests that the greater the MIA, the greater the resultant disturbances in 
adolescent anxiety behavior.   
Previous literature that has shown that animals with low anxiety behavior 
have higher local dopamine release in the nucleus accumbens and this is thought to 
be associated with increased activation of the reward system (Beiderbeck et al., 
2012).  To the best of our knowledge this is the first study that has examined the 
139 
 
effects of LPS specifically on offspring motivation and reward behaviors; however,  
it has been reported that maternal administration of Poly-I:C (4mg/kg, on E15) 
impaired cognitive flexibility, but did not affect motivational behaviors, in adult 
male offspring subjected to an operant conditioning task (Zhang et al., 2012). 
Furthermore, maternal exposure to 3,4-methylenedioxy-N-methamphetamine 
(MDMA, 15mg/kg, twice daily from E14-E20) (which releases DA) did not affect 
food reward nor cocaine self-administration in adult offspring (Thompson et al., 
2009b) and maternal exposure to Poly-I:C (5mg/kg) on E17 resulted in anhedonic 
behavior as demonstrated by the sucrose preference test (Bitanihirwe et al., 2010).  
In the present study, there were no major differences in baseline trials (in which 
animals did not receive amphetamine or saline injections), indicating that MIA does 
not affect normal baseline reward function in adolescent and adult offspring.  
However, amphetamine has been shown to affect reward processing in humans 
(O’Daly et al., 2014) and rats (Wyvell & Berridge, 2000; Schmidt et al., 2013), and 
previous findings demonstrate the ability of amphetamine to potentiate responding 
for a conditioned reward in a normal animal (Fletcher et al., 1998).  Interestingly, 
animals exposed to in utero LPS at E12 appear to escape the characteristic AMPH-
induced increase in reward responding.  Following AMPH injection in adolescence, 
when all other groups increased active lever presses, rewards obtained, and break 
point, the E12 LPS group remained at baseline levels.  Furthermore, E12 LPS had 
increased number of inactive lever presses compared to the relative control group 
during the AMPH trial. Inactive lever presses are associated with non-reward 
seeking behavior (Robinson et al., 2007), indicating the E12 LPS group showed 
increased impulsivity following AMPH injection.  In adulthood, we observed the 
same decreased AMPH response in goal directed behavior with these animals (E12 
LPS), which is consistent with previous studies which have showed that adult rat 
offspring exposed to high fat diet the last week of pregnancy displayed reduced 
sensitization to amphetamine and alterations to mesocorticolimbic system 
functionality (Naef et al., 2008).  Taken together, these data suggest that MIA has 
differential effects on amphetamine intervention in a reward paradigm depending on 
gestational age at which MIA occurs, with E12 as a potential critical age allowing 
for decreased AMPH sensitivity in adolescence and adulthood.  An important 
implication of this finding concerns drug addiction.  The DSM-V defines tolerance, 
or a diminished response to a drug that is repeatedly used, as a hallmark symptom of 
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addiction (APA, 2013), and therefore our findings of reduced sensitivity to AMPH 
following MIA at E12 may indicate a potential susceptibility for drug tolerance and 
subsequent abuse later in life, which is discussed fully in the final discussion.  
In conclusion, our data show that timing of MIA is important determinant of 
neurobehavioral outcome in affected offspring whereby an infection earlier in 
gestation (E12) may have greater consequences for the mesocorticolimbic pathway 
whereas infection in later pregnancy (E16) may have greater consequences for the 
function of the nigrostriatal pathway.   
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Abstract 
Introduction 
Maternal infection during pregnancy increases the risk several neurological and 
psychiatric disorders later in life, many of which have a component of dopaminergic 
(DA) dysfunction. In Chapter 3, we showed that behavioral deficits that emerge after 
MIA are dependent on when the insult occurs. In this study we sought to examine the 
molecular and cellular changes that occur in the midbrain of affected offspring that 
may lead to these behavioral deficits. 
Methods 
Pregnant-Sprague Dawley rats were administered saline or lipopolysaccharide (LPS) 
by intraperitoneal injection on embryonic day 12 or 16.  We then examined a number 
of key inflammatory mediators, along with neurodevelopmental and 
cytoarchitectural characteristics at different stages of offspring development.  In 
vitro studies of VM neurospheres and DA neuron growth were used to supplement in 
vivo findings. 
Results 
Our results show a differential inflammatory response in fetal midbrains depending 
on gestational age of exposure.  LPS exposure at E16 resulted in decreased VM 
neurosphere size after 7DIV.  This was associated with an increased susceptibility to 
neurotoxic effects of pro-inflammatory cytokines for both VM neurospheres and VM 
DA neurons treated in culture.  In utero LPS exposure at later gestational ages also 
altered the cellular architecture of fetal VM stained for TH, a DA neuron marker.  
However, there were no differences in DA neuron number in juvenile, adolescent, or 
adult offspring.  Similarly, LPS exposure did not alter cell number or morphology of 
glial cells in the midbrains of affected offspring. 
Conclusions 
Exposure to MIA in later pregnancy results in developmental alterations in the fetal 
VM, which may result from increased levels of pro-inflammatory cytokines at this 
developmental stage. 
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4.1 Introduction 
Fetal programming is the idea that events during pregnancy influence developmental 
trajectories (Schlotz & Phillips, 2009).  For example, epidemiological and preclinical 
evidence has associated prenatal inflammatory events with offspring susceptibility to 
neurological disorders later in life (Bell & Hallenbeck, 2002; Stolp & 
Dziegielewska, 2009).  Parkinson’s disease (PD) is an adult-onset neurological 
disorder which is highly associated with neuroinflammation because microglial 
activation (McGeer et al., 1988; Imamura et al., 2003) and elevated levels of pro-
inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-
α (TNF-α), and IL-6 (Mogi et al., 1994a; Mogi et al., 1994b; Koziorowski et al., 
2012) are common characteristics of PD brains.  Furthermore, it has been proposed 
that maternal immune activation (MIA) may prime microglia to maintain heightened 
inflammatory processes throughout life, which in turn may alter microglial response 
to cellular processes like protein aggregation or neuron death, subsequently resulting 
in progression of the α-synuclein aggregates into Lewy bodies that are the 
pathological hallmark of PD (reviewed in Glass et al., 2010; Tomé et al., 2013; 
Knuesel et al., 2014).  Hence, fetal programming as a result of MIA has the potential 
to lead to an increased susceptibility to PD later in life.  PD results from the 
degeneration of dopaminergic (DA) neurons of the substantia nigra (SN) in the 
midbrain, cells which differentiate from neural progenitor cells (NPCs) in the ventral 
mesencephalon (VM) (Toulouse & Sullivan, 2008; Hegarty et al., 2013).  
Furthermore, other disorders associated with an increased risk following MIA have 
characteristic components of dopaminergic (DA) dysfunction, including 
schizophrenia (Howes & Kapur, 2009; Howes et al., 2012; Seeman, 2013) and 
ADHD (Levy, 1991; Swanson et al., 2000; Volkow et al., 2011).  Indeed, MIA has 
been shown to induce numerous genetic, structural, and functional alterations to 
dopaminergic development in affected offspring (Meyer & Feldon, 2009; Meyer, 
2013).  As such, understanding the development of these cells within the context of 
MIA will help elucidate contributory factors of MIA processes to disease 
susceptibility in affected offspring.   
 To this end, inflammatory mediators have been investigated with results 
suggesting that they may exert a range of effects in the developing brain.  They are 
known to have productive roles, and in fact IL-1β was sufficient to lead VM NPCs 
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toward DA specificity differentiation (Ling et al., 1998; Potter et al., 1999).  
Furthermore, depending on the concentration, IL-1β, IL-6, and TNF-α acted as either 
neurotoxic (at low-medium concentrations) or neurotrophic (at higher 
concentrations) toward fetal VM DA neurons (Meyer, 2013).  Temporal profiles of 
neurodevelopmental stages also determine the potential effect of cytokines on the 
developing VM.  For instance, in earlier development, TNF-α has been shown to 
enhance cultures of DA neurons (E12.5, mouse), whereas TNF-α inhibited DA 
neuron cultures isolated from E14 or E16 mouse VM (Doherty, 2007).  Along these 
lines, it has been shown that offspring outcome is dependent upon the timing during 
pregnancy at which MIA occurs, and indeed animal models have identified “critical 
developmental windows” during which fetal neurodevelopment is more vulnerable 
to adverse effects of MIA (Andersen, 2003; Marco et al., 2011).  Importantly, these 
critical windows also depend on animal model, including immunogen and dose used 
(Boksa, 2010; Harvey & Boksa, 2012).  In our MIA model, which consists of a 
single exposure to low dose of LPS in rats, superior cervical ganglion (SCG) neuron 
growth was inhibited by LPS exposure only in later stages of rat pregnancy (Straley 
et al., 2014).  This was associated with late gestational modifications to placental 
inflammatory factors and HSD11β2 (Straley et al., 2014), which is a critical 
regulator for fetal development (Cottrell et al., 2014; Togher et al., 2014), 
implicating a role for placental function in neurodevelopment.  Furthermore, in the 
previous chapter we demonstrated that negative behavioral outcomes in MIA 
exposed offspring depend on the timing during pregnancy at which the insult 
occurred.  For instance, motor behavior deficits in juvenile offspring were observed 
following MIA in later pregnancy (E16), but not earlier (E12).  Taken together, these 
findings suggest that the potential for MIA to adversely affect fetal VM and/or DA 
neuron development may be greatest during a later developmental window in our 
model.   
In the current study, we use an LPS rat model of MIA (Straley et al., 2014), 
to examine the impact of in utero exposure to MIA on fetal expression of pro-
inflammatory cytokines as well as VM development and subsequent cellular 
architecture of offspring midbrains in the fetal stages, neonatal period, adolescence 
and adulthood.  Rat VM DA NPCs peak in proliferation at E12 (Gates et al., 2006), 
and differentiate toward the DA lineage which peaks from E13-E15 (Volpicelli et 
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al., 2004).  Furthermore, the DA neurons begin to extend axons at E12/E13 to 
establish functional circuitry, with projections reaching the striatum by E14, and the 
cortex by E16 (Hegarty et al., 2013).  Therefore, we administered LPS on E12 or 
E16 to determine the impact of the timing of exposure to MIA on midbrain 
development in affected offspring.   
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4.2 Materials and Methods 
4.2.1 LPS injections and sample collection 
All experimental animal work was carried out under license with ethical approval 
from the Ethics Committee of UCC.  Sprague-Dawley rats (Biological Services Unit, 
UCC) were maintained in a controlled environment on a 12-hour light/dark cycle 
with ad libitum access to food and water. As the timing of infection during 
pregnancy is often a critical determinant of fetal outcome, pregnant dams received an 
I.P. injection of LPS (50μg/kg) or normal saline on E12 or E16 for most 
experiments.  The first experiment examined chronic vs acute exposure on cytokine 
profiles at P1 and so for these, pregnant rats were injected on E12, E14, E16, and 
E18 (chronic) or just on E18 (acute).   
For embryonic developmental experiments, 48 h post injection, dams were 
anesthetized with inhaled Isoflurane (Abbeyville Veterinary hospital, Cork) and 
culled by decapitation.  Embryos were removed via laparotomy, and washed in ice-
cold Hank’s Balanced Salt Solution (HBSS).  Embryos were removed from the yolk 
sac and transferred to fresh HBSS.  The litter was divided so that some embryos 
were fixed in 4% PFA for 24 h, then cryoprotected for 48h, and other embryos were 
used for obtaining VM samples via micro-dissection as previously described (Long-
Smith et al., 2010).  Briefly, embryos were kept in HBSS on ice until transferred to 
another petri dish with HBSS for VM micro-dissection.  The mesencephalic region 
was dissected out of the fetal brain and then dissection needles were used to cut 
along the dorsal midline to open out the tissue.  Then the lateral edges were trimmed 
to remove the dorsal mesencephalon.  Finally, the tissue was cleaned of the 
meninges.  Half of the VM samples were immediately used for cell culture 
experiments and the other half were snap frozen for PCR.   
For postnatal studies, offspring were divided and culled at different ages in 
order to analyze brains of juveniles (P11), adolescents (P32), and adults (>P60).  The 
whole brains of the offspring were immersed fixed in 4% paraformaldehyde for 24h 
at 4˚C.  They were subsequently transferred to 30% sucrose for cryoprotection and 
incubated at 4˚C. After a minimum of 48 hours in this 30% sucrose, the brains were 
snap-frozen in isopentane that had been pre-cooled in liquid nitrogen, and stored at -
80˚C to await cyrosectioning.   
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Sample embryos/ brains were derived from four different mothers in each 
treatment condition (LPS or vehicle) and sampling interval (E12 or E16). This 
served to minimize potential confounds resulting from litter effects (Zorrilla, 1997), 
and to rule out the possibility that putative differences between LPS and vehicle-
exposed fetuses may stem from individual differences in prenatal development. 
 
4.2.2 Real-time PCR  
A motorized pestle and mortar were used to disrupt the VM samples and total RNA 
was extracted using an RNeasy tissue mini kit (Qiagen).  RNA concentration was 
determined using a Spectrophotometer (NanoDrop Technologies).  500ng of RNA 
was reverse transcribed using a high capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) in a 20μl reaction mixture consisting of 2.0μl 10X RT Buffer, 
0.8μl 25X dNTP mix (100mM), 2.0μl 10X RT Random Primers, 1.0μl Reverse 
Transcriptase, and 4.2μl Nuclease-free H2O, using the following parameters: 25°C 
for 10 min; 37°C for 120 min; 85°C for 5 min; 4°C for at least 10 minutes.  The 
cDNA was stored at -80°C prior to use.  For real time PCR, all samples were run in 
triplicate, with the reaction mix for a single reaction consisting of 1.0 μl 20X 
TaqMan® Gene Expression Assays (Applied Biosystems), 10 μl 2X TaqMan® Gene 
Expression Master Mix (Applied Biosystems), and 8.0 μl RNase-free H2O (Applied 
Biosystems).  19 μl of the mix was added to each well of a 96 well PCR reaction 
plate (Applied Biosystems) as well as 1.0 μl of the relevant cDNA.  The plate was 
centrifuged briefly and then loaded into the qRT-PCR system (StepOne Real-Time 
PCRY System, Applied Biosystems) and run using the following cycling parameters; 
50°C for 2 minutes; 95°C for 10 minutes; and 50 repetitions of 95°C for 15 seconds 
and 60°C for 1 min.  Analysis was carried out using the 2-CT method (Livak & 
Schmittgen, 2001).   
 
4.2.3 Cell culture 
For the preparation of rat VM cultures, embryos were obtained by laparotomy from 
date-mated female Sprague-Dawley rats following decapitation under terminal 
anesthesia induced by the inhalation of isoflurane.  The first experiment consisted of 
neurosphere assays using cells isolated from VM of embryos 2 days post exposure to 
LPS (exposure occurred on E12 or E16).  The second investigation utilized VM cells 
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from E12 or E16 embryos of naive animals which were treated with pro-
inflammatory cytokines as outlined below.  Cultures of VM NPCs were prepared as 
previously described (O’Keeffe and Sullivan 2005).  The cells were seeded in T-25 
culture flasks (Sarstedt) at a density of 2x10
6
 cells per flask in 10 ml of DMEM/F12, 
1% L-Glutamine  (Sigma) supplemented with 2% B27 (Invitrogen), 20 ng/ml 
epidermal growth factor (EGF; SIGMA) and 20ng/ml of basic fibroblast growth 
factor (bFGF; Sigma).  Neurospheres were allowed to proliferate for 2, 4 or 7 DIV in 
a humidified atmosphere containing 5% CO2 at 37˚C, and half of the media was 
replaced every second day.  In the second experiment, neurospheres grown from the 
E12 and E16 VM of naïve animals were treated with IL-1β, TNF-α and IL-6 
(Promokine) every 2DIV for 6days.  Cytokine treatments were all at 10ng/ml, which 
was previously shown to affect NPCs in culture (Crampton et al., 2012).   
For primary cultures of VM DA neuron cultures, dissected VM tissue was 
centrifuged at 1100rpm for 5min at room temperature. The tissue pellet was 
incubated in a 0.1% trypsin-Hank’s Balanced Salt solution for 5min, at 37˚C with 
5% CO2. Fetal calf serum was then added to the tissue, which was then carefully 
triturated using a sterile plugged flame-polished Pasteur pipette, followed by a 25-
gauge needle and syringe. The VM cells were centrifuged at 1100 rpm for 5min. The 
resulting cell pellet was re-suspended in 1ml of differentiation media (Dulbecco's 
modified Eagle's medium/F12, 33mM D-glucose, 1% L-glutamine, 1% FCS, 
supplemented with 2% B27) using a P1000 Gilson pipette, and cell density was then 
estimated using a haemocytometer. Cells were plated on poly-D-lysine (Sigma)-
coated 24-well tissue culture plates at a density of 5 x 10
4
 cells per well in 500μl of 
differentiation media at 37˚C with 5% CO2. E14 and E18 VM cell cultures were 
treated with 100ng/ml of IL-1 or 10ng/ml of TNF- daily for 4DIV, and these 
doses were chosen as they were shown to affect neurite growth in a previous 
publication (Nolan et al., 2011).  
 
4.2.4 Analysis of neuronal complexity 
The neurite length and branching of individual E14 and E18 VM DA neurons was 
measured at 4DIV using Sholl analysis as previously described (Gutierrez & Davies, 
2007; Nolan et al., 2011; Straley et al., 2014). Brieﬂy, neurite length (NL) was 
calculated with the following formula; NL = α x T x (π/2), where α is the number of 
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times the neurite intersects the grid lines, and T is the distance between the gridlines 
on the magnified image (taking into account the magnification factor). VM DA 
neurons with intact processes were analyzed from 20 random ﬁelds per condition, 
where a process that was at least 1.5 times the length of the neuron soma was defined 
as an intact process (which precludes analysis of apoptotic neurons (Hegarty et al., 
2014)).  This is based on previous papers demonstrating that the average size of DA 
neuron soma is 10-20μm and the average length of a primary neurite is 85±10μm 
(Rayport et al., 1992; O'Keeffe et al., 2004), suggesting that our parameters are able 
to account for somatic shape and neurite length diversity as well as exclude cells that 
have initiated the axonal retraction process associated with apoptosis (Collins et al., 
2013).   
 
4.2.5 Immunohistochemistry (embryonic samples) 
Following LPS exposure at either E12 or E16, rat embryo brains were dissected at 
E14 and E18 respectively.  The whole brains were placed in 4% paraformaldehyde 
for overnight post-fixation.  They were subsequently transferred to 30% sucrose for 
cryoprotection and incubated at 4˚C. After a minimum of 48 hours equilibration in 
this 30% sucrose, the brains were snap-frozen in isopentane that had been pre-cooled 
in liquid nitrogen, and stored at -80˚C to await cyrosectioning. Coronal sections 
(20μm) of fixed embryonic brains were cut using a cryostat (Leica M1900) and 
collected as a 1:6 series and subsequently used for immunohistochemistry.  To block 
endogenous peroxidase, sections were treated with 10% H2O2 for 5 min, washed in 
10mM PBS and blocked for 1 h in 10% normal goat serum in 10mM PBS with 0.4% 
Triton-X.  Sections were then incubated in primary antibody to TH (1:1000; mouse 
monoclonal; Millipore) in 1% normal goat serum in 10mM PBS with 0.4% Triton-X 
overnight at 4°C.  Following a 3 x 10 min wash in 10mM PBS, sections were 
incubated with a biotinylated secondary antibody (1:200, goat anti rabbit, Vector 
Labs) for 2 h at room temperature.  Following another 3 x 10 min wash in 10mM 
PBS, sections were incubated in ABC solution (1:200; Vector Labs) for 45 minutes 
at room temperature followed by immersion in diaminobenzidine 
substrate/chromogen reagent for 2-3 min at room temperature.  Sections were 
dehydrated, cleared, coverslipped, and allowed to air dry overnight, and then they 
were imaged using an Olympus AX70 Provis upright microscope.  Negative controls 
150 
 
received the same treatment except PBS was substituted for the primary antibody 
solution.  To estimate the cellular architecture of VM regarding DA neurons, the 
relative number of TH-positive VM cells were expressed as the total number of the 
cells counted per section, and three sections per embryonic brain were analyzed, 
similarly to previous work (Nakao & Brundin, 1996).   
 
4.2.6 Immunohistochemistry (postnatal samples) 
For postnatal immunohistochemistry, a slightly different protocol was used.  Coronal 
sections of fixed brains were cut using a cryostat (Leica M1900) at 20μm thickness 
in 1:6 series, dried at room temperature and stored at −80 °C until 
immunohistochemistry was performed, which has been used previously when 
assessing the numbers of DA neurons in the postnatal midbrain (Sullivan et al., 
1997; O’Sullivan et al., 2010; Costello et al., 2012).  For immunostaining, the slices 
were thawed in incubator for 1hr and rehydrated in 10mM Phosphate Buffered 
Saline (PBS) for 5 min. They were then blocked for 40 mins in 10% normal serum 
(normal goat serum for TH staining and normal donkey serum for GFAP/Iba1 
staining) in 10mM PBS with 0.4% Triton-X. Sections were then incubated with 
primary antibody (TH, 1:1500, Millipore; or co-staining with both: GFAP, 1:1000, 
Dako; and Iba1, 1:1000, Abcam) in 2.5% normal serum in 10 mM PBS with 0.4% 
Triton-X overnight at -4C. Following a 3 x 5 min wash in 10 mM PBS, sections 
were incubated with secondary antibody (TH = Alexa Fluor 488 anti-mouse, 1:500, 
Invitrogen; or co-staining with both: GFAP = Alexa Fluor 594 anti-rabbit, 1:500, 
Invitrogen; Iba1 = Alexa Fluor 488 anti-goat, 1:250, Invitrogen) in 2.5% normal goat 
serum in 10mM PBS with 0.4% Triton-X for 2 h at room temperature.  Following 
another 3 x 5 min wash in 10 mM PBS, sections were incubated with bisbenzimide 
(1:3000) for 4 min at room temperature.  Following 1 more 5 min wash, slides were 
cover-slipped and allowed to dry for at least 24 hours. Once dry, sections were 
imaged using an Olympus AX70 Provis upright microscope. Negative controls 
received the same treatment except PBS was substituted for the primary antibody.  
For the postnatal immunohistochemistry, 1 out of every 6 sections was stained for 
TH or GFAP and Iba1.  Then, we chose different levels throughout the midbrain 
relative to bregma (AP-5.2, -5.6, -6.0, -6.4) to examine, similarly to previous studies 
(Nakao & Brundin, 1996; O’Sullivan et al., 2010).  Representative images were 
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analyzed using Image J software to compare relative numbers of TH, GFAP, and 
Iba1-positive cells, reported as count/ area (μm2).  As we had determined differential 
behavioral outcomes associated with either the nigrostriatal pathway or the 
mesocorticolimbic pathway in the previous chapter, for the P60 group we also sub-
divided the analysis by specific midbrain region, either SN or VTA using anatomical 
landmarks as previously described (Nakao & Brundin, 1996).       
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4.3 Results 
4.3.1 Effect of maternal LPS exposure on postnatal cytokine profiles 
MIA is known to alter the expression of numerous cytokines in the fetal brain 
(Urakubo et al., 2001; Meyer et al., 2005; Arrode-Brusés & Brusés, 2012).  Hence, 
we initially investigated whether LPS exposure in utero would induce changes in 
mRNA expression of pro-inflammatory cytokines in the midbrain of affected 
offspring that are commonly associated with MIA.  Chronic LPS exposure (LPS on 
E12, E14, E16, and E18), acting as a positive control, resulted in significant 
decreases of IL-6, IL-1β, and TNF-α mRNA levels at P1 (Fig 1A, B, C).  I.P. 
administration of LPS to the pregnant dams only on E18 resulted in less robust 
effects, with decreases in IL-1β and TNF-α mRNA expression (Fig 1B, C), but no 
difference in IL-6 mRNA levels (Fig 1 A) in the P1 midbrain.   
 
4.3.2 Differential effect of MIA on developing VM depending on gestational age 
Given that MIA induced different levels of cytokine mRNA in postnatal midbrain 
samples from affected offspring (Fig. 1), we next examined if the inflammatory 
modulators affected VM development, as we have previously shown that 
inflammation impairs the proliferation of rat NPCs from the E14 rat VM (Crampton 
et al., 2012).  Firstly, we cultured VM NPC neurospheres that were isolated from 
embryos that were exposed to in utero saline (control) or LPS on either E12 or E16; 
VM samples were isolated 48h post MIA.  Neurosphere area of the E12 (Fig 2A) and 
E16 (Fig 2B) LPS exposed groups were statistically comparable to the relative saline 
control group at 2DIV.  By 7DIV, however, the area of VM NPC neurospheres 
isolated from the E16 LPS group (Fig 2B) were significantly reduced compared to 
the relative saline controls, whereas the E12 groups (Fig 2A) remained similar in 
area.   
 To determine if the differential alterations in neurosphere size over time in 
vitro were related to exposure to inflammatory cytokines, we next investigated the 
mRNA expression of cytokines in the midbrains from embryos 48h after LPS 
exposure at E12 or at E16.  I.P. administration of LPS to pregnant dams on E12 
resulted in decreased levels of IL-6 (Fig 2D) and increased levels of IL-1β (Fig 2E), 
whereas there were no difference in TNF-α (Fig 2F) mRNA expression for the MIA 
exposed group compared to control.  LPS administered to pregnant rats on E16 
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resulted in increased mRNA expression of IL-1β (Fig 2E) and TNF-α (Fig 2F) as 
well as a trend toward an increase in IL-6 mRNA expression (Fig 2D).   
 As there were different cytokine profiles depending on gestational age of 
LPS exposure (Fig 2D-F), and this was in line with the difference in neurosphere 
growth following in utero LPS exposure at different gestational ages (Fig 2A, B), we 
next wanted to determine which specific cytokines alter the development of VM 
NPC neurospheres.  Neurospheres grown from E12 VM were reduced only when 
grown in the presence of TNF-α, but the diameter of these spheres was not affected 
by either IL-1β or IL-6 (Fig 2G).  In contrast, the diameter of neurospheres 
established from E16 VM was significantly reduced when grown in the presence of 
all three cytokines: IL-1β, TNF-α, and IL-6 (Fig 2H).   
 
4.3.3 Differential sensitivity of VM DA neurons to inflammation 
Given that we have previously shown SCG neuron complexity is affected by in utero 
LPS exposure at E16, but not E12 (Straley et al., 2014), and that maternal 
administration of LPS on E16 decreased VM neurosphere area at 7DIV (Fig 2), we 
next sought to determine the effects of cytokines specifically on VM DA neurons.  
To this end, we applied Sholl analysis, which illustrates neurite length and branching 
with distance from the cell body, to differentiated VM DA neurons which had been 
treated in culture with pro-inflammatory cytokines.  When E18 VM DA neurons 
were grown in the presence of TNF-α, we observed a decrease in DA neuron 
branching (Fig 3E) and neurite length (Fig 3F), whereas IL-1β treatment did not 
result in significant alterations to neuronal complexity (Fig 3E,F).  The growth and 
complexity of E14 VM DA neurons was not altered following 4 day cytokine 
treatments (Fig 3 A-C).   
 
4.3.4 Effects of MIA on DA neuron cytoarchitecture  
Because cytokine mRNA levels were increased in the midbrains of offspring 
exposed to LPS in later pregnancy (Fig 2), and because TNF-α treatment inhibited 
the growth of differentiated DA neurons cultured from the same age (Fig 3), we next 
investigated the number of TH-positive cells in midbrain sections of offspring 
exposed to saline (control) or LPS on E12 of E16.  LPS exposure on E16 reduced the 
total number of TH-positive DA neurons counted in the fetal midbrain 2 days later 
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(Fig 4C), whereas LPS at the earlier time point (E12) did not result in differences in 
TH cell count in embryonic midbrain sections (Fig 4A).  Subsequently, midbrain 
sections were stained for TH at three other time points throughout the offspring 
lifetime, providing cytoarchitecture data for juvenile (Fig 4E-H), adolescent (Fig 4I-
L), and adult (Fig 4M-P) offspring following MIA exposure in utero.  There were no 
differences in TH count/ area at any of these ages, comparing the LPS exposed group 
to relevant saline, age-matched control.  Importantly, because of the differential 
behavior characteristics observed in adulthood, we also analyzed TH cell count 
specifically in the SN and VTA.  When we compared the LPS exposed groups to 
their relative saline age-matched controls, there were no significant differences in 
TH positive cell count/area for either the SN or the VTA (data not shown). 
 
4.3.5 Effects of MIA on glial cytoarchitecture 
Maternal infection increases the risk of a number of neuropsychological disorders 
which include symptoms of altered immune functioning including ASD (Onore et 
al., 2012) and schizophrenia (Strous & Shoenfeld, 2006; Richard & Brahm, 2012).  
Furthermore, MIA has been shown to alter the numbers and morphological 
characteristics of glial cells in the brains of affected offspring (Boksa, 2010; Harvey 
& Boksa, 2012; Meyer, 2014).  Similarly, in vitro studies have shown that IL-1β, 
which is increased in the brains of MIA offspring (Urakubo et al., 2001; Zaretsky et 
al., 2004), alters the differentiation of VM NPCs toward that of glial cell lineage, as 
opposed to neuronal (Crampton et al., 2012).  Therefore, we next examined the 
impact of MIA on glial development in the midbrains of juvenile (Fig 5 A, B) and 
adolescent (Fig 5 C, D) offspring exposed to saline (control) or LPS in utero at 
different gestational ages.  Numbers of astrocytes, as indicated through GFAP 
staining, were not altered by LPS exposure at E12, nor E16 when analyzed at 
juvenile (Fig 5A) or adolescent (Fig 5C) ages.  Similarly, numbers of microglia, 
identified using Iba1 as a marker, in midbrains of control and LPS groups were 
statistically similar at both ages, for both E12 and E16 cohorts (Fig 5B, D).   
 
4.3.6 Effects of MIA on microglial phenotype 
Changes in microglia morphology have been observed following MIA, including 
increased ratio of active to ramified microglia in affected offspring (Knuesel et al., 
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2014; Perry & Holmes, 2014).  Therefore, even though we did not see a change in 
overall microglial cell counts following MIA (Fig 5), it was important to determine if 
exposure to LPS in utero altered the morphology of microglial cells in affected 
offspring midbrains.  We again analyzed the Iba1 stained midbrain sections from 
offspring at juvenile (Fig 6 A, D) and adolescent ages (Fig 6 B, E) following 
maternal administration of saline (control) or LPS on E12 or E16.  Offspring that had 
been exposed to LPS at the later age (E16) demonstrated a trend toward a decrease in 
the number of ramified microglial cells (Fig 6A), but had similar numbers to that of 
the control group in amoeboid numbers (Fig 6D) at the juvenile age.  Inversely, the 
same group demonstrated a trend toward a decrease in amoeboid numbers (Fig 6E), 
and no difference in ramified counts (Fig 6B) when analyzed at the adolescent age.  
Exposure to LPS at E12 resulted in no differences in numbers of ramified or 
amoeboid cells at either offspring age (Fig 6).   
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4.4 Figures and Figure Legends 
 
 
 
 
 
 
 
Figure 1: Postnatal cytokine profiles comparing chronic versus acute LPS 
exposure in vivo. 
(A-C) Quantitative real-time PCR examining the expression of (A) IL-6, (B) IL-1β, 
and (C) TNF-α mRNA in the postnatal (P1) VM, following in utero exposure to 
saline (Cont) or LPS chronically (i.e. on E12, E14, E16, and E18; green bars) or 
acutely (on E18 only; purple bars) as indicated.  Data are expressed as mean ±SEM 
(N=4/group/time point). * P < 0.05, ** P < 0.01, *** P < 0.001, unpaired Student’s 
t-test. 
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Figure 2: Differential sensitivity of the developing ventral midbrain to 
inflammatory cytokines. 
(A-C) A neurosphere assay was carried out using cells isolated from the ventral 
midbrain (VM) of embryos 48h after being exposed in utero to saline (Cont) or LPS 
at E12 (blue bars) or E16 (red bars) as indicated; (A, B) neurosphere area at 2 and 7 
DIV, and (C) representative photomicrographs of neurospheres at 7DIV.  (D-F) 
Quantitative real-time PCR examining the expression of (D) IL-6, (E) IL-1β, and (F) 
TNF-α mRNA in the VM, 48h after in utero exposure to saline (Cont) or LPS at E12 
(blue bars) or E16 (red bars) as indicated (LPS group was compared to saline treated 
control group).  (G-I) A neurosphere assay examining diameter of neurospheres 
established from cells isolated from the (G) E12 or (H) E16 VM and grown for 4DIV 
in the presence of IL-1β, TNF-α and IL-6 (all at 10ng/ml).  (I) Representative 
photomicrographs of the experiments shown in (G, H); scale bar = 50μm.  Data are 
expressed as mean ±SEM (N=3-4/group/time point). * P < 0.05, ** P < 0.01, *** P 
< 0.001, unpaired Student’s t-test.     
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Figure 3: Differential sensitivity of cultured VM DA neurons to inflammatory 
cytokines 
(A) Percentage of total cells, (B) branching and (C) neurite length/cell of TH-
positive DA neurons at 4DIV following daily treatments with IL-1 (100ng/ml) or 
TNF- (10ng/ml) in cultures of E14 rat VM. (D) Representative photomicrographs 
of the experiments shown in (A-C). (E) Branching and (F) neurite length/cell of TH-
positive DA neurons at 4DIV following daily treatments with IL-1 (100ng/ml) or 
TNF- (10ng/ml) in cultures of E18 rat VM (*P < 0.05 compared to controls). (G) 
Representative photomicrographs of the experiments shown in (E, F). Scale bar = 
50μm. Data are expressed as mean ± SEM.      
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Figure 4: MIA alters fetal DA neuron count in later pregnancy, which is 
corrected by P9. 
(A-D) TH positive total cell count of ventral midbrain (VM) from embryos 48h 
following in utero exposure to saline (Cont) or LPS at (A) E12 (blue bars) or (C) 
E16 (red bars).  Representative photomicrographs of (B) E14 VM and (D) E18 VM 
from embryonic immunohistochemistry experiments; scale bar = 100μm.  Data 
expressed as mean ±SEM (N=5-6/group/time point); * P < 0.05.  (E-P) TH positive 
cell counts per area from stained midbrain sections of brains from (E-H) juvenile, (I-
J) adolescent, or (M-P) adult offspring that were exposed to saline (Cont) or LPS at 
(E, I, M) E12 (blue bars) or (G, K, O) E16 (red bars).  Representative 
photomicrographs of postnatal immunohistochemistry experiments, including (F) 
juvenile, (J) adolescent, and (N) adult offspring exposed to in utero insult on E12 
(blue bars), as well as (H) juvenile, (L) adolescent, and (P) adult offspring exposed 
to saline or LPS on E16 (red bars).  Data are expressed as mean ±SEM (N=3-
4/group/time point), unpaired Student’s t-test. Scale bars = 100μm.       
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Figure 5: No difference in offspring midbrain glial cell number following MIA 
(A-D) Graphical representations of cell count / area of (A-B) juvenile and (C-D) 
adolescent offspring midbrains co-stained for (A, C) GFAP and (B, D) Iba1 
following maternal administration of saline (control) or LPS on either E12 (blue 
bars) or E16 (red bars).  Data are expressed as mean ±SEM (N=4/group/time point), 
unpaired Student’s t-test.  (E-H) Representative photomicrographs of adolescent 
midbrains immunofluorescently labelled for astrocytes (GFAP) or microglia (Iba1) 
following in utero exposure to (E) saline (cont) or (F) LPS on E12, or else (G) saline 
(cont) or (H) LPS on E16.  Scale bar = 100μm.      
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Figure 6: MIA does not significantly alter microglial phenotype in offspring 
midbrain 
Graphical representation of (A-B) ramified or (D-E) amoeboid microglia cell count/ 
area in midbrain sections of (A, D) juvenile and (B, E) adolescent offspring exposed 
to saline (cont) or LPS on E12 (blue bars) or E16 (red bars) as indicated.  
Representative photomicrographs of juvenile midbrain section stained for Iba1 
identifying (C) ramified and (F) amoeboid microglial morphology.  Data are 
expressed as mean ±SEM (N=4/group/time point), unpaired Student’s t-test.  Scale 
bars = 100μm. 
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4.5 Discussion 
This study investigated the molecular and cellular aspects of MIA-induced 
alterations of fetal midbrain development.  We discovered intriguing developmental 
alterations in the offspring VM following later pregnancy (E16) LPS exposure, but 
not earlier exposure (E12), and inhibited proliferation may be mediated by increased 
levels of pro-inflammatory cytokines.  Interestingly, we saw no postnatal effects of 
MIA on the cellular architecture of offspring midbrains, suggesting that the 
developmental alterations were compensated for.  Taken all together, our findings 
suggest that the cytokine response and subsequent neurodevelopmental ramifications 
observed in the offspring VM are dependent upon the temporal responsiveness of 
developmental stages. 
Once we established that our model of MIA, a low dose of LPS, would be 
sufficient to induce an inflammatory response in our region of interest (assessed 
though cytokine profiles of P1 VM samples), we investigated the effects of MIA on 
VM neurodevelopment.  We noted that while LPS exposure on E12 resulted in no 
differences in E14 neurosphere area, LPS exposure on E16 resulted in inhibited E18 
VM neurosphere growth after 7DIV.  This is entirely consistent with our recent 
findings that later developmental stages is the critical window of vulnerability to 
MIA in our LPS model (Straley et al., 2014).  Furthermore, the neurosphere findings 
mirror previous work from our group which demonstrated that IL-1β limits 
neurosphere growth, progressively worsening over the 7DIV (Crampton et al., 
2012).  Therefore, we next investigated whether difference in cytokine levels might 
explain the difference in neurosphere growth. 
The inhibition on neurosphere growth of this study was indeed associated 
with differential cytokine mRNA expression levels depending on age of LPS 
exposure.  Specifically, the E16 exposure group had midbrains with significantly 
higher IL-1β and TNF-α mRNA levels, whereas the E12 exposure group 
demonstrated significantly decreased IL-6 but increase IL-1β compared to the 
relative saline control group.  These differential cytokine profiles implicate the 
importance of timing of MIA on resulting inflammatory response and downstream 
effects of that.  For example, IL-1β regulates proliferation and is critical for 
gliogenesis and neurogenesis in the normal brain and in fact the cytokine peaks 
during this stage of development (Deverman & Patterson, 2009; Bilbo & Schwarz, 
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2012).  This suggests the possibility that increases in IL-1β in earlier developmental 
windows may produce beneficial effects.  In agreement with this, some reports 
indicate neuroprotective effects, including up-regulation of NGF and BDNF, 
resulting from mild systemic infection in the CNS (Petcu et al., 2008; Song et al., 
2013).   Furthermore, as IL-6 can have devastating effects on fetal development and 
offspring behavioral outcome (Smith et al., 2007), the decreased IL-6 mRNA levels 
in the E12 LPS group suggests a protective mechanism preventing the developing 
fetus from adverse outcomes associated with MIA-induced IL-6 elevation.  
However, in the E16 exposure group, IL-1β and TNF-α demonstrated significantly 
elevated expression and IL-6 levels were not decreased.  These elevated cytokine 
levels were accompanied by diminished VM neurosphere size at this age.  This is in 
agreement with a plethora of literature suggesting that increased levels of pro-
inflammatory cytokines in offspring brains mediated neurodevelopmental 
ramifications of MIA, and the differential effects of MIA depending on timing of 
exposure (Boksa, 2010; Knuesel et al., 2014). 
In order to confirm our suspicions of differential effects of cytokines on VM 
NPCs depending on developmental age, we then conducted a neurosphere assay with 
VM cells from naive embryos from earlier (E12) or later (E16) developmental time 
points.  E16 neurospheres in this experiment had reduced diameter after 4DIV when 
treated with IL-1β, TNF-α, and IL-6 in culture.  This is consistent with previous 
studies which demonstrated the power of IL-1β to inhibit proliferation of E16 rat 
forebrain NPCs (Wang et al., 2007) and TNF-α to reduce the growth of neurospheres 
made from spinal cord of E13.5 mouse embryos (~E15.5 in the rat) (Deleyrolle et 
al., 2006).  The E12 VM neurospheres of the current study were only diminished 
following TNF-α treatment.  Incidentally, TNF-α mRNA levels were not altered in 
our E12 LPS group providing a possible explanation why we saw no differences in 
neurosphere growth for this group.  Taken together, these data suggest that a 
neurodevelopmental environment characterized by increased levels of pro-
inflammatory cytokines is detrimental only to development of later stage VM 
neurospheres, and not earlier.   
Because IL-1β and TNF-α mRNA expression significantly increased 
following in utero LPS exposure, we next conducted an in vitro study to assess the 
effects of those cytokines on VM DA neuron development in culture.  Only the E18 
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VM cultures (and not E14 cultures) were affected by the treatments, with TNF-α 
significantly reducing neuronal complexity.  This is in agreement with another study 
that demonstrated  the ability of low dose TNF-α (as well as higher concentrations of 
IL-6, IL-1β, and TNF-α) to disrupt dendrite development of cortical neurons 
(Gilmore et al., 2004).  Also, another study found that TNF-α acted in a neurotrophic 
manner to VM DA cultured from E12.5 mice, but the cytokine was neurotoxic at 
later ages (E14 or E16) (Doherty, 2007).  Consistently, we have previously shown 
that IL-1β exerted inhibitory effects on SCG neurons during similar developmental 
window (E18-P1) (Nolan et al., 2011), and that exposure to LPS in utero on E16 also 
resulted in reduced neuronal growth in SCG neurons isolated from affected offspring 
(Straley et al., 2014), but there were no effects in earlier developmental stages.  
Similarly, other studies have indicated roles for TNF-α and IL-1β in altered 
differentiation of NPCs in multiple brain regions (Wang et al., 2007; Cacci et al., 
2008; Zhang et al., 2013).  These findings suggest that MIA-induced upregulation of 
cytokines in the fetal brain may affect the cellular architecture of the developing 
VM.  Indeed, when we analyzed the numbers of TH-positive DA neurons in the 
developing VM, we found significantly decreased numbers following MIA in later 
pregnancy.  This is consistent with previous studies that have found a loss of DA 
neurons grown in culture from LPS (0.1mg/kg on E10, E14 or E18) exposed 
embryos (Snyder-Keller & Stark, 2008).  There are also reports of decreased cell 
counts of TH-immuno positive cells in midbrain sections from offspring exposed to 
LPS (1mg/kg, on E10.5) across the lifespan (Carvey et al., 2003; Ling et al., 2009).  
We were unable to replicate these findings, as our examination of TH cell counts 
across the lifespan revealed no differences between either LPS group compared to 
the relative, age-matched control.  This is presumably due to the extreme difference 
in LPS dosage, as dose-dependent LPS-induced alterations to offspring 
neurodevelopmental outcome have been reported in many animal models (Boksa, 
2010), including guinea pigs (Harnett et al., 2007) and rats (Urakubo et al., 2001).   
Finally, we wanted to examine glial cytoarchitecture in the midbrains from 
offspring at different postnatal ages because it has been shown previously that 
cytokines are sufficient to induce gliogenesis and prohibit neurogenesis (Cacci et al., 
2008; Peng et al., 2008; Crampton et al., 2012) and because MIA has been proposed 
to prime microglia to respond more strongly to subsequent stimuli (Krstic et al., 
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2012; Giovanoli et al., 2013; Knuesel et al., 2014).  Interestingly, there were no 
significant differences in astrocyte or microglia cell count in either the E12 or the 
E16 cohort, in agreement with our TH findings.  Taken together these data suggest 
that our low dose of LPS is not sufficient to induce long lasting changes in the 
cellular architecture of midbrains of offspring across the lifespan.  Although, there 
was a trend toward age-dependent differences in the cell counts of the microglial 
morphological sub-types only in our E16 cohort, which raises intriguing questions 
for future research concerning microglial priming and the implications for multiple-
hits in the etiologies of MIA-associated disorders.    
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Final Discussion 
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5.1 Summary of Thesis 
The present thesis focused on characterizing the behavioral, molecular, and cellular 
consequences of maternal immune activation (MIA) on the midbrain of affected 
offspring.  Though previous studies into the differential effects of MIA on offspring 
neurodevelopmental outcome exist (Boksa, 2010; Harvey & Boksa, 2012), 
conflicting findings resulting from inconsistent animal models and experimental 
methods created a need for a midbrain specific comprehensive investigation.  It is 
essential to understand the neurodevelopmental and behavioral consequences of 
MIA if we ever hope to prevent the adverse effects that lead to increased 
susceptibility for offspring to develop numerous dopamine-associated neurological 
and neuropsychiatric disorders.   
In an attempt to address this, we initially set out to establish a rat model of 
MIA (Chapter 2), and in particular of subclinical chorioamnionitis, which is an acute 
infection often associated with negative neurodevelopmental outcomes including CP 
(Wu et al., 2000; De Felice et al., 2005; Miyazaki et al., 2007).  Importantly, as fetal 
outcome may be dependent on the timing of MIA due to different developmental 
processes which occur at different gestational time points (Andersen, 2003), we 
sought to determine outcomes following MIA at different time points during 
pregnancy in order to establish possible critical windows for our model.  In terms of 
our model, an overwhelming amount of evidence suggested that LPS exposure at a 
later time point (E16) had more robust consequences on the various factors we 
investigated, compared to the earlier gestational age (E12). 
In this study (Chapter 2) we then wanted to determine the effects of our 
animal model on the placenta as the placenta is a key regulator of fetal development 
(Huppertz, 2008; Togher et al., 2014), and placental health is a great indicator of 
neurodevelopmental outcome (O’Keeffe & Kenny, 2014).  In particular, 
investigating placental cytokine response as well as HSD11B2 expression was of key 
interest because cytokines affect neuron development (Deverman & Patterson, 2009; 
Stolp, 2013) and HSD11B2 plays a critical role in protecting the fetus from 
heightened maternal cortisol levels which can have deleterious effects on fetal 
neurodevelopment (Togher et al., 2014).  Interestingly, this initial study 
demonstrated that LPS exposure has a bi-phasic effect on HSD11B2 mRNA 
expression in the placenta in that it increased following MIA on E12, but decreased 
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following MIA on E16. The decrease in the mRNA expression of this enzyme was 
associated with a decrease in maternal cortisol following LPS exposure at the same 
gestational time point.  Also, LPS exposure at E16 (but not at E12) resulted in 
elevated IL-1β mRNA levels in the rat placenta.  Our in vitro treatment of JEG3 
placental cells with this cytokine resulted in a similar down regulation of HSD11B2 
expression, suggesting a role for IL-1β in the regulation of HSD11B2.  Overall, the 
data from these experiments suggested that LPS-induced IL-1β elevation and 
maternal cortisol depletion may mediate the observed down regulation of HSD11B2 
following LPS at E16.  We also demonstrated reduced placental weight, and no 
alterations to fetal weight or CRL following LPS administration on E16, and no 
placental weight changes were observed following exposure to LPS on E12.  Even 
though these larger developmental characteristics were not altered post LPS, there 
were detrimental outcomes regarding neuron growth and complexity following LPS 
exposure at E16 (but not at E12).   
In the next part of the thesis (Chapter 3), we utilized our MIA animal model 
and key critical time points which we established in the Chapter 2 (Straley et al., 
2014) to investigate behavioral consequences of MIA across the lifespan of 
offspring.  We specifically utilized behavioral assays which would provide insight 
into the functioning of dopamine (DA) pathways due to its role in numerous disease 
etiologies, including PD (Toulouse & Sullivan, 2008), schizophrenia (Meyer-
Lindenberg et al., 2002; Howes & Kapur, 2009), drug addiction (Robinson & 
Berridge, 1993; White, 1996), depression (Martin-Soelch, 2009) and ADHD 
(Volkow et al., 2009).  The overall results of this study demonstrated that behavioral 
outcome was determined by gestational age of MIA occurrence, with exposure at 
E16 effecting motor behaviors in juvenile and adult offspring, and LPS exposure at 
E12 altering the response of adolescent or adult offspring to amphetamine (AMPH).   
Specifically, offspring exposed to LPS on E16 demonstrated motor 
impairments as assessed by the bar hold test and open field locomotion at P9, but 
these deficits were later compensated for in adolescence (P30).  Interestingly, 
though, these animals (E16 LPS exposed) later displayed an age-related decline in 
motor function during the rotarod test, as well as the open field test as demonstrated 
by decreased initial locomotion and increased frequency of freezing.  Furthermore, 
the E16 group also demonstrated differences in anxiety behaviors, whereas the group 
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exposed to LPS on E12 did not.  At P9, the animals that had been exposed to LPS on 
E16 demonstrated altered anxiety response to brief maternal separation, measured by 
USV, and at P30 these same animals remained in the center of the open field for a 
greater duration compared to E16 controls.  With regards to the group of animals 
exposed to LPS in utero on E12, they demonstrated differential responding to 
amphetamine as compared to the relative age-matched controls, which were 
subjected to saline on E12.  Previous findings established the ability of amphetamine 
to potentiate responding for a conditioned reward in a normal animal (Fletcher et al., 
1998), yet our animals that had been exposed to LPS at E12 avoided the 
characteristic AMPH-induced increase in reward responding at both adolescent and 
adult ages.  Importantly, offspring exposed to LPS on E16 responded to AMPH 
similarly as their relative age-matched controls, thus indicating a possible critical 
window for differential responding to AMPH in affected offspring.  
In the final stage of this thesis, in Chapter 4, we aimed to determine the 
molecular and cellular consequences that occur in the midbrain of affected offspring 
which might lead to the behavioral deficits we observed in Chapter 3.  In order to 
accomplish this, we first sought to determine the cytokine profiles of offspring 
subjected to our MIA model.  This was based on the knowledge that other MIA 
models have demonstrated increased levels of pro-inflammatory cytokines, including 
IL-1β and TNF-α, in the fetal brain (Urakubo et al., 2001).  Interestingly, results 
demonstrated differential midbrain cytokine profiles which were dependent upon the 
gestational time point at which animals were administered LPS.  Following this, 
based on our previous finding that IL-1β impaired proliferation and altered 
differentiation of VM NPCs in vitro (Crampton et al., 2012), we then investigated if 
MIA and associated inflammatory mediators alter proliferation or development of 
fetal VM neurospheres and primary DA neuron cultures.  LPS exposure at E16 
resulted in decreased VM neurosphere size after 7DIV.  In order to then supplement 
our hypothesis that developmental effects were related to the differential cytokine 
profiles, we then conducted in vitro experiments.  These results indicated that VM 
samples (both neurospheres and primary DA neuron cultures) from later gestational 
ages (≥E16) are more susceptible to neurotoxic effects of pro-inflammatory 
cytokines than cultures isolated from earlier gestational ages.  Finally, due to the 
different onset ages for MIA associated disorders, we wanted to map the 
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cytoarchitecture of offspring midbrains across the lifespan following in utero 
exposure to saline or LPS on E12 or E16.  In utero LPS exposure at E16 decreased 
the number of VM neurons stained for TH, a DA neuron marker.  However, there 
were no differences in DA neuron number in juvenile, adolescent, nor adult offspring 
suggesting that the developmental alterations following MIA exposure are 
compensated for early in life.  Similarly, LPS exposure did not alter cell number or 
morphology of glial cells in the midbrains of affected offspring.   
 
  
171 
 
5.2 Implications of this Work 
This thesis has shown that LPS exposure can induce placental and fetal alterations 
during development, with behavioral consequences for the offspring dependent upon 
the gestational time point when the MIA insult occurs.  The findings of this thesis 
have brought up numerous interesting implications as well as areas for future 
research to consider. 
The initial wider implications from the first study (Chapter 2) is that our 
model of MIA agrees with previous epidemiological evidence associating second 
trimester maternal infection with an increased risk for adverse neurodevelopmental 
outcomes (Sørensen et al., 2009; Atladóttir et al., 2010; Patterson, 2011b).  
Obviously translating developmental dates between species comes with numerous 
caveats, yet there is a mounting body of evidence to suggest that the second week of 
rodent pregnancy correlates with key neurodevelopmental processes in the second 
trimester of human pregnancy (see Chapter 1) (Clancy et al., 2001; Clancy et al., 
2007; Katz, 2007; Semple et al., 2013; Workman et al., 2013).  Therefore, our 
finding that the placental and neuronal alterations post LPS occurred only following 
exposure at E16, suggest that second trimester is a more vulnerable developmental 
window for MIA to alter these parameters.  Importantly, because of the temporal 
specificity and longevity of maternal infection- induced placental changes it is 
possible that placental characteristics may be useful in predicting subsequent risk for 
adverse neurodevelopment and subsequent outcomes in terms of neuropsychiatric 
disease (O’Keeffe & Kenny, 2014).  Therefore, it would be interesting for future 
research to investigate further the precise predictive capabilities of placental 
phenotypes in determining the likelihood of neurodevelopmental disorders in 
affected offspring.  
It would also be interesting for future research to determine what LPS-
induced placenta changes mean for fetal exposure to cortisol  because increased fetal 
exposure to maternal glucocorticoids is associated with a number of adverse 
outcomes including preterm birth and increased risk of neuropsychiatric disorders 
(Entringer et al., 2012; Reynolds, 2012; Togher et al., 2014).  Reduction in placental 
HSD11β2 was shown by others to increase fetal levels of corticosterone (Cottrell et 
al., 2012), and we found a reduction in HSD11β2 post LPS on E16.  As this enzyme 
converts cortisol to its inactive form cortisone, thereby protecting the fetus from 
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excessive maternal cortisol exposure (Togher et al., 2014), it is interesting to 
speculate about the neurodevelopmental ramifications of these observations.  Of 
note, our other observation of reduced maternal cortisol levels following LPS should 
also be taken into consideration for this discussion as the drop in HSD11β2 
expression may be of a sufficient level to protect the fetus from the altered post LPS 
cortisol levels, though maternal cortisol levels are greatly increased during 
pregnancy so it could be that the fetus is still subjected to higher than normal levels 
of cortisol regardless of this drop.  Thus, future research should investigate these 
parameters further.  In order to accomplish this, it would be interesting to compare 
cortisol levels from naive animals with those exposed to our MIA model, at different 
gestational ages, in numerous regions, including maternal circulation, placental and 
fetal compartments, as well as in the fetal brain. 
As we also showed that IL-1β affected HSD11β2 expression in cultured 
placental cells, and LPS exposure in later pregnancy increased IL-1β mRNA 
expression in the placenta of our in vivo study, cortisol is not the only factor worth 
paying attention to post LPS.  As we proposed in the paper (Straley et al., 2014), the 
neurodevelopmental outcome resulting from LPS exposure may also depend on 
changes in pro-inflammatory cytokines, which have been shown to adversely affect 
the developing brain (Boksa, 2010).  It would be interesting for future research to 
investigate differential cytokine expression following LPS exposure because 
neurodevelopmental consequences may involve cytokines coming from the fetus 
and/or the mother.  Elucidating the location associated with the most detrimental up-
regulation in cytokines will help to determine future preventative measures for 
protecting fetal neurodevelopment from MIA-induced, cytokine-mediated 
alterations.  An interesting approach to investigate this would be to utilize 
recombinant cytokines labelled with fluorescent dye to trace the movement of 
maternal cytokines in live pregnancy.   
Following on from this, the thesis also demonstrated an age-related decline in 
motor function for animals exposed to LPS on E16, and these findings have 
important implications for Parkinson’s disease (PD).  The initial decline in 
locomotion our animals demonstrated in the open field could represent a difficulty 
initiating movement, and they also exhibited a greater frequency freezing during the 
testing period compared to controls.  These are both common clinical features of 
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motor symptoms of PD (Jankovic, 2008), suggesting a possible relationship between 
PD and MIA.  Interestingly, these same animals (that were exposed to in utero LPS 
on E16) also demonstrated increased fecal pellet output in the open field, which is a 
measure of increased anxiety in animal studies.  Common non-motor PD symptoms 
include problems with gastrointestinal motility as well as anxiety (Braak et al., 2003; 
Langston, 2006; Taylor et al., 2009), further implicating a possible PD phenotype 
following exposure to in utero LPS in later pregnancy.   
Interestingly, we did not find a loss in DA neurons in the substantia nigra, 
which is the true hallmark of PD (Damier et al., 1999; Sulzer, 2007; Venderova & 
Park, 2012), nor the ventral tegmental area of affected offspring, suggesting that 
motor function was not altered due to loss of DA neurons in the midbrain.  Thus, the 
question arises what cause the deficits in motor behavior?  Future investigations into 
DA production using neurochemical analyses (such as high-pressure liquid 
chromatography, HPLC) could provide insight into this, as MIA has been shown to 
alter concentrations of DA and its metabolites (Ozawa et al., 2006; Ling et al., 2009; 
Kirsten et al., 2010a).  Furthermore, it is possible that DA transmission between the 
substantia nigra and striatum reaches a ceiling effect whereby additional stimulation 
to the DA system (by AMPH) is blunted.  Utilizing HPLC experiments examining 
DA levels in target regions, following AMPH administration in affected animals 
would help to determine this.  Also to this end, it would be interesting to conduct an 
electrophysiological study.  Electrophysiological analysis can provide important 
insights into the function of regionally specific DA neurons, and comparisons 
between DA neuron discharge properties and biochemical measures of 
neurotransmitter regulation can elucidate information about DA regulation in a 
pathway of interest.  Alternatively, the observed motor deficits could be an issue 
with DA receptors, as several neuropsychiatric disorders are associated with 
abnormal dopamine receptor signaling (Girault & Greengard, 2004), and as such a 
simple analysis of DA receptor expression, through immunohistochemistry and/or 
PCR would be useful.  Alternatively, other neurotransmitters such as glutamate, 
which are also involved in motor function and interacts with DA to produce PD 
symptoms, may also be involved in these processes (Chase & Oh, 2000; Rylander et 
al., 2009).   
Even more compelling in this regard, perhaps, is molecular and cellular data 
from Chapter 4.  As MIA can prime microglia for chronic activation, altering 
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microglial response to cellular processes like protein aggregation or neuron death, it 
has been proposed that chronic microglial activation may subsequently result in 
progression of the α-synuclein aggregates into Lewy bodies that are the pathological 
hallmark of PD (reviewed in Glass et al., 2010; Tomé et al., 2013; Knuesel et al., 
2014).  This suggests microglial priming as a result of MIA has the potential to lead 
to an increased susceptibility for PD later in life.  In support of this, PD is highly 
associated with neuroinflammation because microglial activation (McGeer et al., 
1988; Imamura et al., 2003) and elevated levels IL-1β and TNF-α, and IL-6 (Mogi et 
al., 1994a; Mogi et al., 1994b; Koziorowski et al., 2012) are common characteristics 
of postmortem PD brains.  In the current thesis, we demonstrated increased cytokine 
expression in fetal midbrains, and it would be of interest for future research to 
determine similar cytokine profiles across the lifespan in order to ascertain if chronic 
inflammation is characteristic in our MIA model.   
Furthermore, the idea of microglial priming raises intriguing questions for 
future research in the context of multiple-hit scenarios.  Indeed, it has been proposed 
in recent years that PD is the culmination of numerous insults or “hits” which may 
begin with MIA (Carvey et al., 2006; Knuesel et al., 2014) and include microglial 
priming and associated chronic inflammation (Sulzer, 2007; Long-Smith et al., 2009; 
Collins et al., 2012).  Thus, MIA may be the initial step along the path which leads 
to predisposition of disease development later in life.  In complete agreement with 
this, our data demonstrated altered VM neurosphere/ DA neuron development along 
with subsequent deficits in nigrostriatal-mediated behaviors in affected offspring, 
following exposure to LPS at E16.  Furthermore, our subsequent investigation of 
microglial morphology indicated that LPS exposure at E16 resulted in a trend toward 
a difference in the numbers of ramified microglia at the juvenile age and in the 
amoeboid morphology at the adolescent age in the midbrains of affected offspring, 
however these results were not significant.  Due to this, it is interesting to speculate 
what would happen if a subsequent hit occurred.  Others have demonstrated that 
offspring exposed to MIA (Poly (I:C), 5mg/kg, E17) display chronic cytokine up-
regulation along with impairments in working memory in old age, and if the MIA is 
followed by a second hit of Poly (I:C) in adulthood, these outcomes are strongly 
exacerbated along with a surge in microglia activation, mimicking the pathology of 
neurodegenerative progression of AD (Krstic et al., 2012) which incidentally has 
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commonalities with PD pathology (Witt, 2012; Winner & Winkler, 2015).  
Similarly, when MIA (LPS 200μg/kg, every 12h, from E17 to the end of gestation) 
was combined with a secondary insult of hypoxia-ischemia, lesions to the substantia 
nigra as well as motor deficits were greatly increased, compared to either insult 
alone, for affected offspring (Girard et al., 2009).  Along similar lines, findings from 
both clinical and animal studies have suggested that there are lasting changes in the 
brains of cerebral palsy patients (CP) following perinatal insult which manifest as 
mechanisms that prevent regeneration and/or exacerbate brain damage, the processes 
and downstream effects are termed “tertiary brain damage” (Fleiss & Gressens, 
2012).  Persistent inflammation, associated with aberrant gliosis, and epigenetic 
changes are thought to be the major tertiary mechanisms, as they can alter numerous 
neurodevelopmental processes, and importantly the authors implore that many 
instances of tertiary brain damage may only become apparent following a secondary 
insult (Fleiss & Gressens, 2012).  Therefore, if I were to investigate this, it would be 
interesting to conduct the same experiments as I have already done, including the 
behavioral assays as well as investigations into cellular architecture following MIA, 
but with an additional LPS administration in adolescence.  I would choose this 
because of the dynamic neurodevelopmental and re-organizational processes that 
occur during adolescence, and because numerous diseases are associated with insults 
that occur during this developmental stage (schizophrenia, for example (Howes et 
al., 2004)).  Furthermore, if the microglia had been “primed” by in utero LPS 
exposure, the subsequent response following a second hit of the same immunogen 
could potentially result in more robust morphological and cytoarchitectural 
alterations.  
The previous discussion has centered around the consequences of LPS on 
E16, as the majority of alterations were found following insult at that time point.  
However, we did see some behavioral alterations following LPS exposure in the 
earlier age (E12).  Indeed, our other key findings in Chapter 3 demonstrated that 
MIA has differential effects on amphetamine (AMPH) responding depending on 
gestational age at which MIA occurs, and this has interesting implications for drug 
addiction.  The DSM-V defines tolerance, or a diminished response to a drug that is 
repeatedly used, as a hallmark symptom of addiction (APA, 2013), and therefore our 
findings of reduced sensitivity to AMPH following MIA exposure at E12 in adult 
176 
 
animals may indicate a potential susceptibility for drug tolerance and subsequent 
abuse later in life.  Current research poses the theory that drug addiction results from 
a series of events, beginning with an initial drug use voluntarily taken, followed by 
many subsequent exposures along with interactions between conditioned and 
instrumental learning processes, ultimately resulting in compulsive drug seeking 
behavior (Everitt & Robbins, 2005; Everitt et al., 2008).  Regardless of behavioral 
outcome, repeated exposure to drugs of abuse induces adaptations within the brain 
that compensate for the drug exposure (Chao & Nestler, 2004).  Furthermore, studies 
in animal models demonstrates that impulsivity behavior is associated with an 
increased predisposition for drug seeking behavior/ drug abuse , as well as an 
increased probability of relapse (Everitt et al., 2008); human studies have also 
implicated personality differences, including impulsivity or sensation seeking, in 
vulnerability to drug use and abuse (Hawkins et al., 1992; Kelly et al., 2006; White 
et al., 2006).  Taken together, these findings suggest that an individual with an initial 
blunted response to a drug, and who is prone to impulsive behavior may experiment 
again with the substance, resulting in the eventuality of habituation and biological 
dependency on the substance. Therefore, it would be of particular interest for future 
research to establish the effect of MIA more clearly on impulsive behavior of 
offspring as well as the propensity to engage in drug seeking behavior.  In order to 
elucidate such information, there are numerous ways of measuring impulsivity in 
animals, most of which utilize similar food reward paradigms that I used for my 
investigations into motivation and reward.  If I were to do that, it would be 
interesting to administer a range of food reward paradigms (some of which are 
described here: Everitt et al., 2008), following LPS exposure, that would target 
impulsive behaviors of the animals.  For example, monitoring the anticipatory 
responses made before a food reward, or else a delay-of-reward task paradigm, in 
which the animal learns that it can choose a small immediate reward or wait for a 
larger but delayed reward, are both interesting experimental possibilities.  In order to 
examine if MIA increases drug seeking behavior in affected offspring, it would be 
interesting to use a drug self-administration paradigm following in utero LPS 
exposure.  In this type of scenario, animals would be exposed to chronic 
administration (>40 days) of a drug, such as cocaine or AMPH, after which a certain 
percentage of control animals begin to demonstrate addiction-like behaviors 
(Deroche-Gamonet et al., 2004; Everitt et al., 2008).  This test alone could 
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demonstrate if MIA has the ability to increase likelihood of drug seeking in affected 
offspring.  Though, it would be even more compelling if the animals were subjected 
to a subsequent punishment paradigm, in which a punishment, such as a foot shock 
(Pelloux et al., 2007), is administered at the same time as the drug reward because 
maintaining drug use despite aversive consequences is characteristic of addictive-
like behaviors (Deroche-Gamonet et al., 2004). 
Within this context, it is interesting to speculate the reasons for different 
AMPH responding we observed in our study.  AMPH-induced effects on locomotor 
behavior has been attributed primarily to the ability of the drug to bind to dopamine 
transporter (DAT) in the nucleus accumbens and increase DA release (Naef et al., 
2008).  DAT is the main membrane protein responsible for clearing dopamine from 
the synapse and therefore DAT is critical for terminating DA signaling (Zahniser & 
Sorkin, 2004).  Furthermore, DAT is implicated in numerous DA-related disorders 
associated with nucleus accumbens and the mesolimbic pathway including ADHD 
(Spencer et al., 2007; Volkow et al., 2007) and addiction, including alcohol (Repo et 
al., 1999; Samochowiec et al., 2006) and drugs of abuse (Zhu & Reith, 2008).  
Indeed, studies with knockout mice have demonstrated the contribution of DAT to 
the reinforcing, motivational, and rewarding effects of psychomotor stimulants such 
as cocaine or amphetamine (Rocha, 2003).  Thus, DAT contributes to the potential of 
psychomotor simulants to be abused (Zahniser & Sorkin, 2004).  DAT is regulated 
by acute AMPH exposure, which causes rapid up-regulation and slower down-
regulation of DAT (Zahniser & Sorkin, 2009).  Furthermore, uptake of amphetamine 
inhibits DAT transport of dopamine, resulting in the characteristic increase in 
extracellular DA associated with AMPH administration (Zahniser & Sorkin, 2004).  
Thus, altered AMPH responding in LPS exposed offspring may implicate a MIA-
induced problem with DAT.  Therefore, it would be of interest for future studies to 
determine the effects of MIA on DAT expression/ function in affected offspring. 
As mentioned previously, basal levels of DA could be altered following in 
utero LPS exposure, and therefore an initial inquiry should be made into the 
transmission of DA from the VTA to the nucleus accumbens in drug naive animals 
as well as following AMPH treatment, in order to determine if MIA results in 
blunted AMPH-induced stimulation of this DA pathway.  Another important aspect 
of this would be to examine postsynaptic receptors, such as D1 and D2, because 
these would need to be functioning properly in order to stimulate behaviors.  
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Furthermore, impulsivity (which predicted the intake escalation of cocaine), was 
associated with low D2 and D3 DA receptor availability in the ventral striatum of 
rats (Dalley et al., 2007).  Also, reduced D2 receptors in the dorsal striatum have 
been observed in recovering alcoholics and abstinent cocaine, heroin and 
methamphetamine addicts (Volkow & Wise, 2005; Volkow et al., 2014).  Thus, it is 
interesting to speculate whether the postsynaptic receptors of affected offspring were 
desensitized and/or decreased in number, resulting in the delayed AMPH response 
we observed in the open field test, and whether this might contribute to drug abuse 
vulnerability. 
To conclude, this thesis has indicated later rat pregnancy (E16) as vulnerable 
time for MIA to affect the development of the nigrostriatal pathway and subsequent 
behavioral outcomes, possibly implicating a role for MIA in increased risk for 
disorders associated with motor behavior, like PD.  These effects are likely mediated 
through alterations in the placenta as well as altered inflammatory mediators.  This 
thesis has also shown that MIA in earlier rat pregnancy (E12) results in a differential 
response to amphetamine in affected offspring, implicating a role for MIA in 
mesocorticolimbic functional alterations, possibly leaving vulnerability for disorders 
associated with this pathway.  Epidemiological evidence has correlated first trimester 
(often equated to first half of rat pregnancy (Clancy et al., 2007)) human bacterial 
infection to increased risk of schizophrenia (Sørensen et al., 2009), a disease 
associated with malfunctioning mesocorticolimbic system, differential AMPH 
responding with characteristic excessive dopamine release in response to the drug 
(Breier et al., 1997), as well as increased risk of substance addiction (Chambers et 
al., 2001).  Taken together, this may implicate a role for MIA in increased risk for 
disorders associated with the mesocorticolimbic pathway, including drug abuse or 
schizophrenia.  While results of preclinical studies cannot be directly translated to 
humans, the current thesis suggests that timing of MIA could be useful in speculating 
subsequent adverse neurobehavioral outcome and associated risk factor of 
neurodevelopmental disorders associated with dopaminergic pathways.  Using this 
information we may then be able to more appropriately target preventative therapies 
that could protect the developing fetus from adverse neurodevelopmental outcomes.  
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Figure 5.1: Summary figure outlining the overarching findings of this thesis 
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Appendix A: List of Abbreviations 
 
5-HIAA: 5-hydroxyindoleacetic acid 
ACTH: Adrenocorticotropic hormone  
AD: Alzheimer’s disease 
ADHD: Attention Deficit Hyperactivity Disorder  
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AMPH: Amphetamine  
ASD: Autism spectrum disorders 
BAL: Bronchoalveolar 
BDNF: Brain derived neurotrophic factor 
CP: Cerebral Palsy 
CMV: Cytomegalovirus 
CNS: Central Nervous System 
CNV: Copy number variants 
CORT: Cortisol 
CSF: Cerebrospinal fluid 
DA: Dopamine/Dopaminergic  
DAT: Dopamine (active) transporter 
DC: Dendritic cell 
DISC: Disrupted in schizophrenia 
DR: Dopamine receptor 
ds-RNA: Synthetic double-stranded RNA 
E: embryonic day 
EPH: Ephrin 
FGF8: Fibroblast growth factor 
FGFb: Basic fibroblast growth factor 
GA: Gestational  
GABA: γ-amionobutyric acid 
GAD67: Glutamic acid decarboxylase 67 
GDNF: Glial cell line-derived neurotrophic factor 
GFAP: Glial fibrillary acidic protein  
GU: Genitourinary  
HPA: Hypothalamic pituitary adrenal 
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hs-CRP: High-sensitivity c-reactive protein 
H1N1: Human influenza virus 
HSD11B2: 11β-hydroxysteroid dehydrogenase type 2 
IFN: Interferon 
IL: Interleukin 
I.N.: Intranigral 
I.P.: Intraperitoneal  
IRF: Interferon regulatory factor 
I.V.: Intravenously 
LI: Latent inhibition 
LPS: lipopolysaccharide 
LTP: Long term potentiation  
NF-kβ: Nuclear translocation of nuclear factor-kappaβ 
NPC: neuronal precursor cell 
MAPK: Mitogen-activated protein kinase 
MCP: monocyte chemoattractant protein 1  
MIA: maternal immune activation 
MIG: monokine induced by IFN-γ 
MIP: macrophage inflammatory protein 
MWM: Morris water maze 
NAc: Nucleus accumbens 
NMDA: N-methyl-D-aspartate 
NO: Novel object 
NPC: Neuronal progenitor cell 
Nurr1: Nuclear receptor related 1 protein 
NGF: Nerve growth factor 
NLR: NOD-like receptors 
NOD: Nucleotide binding oligomerization domain  
NT: Neurotrophin 
OF: Open field  
PCD: Programmed cell death 
PD: Parkinson’s disease 
PDS: Prenatal determinants of schizophrenia 
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Poly(I:C): Polyinosinic:polycytidylic acid 
PFC: Prefrontal cortex 
PPI: Pre-pulse inhibition 
PRR: Pattern-recognition receptor  
PVL: Periventricular leukomalacia  
ROS: Reactive oxygen species 
SCG: Superior cervical ganglion 
Shh: Sonic hedghog 
SNpc: Substantia nigra pars compacta 
SSD: Schizophrenia spectrum disorders 
TH: Tyrosine hydroxylase  
TIR: Toll-IL-1 
TNF: Tumor necrosis factor 
TLR: Toll like receptor  
UADD: Undifferentiated attention deficit disorder 
uNK : Uterine natural killer cells 
USV: ultrasonic vocalization 
UTI: Urinary tract infection 
VM: Ventral mesencephalon 
VTA: Ventral tegmental area 
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